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Both genetic and environment factors influence susceptibility to substance use disorders. 
However, the genetic basis of these disorders is largely unknown. We previously identified 
Hnrnph1 (heterogeneous nuclear ribonucleoprotein H1) as a quantitative trait gene for 
reduced methamphetamine (MA) stimulant sensitivity. Mutation (heterozygous deletion of 
a small region in the first coding exon) in Hnrnph1 also decreased MA reinforcement, 
reward, and dopamine release. 5’UTR genetic variants in Hnrnph1 support reduced 5’UTR 
usage and hnRNP H protein expression as a molecular mechanism underlying the reduced 
MA-induced psychostimulant response. Interestingly, Hnrnph1 mutant mice show a two-
fold increase in hnRNP H protein in the striatal synaptosome with no change in whole 
tissue level. Proteome profiling of the synaptosome identified an increase in mitochondrial 
complex I and V proteins that rapidly decreased with MA in Hnrnph1 mutants. In contrast, 










MA-induced increase. Altered mitochondrial proteins associated with the Hnrnph1 
mutation may contribute to reductions in MA behaviors. hnRNP H1 is an abundant RNA-
binding protein in the brain, involved in all aspect of post-transcriptional regulation. We 
examined both baseline and MA-induced changes in hnRNP H-RNA interactions to 
identify targets of hnRNP H that could comprise the neurobiological mechanisms of 
cellular adaptations occurring following MA exposure. hnRNP H post-transcriptionally 
regulates a set of mRNA transcripts in the striatum involved in psychostimulant-induced 
synaptic plasticity. MA treatment induced opposite changes in binding of hnRNP H to 
these mRNA transcripts between Hnrnph1 mutants versus wild-types. RNA-binding, 
transcriptome, and spliceome analyses triangulated on hnRNP H binding to the 3’UTR of 
Cacna2d2, an upregulation of Cacna2d2 transcript, and decreased 3’UTR usage of 
Cacna2d2 in response to MA in the Hnrnph1 mutants. Cacna2d2 codes for a presynaptic, 
voltage-gated calcium channel subunit that could plausibly regulate MA-induced 
dopamine release and behavior. The multi-omics datasets point to a dysregulation of 
mitochondrial function and interrelated calcium signaling as potential mechanisms 
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CHAPTER I: INTRODUCTION 
Molecular and Behavioral Response to Methamphetamine 
Overview 
The rate of overdose deaths involving psychostimulants with abuse potential [drugs such 
as methamphetamine (MA)], increased nearly five-fold from 2012 to 2018 in the U.S. 
(Hedegaard et al., 2020). MA is a highly addictive psychostimulant drug that induces 
neurotoxic effects and neurocognitive deficits following chronic administration. The 
widespread misuse of MA can destroy the social fabric of communities; thus, MA 
dependence presents a significant public health concern. After being a major drug of abuse 
in the 1970s and 1980s, MA has made a comeback as evident by the surge in overdose 
deaths due to MA. A major factor for its rise is the ease of manufacturing, thus, making 
MA highly accessible (Galbraith, 2015).  While it is important to address the opioid crisis, 
the MA crisis that has fallen by the wayside should not be neglected. While there are 
medications available for treating opioid dependence (e.g. buprenorphine) and reversing 
opioid overdose (e.g. naloxone), there are currently no FDA-approved drugs to manage 
addiction to MA. There is an urgent need for effective therapeutics to mitigate the negative 
effects of MA, which will be discussed in the following section. Studies aimed to 
understand the relationship between sensitivity to initial drug effects and subsequent use 
in both humans and animal models suggest that the initial response to drugs often predict 
future use or abuse (Volkow et al., 2010; de Wit and Phillips, 2012). Because substance 




molecular mechanisms of drug action and the rapid adaptations following acute 
administration will help inform novel therapeutic targets. 
Methamphetamine: Mechanisms of Action 
MA is a powerful synthetic amphetamine-type stimulant and frequent users of MA are 
more likely to become addicted to MA because of its better penetration in the brain (high 
lipid solubility) and longer duration of action (Nordahl et al., 2003; Won et al., 2013). MA 
is a substrate for monoamine transporters and competes with monoamines (mainly 
dopamine (DA), serotonin, and norepinephrine) and their respective transporters for 
reuptake (Rothman et al., 2001; Haughey et al., 2002; Adinoff, 2004). Once transported 
into the nerve terminal, MA enters synaptic vesicles via the vesicular monoamine 
transporter 2 (VMAT2) to and reverse its transport to promote efflux of monoamines into 
the cytosol (Fleckenstein et al., 2007; Siciliano et al., 2014). The elevated level of cytosolic 
monoamine causes reverse transport of monoamine into the synapse (Cruickshank and 
Dyer, 2009). In this way, MA elevates the extracellular monoamine by inducing synaptic 
vesicle depletion to increase intracellular monoamine and by promoting efflux through 
plasma membrane monoamine transporters. In addition, monoamine oxidase that is crucial 
for oxidative metabolism of monoamines is inhibited by MA (Sulzer et al., 2005), which 
further increases the synaptic level of monoamines for binding and stimulating 
postsynaptic monoamine receptors to shift neuronal and behavioral phenotypes.  
Monoamine transporters, particularly dopamine transporters (DAT), are molecular 
targets that mediate abuse-related effects of psychostimulants such as amphetamine and 




reduce the cell surface level of DAT, resulting in accumulation of DAT in intracellular 
endosomes (Saunders et al., 2000; Chi and Reith, 2003; Sorkina et al., 2003). A mutation 
in DAT that impairs substrate transport but not substrate binding has no effect on 
amphetamine-induced DAT internalization when amphetamine is applied extracellularly 
(Kahlig et al., 2006). However, intracellular application of amphetamine leads to 
internalization of the uptake-impaired DAT, which indicates that DAT transport is not 
necessary for amphetamine-induced DAT internalization but rather the increase in 
intracellular amphetamine is the essential component for this regulation (Kahlig et al., 
2006). Many of these earlier studies did not consider amphetamine-induced internalization 
of DAT is dependent upon the time of amphetamine exposure (Robertson et al., 2009). 
More recent studies indicate that the transient, rapid increase in DAT induced by 
amphetamine occurs within seconds and diminishes by 2.5 minutes (Johnson et al., 2005). 
Using a number of methods to tag and monitor endocytosis and recycling of DAT in DA 
neurons, the Amara lab has demonstrated that DAT internalized by DAT undergoes 
recycling and returns to neuronal surface (Hong and Amara, 2013). 
Given that DA in the brain is important for the stimulant and rewarding effects of 
psychostimulants (Wise, 2004), the increase in DA induced by MA in key brain regions 
may largely account for the abuse potential of MA (Baumann et al., 2002). The major DA 
pathways include the mesolimbic, mesocortical, and nigrostriatal pathways (Wise, 2004) 
and DA release exerts different functional effects within these pathways including feelings 
of reward, decision making, and motor movement, respectively. The mesolimbic pathway 




tegmental area (VTA) and projecting and terminating primarily in the nucleus accumbens 
(NAc) (Adinoff, 2004). Activation of the mesolimbic pathway by MA is accompanied by 
an increase in the extracellular concentration of  DA in the NAc to mediate feeling of 
pleasure and reward (Juarez and Han, 2016). The VTA also provides dopaminergic 
innervation from the VTA to the prefrontal cortical regions (orbitofrontal cortex and 
anterior cingulate) known as the mesocortical pathway, which is known to play a role in 
inhibitory control and decision making (Gardner and Ashby, 2000). Lastly, the nigrostriatal 
pathway that originates in the zona compacta of the substantia nigra to the caudate putamen 
(or dorsal striatum) mediates motor activity (Bourdy et al., 2014). These neurons undergo 
MA-induced synaptic and neural circuit adaptations following acute and chronic MA 
exposure that ultimately lead to a transition into MA-dependent state. These three pathways 






Figure 1. Initial Actions of Drugs of Abuse on the Mesocorticolimbic and Nigrostriatal 
Pathway. 
Dopaminergic neuron projections from the VTA to the NAc and mPFC comprise the 
mesocorticolimbic system while dopaminergic neuron projections from the SNc to the striatum 
make up the nigrostriatal pathway. There are three ways for drugs of abuse to increase DA in these 
pathways: 1) direct activation of dopaminergic neurons; 2) indirect disinhibition of dopaminergic 
neuron by inhibiting GABAergic neurons; 3) interference of DA reuptake at the terminals. 
Psychostimulants like MA block reuptake of DA at synaptic terminals. Diagram is modified and 
adapted from Lüscher, 2013. 
 
 
Dopamine Receptor Signaling 
All drugs of abuse elicit their effect by activation of the mesolimbic reward pathways. MA 
reverses DAT to lead to a buildup of synaptic DA to activate dopamine receptors on target 
neurons (Drago et al., 1998; Tomkins and Sellers, 2001; Zhu and Reith, 2008). Through 
gene cloning procedures, pharmacological and genetic manipulation, five distinct 
dopamine receptor subtypes were isolated and structurally and functionally characterized 




Gainetdinov 2011; Missale et al. 1998; Rankin et al. 2009). All dopamine receptors are 
rhodopsin-like seven-transmembrane receptor (also known as G protein-coupled receptors 
because these receptors are coupled to G proteins for signal transduction) (Levey et al., 
1993; Drago et al., 1998). Stimulation of brain dopamine receptors regulates locomotion, 
motivation, and working memory (Rankin et al., 2009). 
The general property of D1-like dopamine receptor is the capability to activate 
adenylyl cyclase (AC). Activation of D1-like dopamine receptor is coupled to Gs or 
Golf family of G proteins to stimulate cAMP production by AC, leading to increase in 
protein kinase A (PKA) activity. D1-class receptors are expressed at the highest level in 
the nigrostriatal, mesolimbic, and mesocortical areas and found almost exclusively on 
postsynaptic DA receptive cells such as GABAergic MSNs in the striatum (Beaulieu and 
Gainetdinov 2011). In general, activation of PKA by D1 signaling alters Ca2+ and K+ 
conductance to enhance excitatory glutamatergic input in MSNs shifting the cells into a 
more depolarized state (Surmeier et al., 2007). Activation of postsynaptic D1 receptors on 
postsynaptic neurons  is required for manifestation of locomotor activity (Missale et al., 
1998).  
The most studied intracellular effect mediated by D1 dopamine receptor is the 
activation of the cAMP pathway (Hyman et al. 2006; Nishi et al. 2011). In striatal MSNs 
of the direct pathway, DA acting on D1 receptors activates AC for induction of the cAMP-
PKA signaling cascade, whereby the increased level of cAMP leads to the activation of 
PKA. A major downstream target of this pathway is DARPP-32 (dopamine and cAMP-




striatonigral neurons of the direct pathway and on D2-receptor-enriched striatopallidal 
neurons of the indirect pathway. Activated PKA phosphorylates DARPP-32 at Thr34, 
which in turn inhibits protein phosphatase-1 to control phosphorylation state of a cascade 
of downstream effectors including neurotransmitter receptors, ion channels and pumps, and 
transcription factors. The two other signaling cascades coupled to D1 receptor activation 
are 1) phospholipase and inositol 1,4,5-triphophate activation for increase in calcium to 
activate CaMKII (Ca2+/calmodulin-dependent kinase II) and 2) Src family 
kinase/RAS/ERK signaling to induce histone H3 phosphorylation (Nishi et al.  2011). 
Collectively, all three distinct signaling pathways mediated by stimulation of D1 receptor 
lead to phosphorylation and activation of the cAMP-response element binding protein 
(CREB) in the nucleus for transcriptional activation of genes to alter the activity of the 
neurons which express those genes, ultimately leading to changes in synaptic plasticity. 
 
The D2 class of DA receptor is coupled to Gi or Go which inhibits AC causing 
a decrease in PKA activity (Surmeier et al., 2007). The reduction in PKA signaling alters 
Ca2+, NA+, and K+ conductance to decrease the glutamatergic innervation to prevent 
spiking. Unlike D1 receptors which are predominantly expressed postsynaptically, D2-like 
DA receptor including D2DAR and D3DAR are found both postsynaptically on DA target 
cells and presynaptically on dopaminergic neurons (Nagy et al., 1978; Sokoloff et al., 2006). 
The striatum, NAc and olfactory tubercle contain the highest levels of D2 DA receptor 
(Beaulieu and Gainetdinov 2011). Besides difference in expression level between D1 and 




DA receptor genes have no introns in their coding sequence and genes that code for D2-
class receptors contain various number of introns (Beaulieu and Gainetdinov 2011; Missale 
et al. 1998). The presence of introns allows for alternative splicing to generate DA receptor 
splice variant, and the most notable example is the differential splicing of the D2 dopamine 
receptor gene to give rise to two D2DAR isoforms with different localization and function. 
The two alternative spliced isoforms of D2DAR are named D2S (D2-short) and 
D2L (D2-long), where D2S is generated by splicing of an 87-base-pair exon between 
introns 4 and 5 to yield a receptor product that is missing a stretch of 29 amino acids in the 
third intracellular loop (Nagy et al., 1978; Usiello et al., 2000). The two isoforms have 
distinct functions due to differences in anatomical, physiological and pharmacological 
properties. The D2S isoform is expressed on presynaptic dopaminergic neurons and 
functions as an autoreceptor to regulate DA synthesis and release in response to changes 
in extracellular dopamine concentration (Wolf and Roth, 1990; Missale et al., 1998; De 
Mei et al., 2009). The highest expression D2S is found in midbrain dopaminergic terminals 
(Fig. 1). As an autoreceptor, presynaptic D2S provides a negative feedback mechanism for 
regulating dopaminergic response. In condition of high synaptic dopamine level, in the 
case of dopamine transporter blockade by drugs of abuse, D2S becomes activated to slow 
the firing rate of presynaptic DA neurons and inhibit DA synthesis and release (De Mei et 
al., 2009). Thus, the main regulatory role of D2S is to counteract the effect of drugs of 
abuse. Due to its ability to exert feedback inhibition, dysregulation of D2S is highly 




Several mechanisms have been proposed as to how D2S exerts auto-inhibition of 
DA synthesis and release. One of such mechanism is that D2S reduces phosphorylation of 
tyrosine hydroxylase (TH), which is an enzyme involved in the synthesis of catecholamine, 
resulting in decrease in dopamine synthesis (Lindgren et al., 2003). A reduced level of 
activated phosphorylated TH was found in D2R1/- mice (with knockout of both D2S and 
D2L isoform) but not in D2L-/- mice. In addition to modulating DA synthesis, D2S 
controls release of DA via regulation through protein-protein interaction for trafficking of 
DAT to the plasma membrane of nerve terminals (Lee et al. 2007). Disruption of D2S and 
DAT interaction leads to increased locomotor activity in mice, a behavior output similar to 
what has been observed in DAT knockout mice. Pharmacological studies have shown that 
a lower concentration of DA receptor agonist is needed for activation of the presynaptic 
D2-class autoreceptors compared to that of postsynaptic D2 receptors (Beaulieu and 
Gainetdinov 2011). For this reason, the same D2 dopamine receptor agonist can induce a 
biphasic effect where low dose can lead to decrease in locomotor activity and high dose 
results in increase in locomotor activity.  
On the other hand, D2L is predominantly expressed on postsynaptic medium spiny 
neurons (MSNs). Activation of D2L inhibits adenylyl cyclase (and thus decrease in cAMP 
level and inhibition of PKA) to decrease DARPP-32 phosphorylation at Thr34 and also 
stimulates calcium-dependent PP2B to further dephosphorylate DARPP-32 (Bateup et al. 
2008). D2L-mediated dephosphorylation is lost in MSNs of both D2L-/- and D2R-/- mice, 
demonstrating the involvement of the D2L isoform in postsynaptic regulation. At the 




D2L involving serine/threonine kinase AKT signaling. In a parallel pathway (in addition 
to PKA inactivation), D2L signaling recruits -arrestin and PP2A to downregulate AKT 
phosphorylation and activity to result in inactivation of GSK3 (threonine/serine kinase 3) 
for regulation of dopaminergic associated behavior (Beaulieu et al. 2005).  
 
Methamphetamine-Induced Hyperlocomotion 
The rapid release of monoamines, mainly DA, from nerve terminals, is the early 
neurochemical event that drives the acute behavioral effects in response to MA, include 
motor stimulation, increased energy, alertness and active waking state (Hassan et al., 2016). 
The psychomotor stimulant theory of addiction states that the common action shared by 
addictive substances is their ability to cause psychomotor activation by stimulating 
dopaminergic fibers and their output projection as discussed in the previous sections (Wise 
and Bozarth, 1987). Behavioral studies involving manipulating DA levels established a 
role for DA in unconditioned behavior, such as locomotor activity (Costall and Naylor, 
1975; Beninger, 1983). The onset of MA-induced locomotor activity correlates with the 
onset of DA efflux in the striatum and nucleus accumbens in the time-dependent manner 
(Figure 2) (Shimosato et al., 2003). Based on this observation, one can hypothesize that 
agents that bind to DAT, VMAT2, or DA receptors to antagonize or partially substitute for 
the effect of MA may be useful for treatment of MA addiction. 
It is important to note that the neurocircuitry and molecular mechanisms underlying 
drug-induced locomotor activity are in part shared with those that mediate the reward and 




1988; Deminiere et al., 1989). Thus, it is reasonable to hypothesize that common, shared 
genetic factors influence locomotor and addiction-relevant traits. In fact, our lab has 
observed such phenomenon with the gene, heterogeneous nuclear ribonucleoprotein 
(Hnrnph1), which we first mapped using forward genetics and validated for MA-induced 
locomotor activity (Yazdani et al., 2015), and we subsequently found plays a role in MA-
induced reward, MA-induced reinforcement, and MA-induced change in extracellular level 











Figure 2. Effect of methamphetamine locomotion activation in mice. 
MA increases locomotor activity (A) that is correlated with increase in DA release in the NAc (B). 
These two plots are replotted from data generated in Shimosato et al. (2003) in which they 
performed a series of experiments to demonstrate that the onset of MA-induced locomotor activity 
correlates with the onset of dopamine release in nucleus accumbens in the time-dependent manner. 
 
Genetic Factors that Drive Acute Drug Action of Addictive Drugs 
Initial response to drugs can predict future use or misuse in both humans and model 
organisms (de Wit and Phillips, 2012), suggesting that understanding the initial actions of 
addictive drugs can yield potential therapeutic interventions in the treatment of addiction. 
Studies in humans and model organism demonstrated that there are individual differences 
in initial, acute responses to drugs of abuse (Deminiere et al., 1989), pointing out that the 
possibility of genetic factors influencing the initial response, and thus impacting 









































vulnerability to future use. For example, genetic variation can be found in a gene that affect 
the rate at which drugs are metabolized which affect one’s sensitivity to the drug effects 
and risk for repeated use. 
The use of longitudinal and laboratory-based studies in human demonstrated that 
subjects experiencing greater positive acute effects chose to consume the drug again when 
given the choice (de Wit and Phillips, 2012).  The use of inbred mouse and rat strains to 
examine individual differences in sensitivity to initial drug effects (via locomotor activity 
assessment) in relation to likelihood of self-administrating drug also provided evidence 
that initial drug responses predict future use, where a greater acute locomotor activation 
was predictive of greater of self-administration (Deminiere et al., 1989; Piazza et al., 1989; 
Shabani et al., 2011). In fact, there are many shared genetic factors that influence initial 
sensitivity and subsequent drug intake (de Wit and Phillips, 2012). 
 
Role of RNA-Binding Proteins in Addiction 
Overview 
RNA-binding proteins (RBPs) contain RNA binding domain and bind to RNAs and 
regulate every aspect of their life cycle including transcription, posttranscriptional editing, 
splicing, export into the cytoplasm, stability, translation, and finally degradation (Glisovic 
et al., 2008). RBPs bind to RNAs to form ribonucleoprotein (RNP) particles that permit 
spatiotemporal localization of the RNAs for translation in the proper location at the 
appropriate time (Tolino et al., 2012). mRNA trafficking and local protein synthesis allows 




mRNAs in neurons relies heavily on RBPs binding to cis-acting elements within the 
mRNAs for transport from cell body to distal axons and dendrites (Schuman, 1999; 
Czaplinski, 2014; Thelen and Kye, 2020). While there is an abundance of evidence 
implicating RBPs neurological diseases including autism, schizophrenia, amyotrophic 
lateral sclerosis, and neurodegeneration (Conlon and Manley, 2017; Zhou et al., 2018; Park 
et al., 2020),  the role of RBPs in neuropsychiatric disorders like the addictions is less 
established. However, given the accumulating evidence that RBPs maintain proper 
synaptic function through regulating neuronal protein homeostasis (Sephton and Yu, 2015; 
Klein et al., 2016; Thelen and Kye, 2020), it is logical to hypothesize that RBPs play a role 
in synaptic plasticity that is important for all stages in the addiction cycle (Bryant and 
Yazdani, 2016), including rapid cellular adaptations induced by acute exposure as well as 
persistent changes in protein expression that mediate synaptic plasticity. Many RBPs 
regulate mRNA trafficking and local protein synthesis in synaptic plasticity (Ule and 
Darnell, 2006; Tolino et al., 2012; Thelen and Kye, 2020). 
Function of RNA-Binding Proteins in Synaptic Plasticity: Implications for Addiction 
Drug-induced synaptic plasticity refers to the neural circuit adaptations and the ability for 
the synapse to modify their synaptic strength following initial  and  repeated drug exposure  
in the establishment of addiction (Luscher and Malenka, 2011; Lüscher, 2013). Excitatory 
synaptic plasticity involves depolarization of neurons for activation of glutamate receptors 
and calcium influx for induction of long-term potentiation (Nestler, 2001). Post-
transcriptional gene regulation by RBPs is necessary for activity-dependent synaptic 




exert diverse actions in the synapse, including alternative splicing to increase transcriptome 
and proteome diversity, and mRNA transport in response to neural activity (Glisovic et al., 
2008; Fu and Ares, 2014), both of which will be explored in this section.  
Transcriptomic studies indicate that the brain exhibits more alternative splicing 
than the other tissues (Yeo et al., 2004; Pan et al., 2008). Emerging evidence indicates an 
interplay between activity-dependent alternative splicing and synaptic plasticity 
(Thalhammer et al., 2020). Exon 19 of NMDA receptor 1 was shown be alternatively 
spliced in response to neuronal activity (Ehlers et al., 1995). The RBP neuro-oncological 
ventral antigen (Nova), acting in concert with heterogeneous ribonucleoprotein A1 and H 
and neuroblastoma apoptosis-related NAPOR represses exon 19 inclusion in the forebrain 
(Zhang et al., 2002; Han et al., 2005; Ule and Darnell, 2006). In addition, the identification 
Nova target RNAs via CLIP-seq (cross-linking immunoprecipitation followed by 
sequencing) revealed an RNA-network that was enriched for the synapse and axon 
guidance, suggesting this RBP to have a role in synaptic physiology (Ule et al., 2005b). 
Interestingly, many of the Nova target RNAs involved in synaptic plasticity exhibit 
alternative splicing patterns in the absence of Nova, suggesting the contribution of 
additional RBPs. Combination of CLIP-seq, other omic approaches, and electrophysiology 
like those employed in the study of Nova will be necessary for understanding the 
complexities of RBP-mediated splicing that regulate synaptic plasticity. 
There are two ways in which temporal and spatial regulation of gene expression 
and protein synthesis are regulated for drug-induced neurotransmission. One, synaptic 




(Doyle and Kiebler, 2011). Second, localized mRNAs and components of the translational 
machinery are present at the dendrites, where local translation can take place on demand 
(Schuman et al., 2006; Fernandez-Moya et al., 2014).  The latter requires the help of RBPs 
to actively transport mRNA transcripts from the cell body to the dendrites. Over the years, 
researchers have identified a handful of RBPs that are termed translational regulators of 
dendritic mRNAs that responds to synaptic activations. The cytoplasmic polyadenylation 
element binding factor (CPEB) is involved in NMDA-dependent long-term potentiation 
(Si et al., 2003; Alarcon et al., 2004). Specifically, CPEB functions to disinhibit translation 
in neuronal synapse to promote translations of mRNAs that  are constitutively repressed 
(Huang et al., 2002). Following NMDAR stimulation in the synaptosome of primary 
neurons, CPEB is activated by the kinase Aurora and phosphorylated by CaMKII for 
dendritic localization and translational activation CaMKII, which in turn activates CPEB 
via phosphorylation, thus establishing a positive feedback loop (Atkins et al., 2005). In 
addition, NMDAR-activated CPEB also play a role in polyadenylation of a set of synaptic 
RNAs (Du and Richter, 2005).  
In contrast, fragile X mental retardation protein (FMRP) mediates translational 
inhibition and plays a role in metabotropic glutamate receptor (mGluR)-dependent long-
term depression (Huber et al., 2002). FMRP  is implicated in an array of neuropsychiatric 
disorders including autism, ADHD, bipolar disorder, schizophrenia as well as the 
addictions (Fernández et al., 2013). inhibition of synthesis of  cytoskeletal regulatory 
proteins (e.g., microtubule associated proteins) is required for proper synapse development 




(gene name for FMRP) mRNA to the dendrites followed by rapid translation of FMRP 
(McBride et al., 2005). Furthermore, there are many examples linking FMRP to 
psychostimulant neuroplasticity. In one example, deletion of FMRP disrupts cocaine-
induced synaptic plasticity by increasing AMPA/NMDA receptor ratio and glutamatergic 
transmission (Smith et al., 2014). In another example demonstrating activity-dependent 
function of FMRP, DRD1 activation in prefrontal cortical neurons phosphorylates FMRP, 
resulting in synthesis of synaptic proteins needed for glutamate receptor trafficking (Wang 
et al., 2008, 2010).  
The three RBPs discussed in this section are involved in activity-dependent 
synaptic plasticity either at the level of alternative splicing that is NMDAR-dependent 
(Nova), or mRNA trafficking and protein synthesis that is NMDAR-dependent (CPEB) or 
mGluR-dependent (FMRP). These examples shed light on the diverse function of RBPs in 
modulating different types of synaptic plasticity in response to neuronal stimulation. 
Following drug administration, these RBPs are required to coordinate splicing and 
translation in the VTA, which can have downstream consequences in neurotransmission in 
the striatum and prefrontal cortex. Besides FMRP playing a role in synaptic plasticity 
associated with psychostimulant addiction behaviors, evidence will be presented that 
another RBP, hnRNP H1, contributes to rapid presynaptic and postsynaptic cellular 
adaptations in response to MA administration that influences subsequent behavioral 




Role of RNA-Binding Proteins in Mitochondrial Function 
The excessive amount of DA within the dopaminergic terminals and synaptic cleft caused 
by MA is oxidized to quinone or semi-quinone to generate reactive oxygen species, H2O2, 
OH-, and O2- (LaVoie and Hastings, 1999; Baumann et al., 2002). The accumulation of 
these reactive oxygen species (ROS) leads to a series of oxidative stress reactions to 
promote organelle damage and protein misfolding and trigger cell death (Limanaqi et al., 
2018). All these events converge to produce neurotoxicity within the DA terminals. The 
mitochondria, which generate energy through oxidative phosphorylation and ATP 
production, represent a major site of MA-induced ROS production in neurons (Dawson 
and Dawson, 2017). Multiple studies demonstrated that inhibition of the electron transport 
chain (ETC) and promotion of oxidative stress by MA can lead to mitochondrial 
dysfunction (Annepu and Ravindranath, 2000; Beer et al., 2004; Shin et al., 2017). 
Specifically, DA oxidation-generated ROS inhibit complexes I, II, III, IV and V of the ETC 
to lead to imbalance of oxidation and energy production (Burrows et al., 2000). The 
changes in mitochondrial enzymes in response to MA have been heavily investigated in 
recent years. Studies have found inhibition of striatal complex I activity after acute 
exposure to MA (Annepu and Ravindranath, 2000; Beer et al., 2004) and a decrease in 
striatal complex II activity with no change in complex I in response to rapid binge exposure 
to MA (Brown et al., 2005). MA treatment in vitro led to reduction in mitochondrial 
complex IV proteins in a time-dependent manner (Wu et al., 2007). All these studies shed 




in turn promotes presynaptic toxicity in nerve terminals and impact synaptic ATP 
production needed for vesicle fusion, neurotransmitter release and recycling. 
Mitochondria are abundant at the axons and dendrites and generate ATP for 
calcium buffering, vesicle release and recycling (Vos et al., 2010; Devine and Kittler, 2018). 
In addition, mitochondria are also present to synthesize ATP and regulate calcium needed 
for synaptic transmission and plasticity (Harris et al., 2012; Todorova and Blokland, 2017). 
Thus, maintaining mitochondrial function so that the mitochondria can respond to changes 
in synaptic activity requires coordinated regulation of the mitochondrial gene and protein 
expression (Schatton and Rugarli, 2018). Recent studies have identified a set of RBPs that 
regulate expression of mRNAs coding for mitochondrial proteins (a subset of these RBPs 
are highlighted in Table 1). RBPs transport mitochondrial RNAs from the nucleus 
(nuclear-coded mRNAs) to the mitochondria for organelle-coupled translation (Williams 
et al., 2014). In this way, RBPs chaperone these nuclear coded mRNAs toward the outer 
membranes of the mitochondria and recruit translation activators to initiate translation 
followed by transport into the mitochondrial for complex assembly (Béthune et al., 2019; 
Rossoll and Bassell, 2019).  
The coordinated regulation of mitochondrial function by RBPs suggests that 
experimental targeting of these RBPs can modulate mitochondria to influence 
neurotransmission in response to drugs of abuse. Multi-omics approaches can be used to 
identify the consequences of dysfunction on the basal and drug-induced transcriptome and 
proteome of mitochondrial proteins and thus inform which RBPs may be important for 




Table 1. Examples of RBPs regulating mRNAs encoding mitochondrial proteins.  
The content of this table is selected from (Schatton and Rugarli, 2018) to highlight the 
RBPs binding to different regions within their target RNA and biological effect on binding. 
RBP 
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Heterogenous Nuclear Ribonucleoprotein H1 
Overview 
The class of heterogeneous nuclear ribonucleoproteins (hnRNPs) is  comprises 20 hnRNPs 
labeled from A through U (Dreyfuss et al., 1993) that possess multi-functional roles in 
RNA biogenesis and metabolism, ranging from transcription, splicing, and mRNA stability 
in the nucleus (Arhin et al., 2002; Han et al., 2010) and translation and degradation in the 
cytoplasm (Han et al., 2010; Uren et al., 2016). The use of fine-scale gene mapping with 
interval-specific congenic mouse lines identified Hnrnph1, (gene-coding for 
heterogeneous nuclear ribonucleoprotein H1 or hnRNP H1), as the quantitative trait gene 
(QTG) for sensitivity to MA-induced locomotor activity (Yazdani et al., 2015). Mice with 
a heterozygous deletion in the first coding exon of this gene showed reduced MA-induced 
behavioral responding and DA release (Ruan et al., 2020a). This mutation resulted in a 
two-fold increase in hnRNP H protein level in the synaptosome and an enrichment of 
proteins  indicative of mitochondrial dysfunction (Ruan et al., 2020a). Besides hnRNP H1, 
genetic mutations in other genes encoding for RBPs including FMRP (Li et al., 2020), 
PTBP1 (Spellman and Smith, 2006), EFTUD2 (Lines et al., 2012), and SF3B4 (Bernier et 
al., 2012), have been implicated in neuropsychiatric disorders including the addictions, 
especially FRMP (Smith et al., 2014)  as previously discussed. hnRNP H1 shares a 96% 
protein sequence homology with hnRNP H2 (Honoré et al., 1995) and there are no 
antibodies that have been demonstrated to distinguish between the two gene paralogs. 
Because hnRNP H1 and hnRNP H2 cannot be differentiated at the protein level, I will 




Structural Domains of hnRNP H1 
hnRNP H1 contains three quasi-RNA recognition motifs (qRRMs) as RNA binding 
domains and two glycine-rich (GY and GYR) domains as illustrated in Figure 3 
(Dominguez and Allain, 2006; Van Dusen et al., 2010). While qRRM3 conforms to a 
canonical -sheet structure, qRRM1 and qRRM2 are more structurally distinct and come 
together to form a more exposed RNA-binding surface that will allow the RBP to interact 
with the highly stable G-rich secondary structure within target RNAs (Dominguez and 
Allain, 2006).  Deletion of the three qRRMs from Hnrnph1 (a splice variant of the 
paralogue Hnrnph3) produces a truncated protein that cannot participate in RNA 
metabolism (Honoré, 2000), indicating the RNA binding property of hnRNP H1 is 
conferred by the qRRMs.  
The two glycine-rich domains in hnRNP H1 are known to mediate protein 
interactions with other proteins, including other RBPs, to form multi-protein complexes 
needed for transcriptional and post-transcriptional (Van Dusen et al., 2010).  The central 
GYR domain contains a nuclear localization signal (NLS) that allows hnRNP H1 to shuttle 
protein between the nucleus and cytoplasm. Van Dusen et al. (2010) discovered that the 
NLS within hnRNP H1 interacts with the import receptor Trn1 which facilitates the 
movement between the nucleus and cytoplasm. While hnRNP H1 is mainly nuclear 
restricted, activity-dependent translocation of hnRNP H1, e.g., in response to stress, can 
induce translocation of hnRNP H to the cytoplasm (Wall et al., 2020). These observations 






Figure 3. Domains and post translation modifications of hnRNP H1.  
hnRNP H1 contains three RNA recognition domains, including RRM1, RRM2, and RRM3, which 
interact with RNAs during post-transcriptional regulation. The GYR and GY domains interact with 
other RBPs or proteins to form these multiprotein complexes. The NLS within the GYR domain 
allows hnRNP H1 to shuttle between the nucleus and cytoplasm. hnRNP H1 can be post-
translationally modified at the level of phosphorylation and methylation. The signaling events that 
mediate this change are not well characterized.  
 
 
Function of hnRNP H1 in the Central Nervous System and the Addictions 
Whole exome sequencing identified variants in HNRNPH2 on the X chromosome that 
were associated with Bain type intellectual disability in a cohort of six females from 
independent families with neurodevelopmental disability (Bain et al., 2016). It is 
particularly interesting that variants are found within the NLS of HNRNPH2, in particular, 
the Arg206Trp mutation was found in four of the six subjects. Subsequently, in 2018 and 
2020, two groups found the same pathogenic variant, Arg206Trp within HNRNPH1 in 
patients showing Bain type syndromic neurodevelopmental disorder with a syndrome 
comprising developmental delay, intellectual disability, autism, hypotonia, and seizures 
(Pilch et al., 2018; Reichert et al., 2020). Breeding data from our lab indicated homozygous 
deletion of Hnrnph1 is embryonic lethal. These observations implicate a role of hnRNP H1 




of mRNAs coding for proteins needed during development such as neuronal differentiation. 
Interestingly, transcriptome analysis found Hnrnph1 to be downregulated during early 
stages of the oligodendrocyte differentiation process (Swiss et al., 2011; Wang et al., 2012). 
While human genome-wide association studies have not identified Hnrnph1 to be 
associated with the addictions, hnRNP H1 post-transcriptionally regulates genes involved 
in the addictions, including Oprm1 (gene encoding for the mu opioid receptor or MOR) 
(Song et al., 2012; Xu et al., 2014) and glutamate NMDAR1 receptor (Han et al., 2005). 
The single-nucleotide polymorphism (SNP) (rs9479757) within the intron of the OPRM1 
gene was found in group of heroin addicts with the AG phenotype to be associated with 
mild addiction and the GG phenotype to be associated with more severe addiction (Xu et 
al., 2014). hnRNP H was found to bind to this G-containing SNP site to promote alternative 
splicing of nearby exon. Specifically, the G-to-A transition weakened the binding of 
hnRNP H, resulting in exon 2 skipping and increased expression of MOR protein (Xu et 
al., 2014). Identification of post-transcriptional regulators that bind to the 5’UTR of 
OPRM1 via mass spectrometry detected the presence of hnRNP H1 and F (Song et al., 
2012). Follow-up validation studies indicated that hnRNP H1 and F repress MOR 
translation though binding to the 5’UTR in a sequence-specific manner (Song et al., 2012). 
The studies from these two research groups provide evidence for the multi-functional roles 





Activity-Dependent Function of hnRNP H1 
hnRNPs are highly  dynamic and respond to cellular cues and stimuli by changing RNA 
binding, subcellular localization, and protein interactions (Szostak and Gebauer, 2013; 
Hentze et al., 2018). hnRNPs  can shuttle between the nucleus and cytoplasm and exert 
different regulatory effects on RNAs between the two compartments to support efficient 
recovery from cellular stress (Guil et al., 2006; Fukuda et al., 2009; Backlund et al., 2020). 
hnRNPs such as hnRNP A1  can associate with other RBPs in stress granules to sequester 
mRNAs in response to stress (Guil et al., 2006) and K (Fukuda et al., 2009). Stress granules 
are membrane-less organelles that are transiently formed to harbor translationally arrested 
mRNAs that might have accumulated in the cytoplasm in response to acute stress (Reineke 
and Neilson, 2019). The formation and decomposition of these stress granules are highly 
dynamic and complex, requiring over 100 RBPs (Aulas and Velde, 2015). Chronic stresses 
cause persistent formation of these stress granules, resulting in protein aggregations found 
in the pathophysiology of neurodegenerative diseases (Aulas and Velde, 2015; Wolozin 
and Ivanov, 2019). A recent study demonstrated that hnRNP H accumulates in the 
cytoplasm and localizes to the stress granules via its RRM3 domain in response to stress 
(Wall et al., 2020). Proteomic characterization of the stress granule composition also 
identified hnRNP H as a component of the stress granules, similar to hnRNP A1 and K 
(Markmiller et al., 2018). The association of hnRNP H with stress granule formation 





Our lab previously associated DRD1 activation with an increase in 
immunocytochemical staining  but no change in protein level of hnRNP H in response to 
DRD1 agonist in primary rat cortical neurons, suggesting that potential post-translational 
modifications of hnRNP H and/or its association with other proteins or target RNAs could 
underlie this aberrant, DRD1-mediate change in hnRNP H staining  (Ruan et al., 2018). 
Proteomic analyses to detect post-translational modifications in hnRNP H identified 
numerous phosphorylation residues and an arginine methylation site located downstream 
of the NLS (Figure 3) (Kim et al., 2002, 2014a). Activation of proteins for post-
translational modification of hnRNP H (e.g., via kinase signaling cascades) can influence 
functional localization, RNA binding, and protein interactions. 
 
Global Methods for Studying RNA-Binding Protein Interaction Networks 
Overview 
The transcriptional and post-transcriptional regulation of gene expression by RBPs are 
important for many biological processes. Characterizing RNA-binding preference of RBPs 
by assessing their target RNAs and binding site selection can reveal insights into their 
biological functions. UV-mediated crosslinking of protein-RNA complexes in biological 
samples is the most widely accepted strategy for genome-wide profiling and mapping of 
RBP-RNA interactions both in vitro and in vivo (Li et al., 2014; Nechay and Kleiner, 2020). 
Various variations of this prototypical method have been developed to improve the 
sensitivity, resolution, and efficiency (Lee and Ule, 2018; Sternburg and Karginov, 2020; 




continually updated to aid in the processing and analyzing the experimental data for 
binding site and binding target  (Wang et al., 2015; Bottini et al., 2017; Uhl et al., 2017) 
Crosslinking Immunoprecipitation Combined with RNA-Sequencing 
Crosslinking immunoprecipitation followed by RNA sequencing (CLIP-seq) was first 
reported and performed by Dr. Robert Darnell’s group to generate an RNA-binding map 
for Nova in the mouse brain (Licatalosi et al., 2008). This method provides a robust and 
unbiased means to identify functional protein-RNA interactions and define binding sites at 
single nucleotide resolution (Van Nostrand et al., 2016).  In CLIP-seq, the use of UV 
irradiation at 254 nm activates the photo reactivity of nucleic acids to crosslink to protein 
and permits the capture of RBP-RNA complexes and defining the position of binding sites 
(Ule et al., 2005a). CLIP-seq can be applied to any type of samples, even post-mortem 
human tissue (Lee and Ule, 2018).  
The following steps I will be describing are summarized from the Lee and Ule’s 
(2018) review, which provides a comprehensive overview of core CLIP-seq steps. The next 
step following UV crosslinking includes cell lysis for purification of total cell and 
fractionated cells, which capture RBP-protein interactions in a cellular sub-compartmental 
manner (Sanford et al., 2008).  Following this step is RNA fragmentation via limited RNase 
digestion, typically RNase I that cleaves nucleotides at random positions to minimize 
sequence bias of RNA fragmentation and produce RNA fragments of appropriate size for 
next-generation sequencing (Haberman et al., 2017) . The portion of RNA that is bound by 
the RBP is protected from RNase digestion. The following step is to capture the RBP-RNA 




the crosslinked RBP-protein contacts. Unlike RNA-immunoprecipitation followed by 
sequencing (RIP-seq), which does not require crosslinking and RNase and only identifies 
RNAs enriched in the IP, CLIP-seq can also detect the precise position of the binding sites, 
which is defined by the crosslinking site. The captured RBP-RNA complex is subjected to 
SDS-PAGE, membrane transfer, digestion of the RBP, and followed by RNA extraction to 
release the bound RNAs. Finally, sequencing adaptors are ligated to the extracted RNAs 
for next-generation sequencing. Each of these steps described here is subjected to 
optimization and variation to more accurately identify the mRNA transcripts interacting 
with RBPs in vivo. 
Two parameters in CLIP-seq data need to be examined computationally, including 
sensitivity and selectivity (Chakrabarti et al., 2017). First, sensitivity refers to the number 
of unique cDNAs in the sequencing library (Chakrabarti et al., 2017). Duplicated cDNAs 
as a result of PCR amplification step can be identified using unique molecular identifiers 
(UMIs) in the cDNA during library preparation (Smith et al., 2017). Second, specificity 
refers to the identification of significant crosslinking events or peaks (Chakrabarti et al., 
2017). Peak calling is an essential step in CLIP-seq analysis and determines the specific 
signal over background noise (Bottini et al., 2017). There are a number of publicly 
available peak calling programs that use different statistical models. The selection of a 
suitable peak calling program depends on the CLIP protocol used to produce the dataset 
(Chakrabarti et al., 2017) and might require literature search to compare the utility of the 
available peak calling programs. If possible, the addition of a control condition such as 




After a list of significant peaks are identified, the next step is to characterize the 
RBP-RNA interactions by closer examination of the peaks. The regulatory role of the RBP 
on transcription and post-transcription regulated can be evaluated by quantifying the 
distribution of the peaks across mRNA subregions, including the 5’UTR, 3’UTR, intron, 
and coding sequence (CDS). The signatures of the peak-associated binding sequences 
signatures can be detected via de novo motif discovery programs such as MEME (Bailey 
et al., 2009) and Homer (Heinz et al., 2010). The output from these programs includes a 
list of sequence enriched in the CLIP peaks from the peak calling program. To gain insight 
into the molecular and biological functions of the RBP, target RNAs that are associated 
with the peaks are subjected to pathway and gene ontology (GO) enrichment analysis to 
determine whether the RBP regulates a subset of targets with a particular biological 
relevance. By coupling CLIP-seq datasets with other omic datasets including transcript 
expression, alternative splicing, and protein expression profile, the functional impact of the 
RBP on the target RNAs can be assessed. A multi-omics approach can also narrow down 
the RBP-RNA interactions that warrant validation and testing for functional relevance, e.g., 
at the cellular or behavioral level. 
Besides performing genome-wide functional validation at the genome-wide scale 
like with RNA-seq and/or mass spectrometry, CLIP-seq experiments can be validated by 
candidate approach, which involving picking only the most significant targets or a set of 
targets that are enriched for a relevant biological pathway or function (Thomson et al., 
2011). The type of validation experiments can be performed at the level of physical 




mRNA transcript of interest can be validated using in vitro electrophoretic mobility shift 
assays, which involve the incubation of a candidate RBP with a radiatively labeled 32-P 
RNA fragment containing the binding site identified through CLIP-seq followed by 
electrophoresis using a polyacrylamide gel to observe a shift if the RBP binds to the RNA 
fragment (Fillebeen et al., 2014). For in vivo method of validation in cell or tissue, RNA-
immunoprecipitation with an RBP-specific antibody followed by a northern blot or qPCR 
can be used to verify whether the RBP “pulls down” or associates with the mRNA 
transcripts of interest (Gagliardi and Matarazzo, 2016). In terms of functional validation, 
knockdown/knockout or overexpression of the RBP followed by quantification of gene 
expression, mRNA stability, or splicing of the target RNAs can be performed to 
characterize the impact of RBP-RNA interaction(s) on transcription and post-transcription 
regulation of the target RNAs (Bottini et al., 2017). The type of validation study that is 
chosen often depends on the experimental questions that researchers are trying to answer. 
Incorporation of Transcriptome-Wide Profiling by RNA-seq 
With the advances in CLIP-seq technologies, the detection of binding peaks for a given 
RBP have become quite precise and sensitive and can detect thousands of binding events. 
Given that interactions between an RBP to an mRNA transcript can be transient, how do 
we parse out those RBP binding peaks that have functional relevance from those that do 
not? The coupling of transcriptome profiling by RNA-seq with CLIP-seq would allow us 
to provide one proximal level of functional consequence. A R-based program recently 
developed by the Keleş Lab (Chen and Keleş, 2020), called SURF,  permits integrative 




regulation events followed by the association of the these events to the CLIP peaks 
associated with the RBP. The incorporation of transcript information also allows permits 
normalization of CLIP peaks so that there is no bias toward those transcripts that are more 
highly expressed in the cells (Ule et al., 2005a). In summary, incorporating RNA-seq with 
the CLIP-seq analysis pipeline streamlines the follow-up validation procedure and 
facilitates verification of differential transcription and e.g., differential exon usage 
indicative of splicing.  
Other Methods 
CLIP-seq relies on crosslinking and immunoprecipitation to identify RNA interactions 
with a given RBP, and both of these procedures have limitations. Antibodies for the 
endogenous or epitope-tagged protein for immunoprecipitation might not always be 
available or feasible. UV-crosslinking is often insufficient to capture all RBP-RNA 
interactions and sometimes captures transient interactions that are not biologically 
meaningful (Riley and Steitz, 2013). The RBP binding events identified through CLIP-seq 
are “averaged” across a heterogenous population of cells, meaning that CLIP-seq fails to 
account for differences in transcriptional and post-transcriptional states between tissues 
and cell types (Lin and Miles, 2019). Cell type-specific profiling of the RBP-RNA 
interactome can be achieved through conditionally tagged (cTag) CLIP technology, which 
involves knocking in an extra copy of the RBP’s last coding exon fused with GFP sequence 
downstream of the last coding exon that is flanked by loxP sites (Figure 4) (Hwang et al., 
2017; Ule et al., 2018). In this way, when crossed with a cell type specific Cre driver line, 




type specific tagging of the RBP for CLIP experiments with a GFP antibody. This 
technique is highly useful when there is no specific antibody for the RBP.  
 
Figure 4. Schematics for cTag-CLIP.  
The latent GFP-tagged RBP contains an extra copy of the last exon fused with GFP and loxP sites 
flanking the endogenous last exon. Cell type specific Cre-mediated excision of the endogenous last 
exon results in the expression of the GFP-tagged RBP. The GFP tagged to the last exon of the RBP 
can be used to identify and isolate RBP in a cell-type specific manner when used with Cre driver 
mouse line or even promoter-specific AAV-Cre viral vector. The diagram is  adapted from Ule et 
al., 2018. 
 
There are other techniques for profiling RBP-RNA interactions that do not require 
crosslinking and immunoprecipitation. TRIBE (targets of RNA-binding protein identified 
by editing) has been developed, which entails the fusion of an RBP to the catalytic domain 
of an RNA-editing enzyme that converts adenosine to inosine (McMahon et al., 2016).  
RNA-seq is then performed to identify transcripts with edited sites as RNA targets 
(McMahon et al., 2016). The RBP binding sites are defined by the location of the 
adenosine-to-inosine converted sites along the mRNA transcripts. In this way, no antibody 




capturing of RNA targets by restricting the expression of the fusion protein to a particular 
cell type. Another technique, called RNA-tagging, utilizes a very similar strategy as TRIBE, 
in that a poly-U polymerase (which adds U nucleotides to the 3’ end of RNAs) is fused to 
the RBP and is capable of adding U nucleotides to the 3’ end the mRNA transcripts  which 
recruits binding of the RBP (Lapointe et al., 2015). The binding sites are defined by the 
covalent marks left on the RNA by the RBP, and RNA targets are defined by the U-tagged 
mRNA transcripts. The strength of RNA-tagging compared to CLIP-seq is the ability to 
parse out transient and non-productive binding events because the time the RBP is bound 
to the RNA is reflected by the number of U’s added by poly-U polymerase. 
The major downside to these alternative techniques is the need for gene editing of 
the RBP which could disrupt its endogenous function and its interactions with target RNAs. 
With this said, the versatility and advantages offered by cTAG-CLIP, TRIBE, and RNA 
Tagging as well as other similar techniques should be considered when deciding on 
experimental technique used to study RBP binding targets.  
 
RNA Binding Targets of Heterogenous Nuclear Ribonucleoprotein H1 
Overview 
Alternative splicing is the process by which exons or introns are differentially 
included/excluded to produce distinct mRNAs from the same pre-mRNAs to increase 
protein diversity (Martinez-Contreras et al., 2007). It was established very early on that the 
hnRNP class of RBPs bind in sequence-specific manner onto mRNAs to define and control 




can be gleaned from studying hnRNP proteins splicing function over the years that also 
apply to hnRNP H1. First, binding of hnRNP to an exon often blocks splicing by preventing 
the binding of spliceosome components, resulting  in exon retention (Martinez-Contreras 
et al., 2007). Interestingly, the bound hnRNP can also propagate along an mRNA to 
occlude binding of spliceosome components to bind to inhibit splicing of adjacent sites 
(Zhu et al., 2001). Second, binding of hnRNP to an intron often inhibits intron splicing by 
blocking functional interaction between splicing factors, resulting in intron retention 
(Spellman and Smith, 2006). Third, cooperative interactions of multiple bound hnRNP 
proteins loop out portions of mRNAs to promote exon skipping when bound to exon or 
stimulate intron exclusion (Martinez-Contreras et al., 2006). Genome-wide analysis  
following hnRNP H  knockdown in cell lines indicated a large number of alternative 
splicing events to be influenced by hnRNP H (Katz et al., 2010; Huelga et al., 2012; Wang 
et al., 2012; Uren et al., 2016). In this section, I will describe a few notable neural splicing 
targets of hnRNP H that have been reported in the literature to highlight the different 
splicing strategies employed by hnRNP H. 
Non-Receptor Tyrosine Kinase c-Src 
c-Src is highly expressed in neural cells and is important for controlling neural 
development and function (Yagi, 1994). Analysis of c-Src splicing indicated inclusion of 
the N1 exon in neurons, and such an exon exclusion event requires an intronic splicing 
enhancer sequence downstream of the N1 exon (Black, 1992). UV crosslinking-linking  
combined with gel mobility assay identified several proteins that bind to the intronic 




(Min et al., 1995, 1997; Chou et al., 1999).  Furthermore, immunoprecipitation with an 
anti-hnRNP H antibody  demonstrated binding of hnRNP H to the c-Src mRNA after the 
assembly of spliceosome (Chou et al., 1999). Closer examination of the sequence 
composition around the intronic enhancer sequence of c-Src indicated G-rich elements that 
have been proposed to promote tight binding of hnRNP H (Matunis et al., 1994). In 
considering the splicing strategies of hnRNP proteins, the association of hnRNP H with 
other proteins nearby c-Src exon 1 supports the looping-out model of splicing for exon 
skipping. 
Acetylcholinesterase Isoforms 
The enzyme acetylcholinesterase hydrolyzes and clears the neurotransmitter, acetylcholine, 
from synaptic cleft to terminate synaptic transmission (Soreq and Seidman, 2001). The 3’ 
end of acetylcholinesterase pre-mRNA undergoes alternative splicing to different isoforms 
containing different C-terminal ends, with each isoform showing tissue-specific expression 
(Massoulié et al., 1998). hnRNP H  contributes to splicing of the particular 
acetylcholinesterase isoform that is predominately expressed in neurons (Nazim et al., 
2016). There are two polyadenylation sites (proximal and distal) within the exon that 
undergoes alternative splicing that can signal the start of polyadenylation and two 3’ splice 
sites (proximal and distal) (Massoulié et al., 1998). hnRNP H binds to the G-runs upstream 
of the distal 3’ splice site and activates this site to generate the splice isoform that contains 
the distal polyadenylation site. Tissue-specific splicing of acetylcholinesterase relies on the 
competitive regulation of hnRNP H and another protein CstF64 (Nazim et al., 2016). In 




activates the proximal polyadenylation site upstream of hnRNP H binding site to generate 
non-neuronal specific isoforms of acetylcholinesterase. This example indicates that hnRNP 
H binding near 3’ end of genes can determine both the splice site and the polyadenylation 
site. 
NMDA R1 receptor  
Exon 19 of the NMDA R1 receptor mRNA transcript is an example of neuron-region-
specific exon that is alternatively spliced by hnRNP H (Han et al., 2005). This exon is 
included in the forebrain and skipped in the hindbrain (Wang and Grabowski, 1996; Zhang 
et al., 2002). NMDA R1 receptor plays an important role in impacting drug-induced 
synaptic plasticity and exon 19 inclusion promotes the trafficking of NMDA R1 receptors 
to the synapse (Ehlers et al., 1995; Mu et al., 2003). The control mechanisms underlying 
exon 19 inclusion versus exclusion are determined by the motif pattern surrounding or 
within this exon (Han et al., 2005). The presence of two exonic UAGG motifs and one 
intronic GGGG motif proximal to the 5’ splice site promotes binding of hnRNP A1 to the 
UAGG motif (for exon skipping) and hnRNP H to the GGGG motif (for exon inclusion), 
where binding of one RBP disrupts the binding of the other to produce different isoforms 
(Han et al., 2005) . This competitive binding of hnRNP A1 and H at the 5’ splice site of 
exon 19 of the NMDA R1 receptor mRNA transcript determines the type of isoform that 




Proteolipid Protein (PLP) and Telomere Repeat-Binding Factor (Trf2) 
hnRNP H has been shown to regulate mRNA transcripts coding for genes necessary for 
neuronal cells differentiation and neuron development (Wang et al., 2007; Grammatikakis 
et al., 2016b). The PLP/DM20 ratio (both of which are myelin proteins) regulates 
oligodendrocyte differentiation process and brain development (Hobson et al., 2006; Wang 
et al., 2006). Differentiated oligodendrocytes contain a higher level of PLP whereas 
oligodendrocyte progenitor cells have a higher level of DM20, which is an isoform of PLP 
containing a truncated exon 3 of PLP (Gudz et al., 2002), suggesting that the alternative 
splicing of these two myelin proteins to be tightly controlled. Wang et al. (2007) showed 
that hnRNP H and F synergistically and selectively bind to the G-rich 5’ splice site in exon 
3 of PLP to promote alternative splicing and generate DM20. More specifically, knocking 
down hnRNP H and F increased in the PLP/DM20 ratio, demonstrating a decrease in 
hnRNP H and F expression might be necessary for the initiation of oligodendrocyte 
differentiation. Another group of researchers also found that hnRNP H plays an inhibitory 
role in neuronal cell differentiation and regulates the alternative splicing of exon 8 of the 
neuronal differentiation factor, TRF2 (Grammatikakis et al., 2016b). There are two 
isoforms of TRF2 mRNA transcripts: TRF2-S (truncated exon 7) and TRF2-L (full length 
exon 7), where TRF2-S promotes transcription of neural genes in neurogenesis and TRF2-
L inhibits their expression and is expressed at high level in undifferentiated neurons 
(Grammatikakis et al., 2016a). In fact, the alternative splicing mechanism of TRF2 exon 7 
by hnRNP H is similar to that of PLP and exon 3, where hnRNP H binds to the 5’ splice 




The main conclusions that can be drawn from the review of different splicing events 
mediated by hnRNP H include: 1) the presence of G-rich motif near the splice site can 
enhance binding of hnRNP H; 2) cell-specific, brain-region-specific and/or time-specific 
expression of hnRNP H drive the expression of different mRNA isoforms; 3) hnRNP H 
shows both competing and cooperative association with other hnRNP proteins to regulate 
splicing, as demonstrated by interaction with hnRNP F and A1 in the above examples. 
 
Genome-Wide Characterization of hnRNP H RNA-interactome 
Overview 
hnRNP H proteins contribute to multiple aspect of RNA metabolism. Dissecting this multi-
functional aspect of its functions and identifying its diverse range of RNA-binding targets 
require high-throughput analyses combining RNA-seq, RIP-seq, CLIP-seq, and proteomics.  
These omics analyses can yield new insight into the hnRNP H RNA-binding interactome 
and its role in splicing, gene expression, mRNA stability, and translation. In this section, I 
will provide a detailed description and summary of each approach.  
Knockdown of hnRNP H on Splicing and Gene Expression 
In the first genome-wide analysis of splicing events and gene expression regulated by 
hnRNP H in oligodendrocyte progenitor cells, Wang et al. (2012) performed gene- and 
exon-level transcriptome analysis to examine splicing events and gene expression in 
oligodendrocytes treated with siRNA to knock down expression of hnRNP H compared to 




Out of those exons that showed alternative splicing, 67% of them contained nearby G tracts. 
The density, length, and proximity of the G tracts to the 5’ splice spice correlated with the 
splicing enhancer function of hnRNP H. Knocking down of hnRNP H resulted in 
differentially expressed genes that are involved in the transition from oligodendrocyte 
progenitor cells to oligodendrocyte, possibly through interacting with G runs in the 3’UTR 
of the mRNAs by affecting message stability (Wang et al., 2012). In summary, this study 
implicated the role of hnRNP H on splicing and gene expression in oligodendrocyte. 
Cooperative Interaction of hnRNP H with other RNA Binding Proteins 
In another high-throughput study, splicing-sensitive microarrays, CLIP-seq, and RNA-seq 
were used to understand the mechanisms of how six major hnRNP proteins (Al, A2/B1,  F, 
H1, M, and U) coordinate alternative splicing in human cells (Huelga et al., 2012). In their 
analysis, hnRNP H was found to bind both flanking intronic and exonic regions that were 
alternatively spliced. The sequence motifs for hnRNP H were most enriched for G-rich 
sequences.  A fundamental finding from this study was these hnRNP proteins cooperate 
with each other to regulate alternative splicing events. 
Impact of hnRNP H Binding on Gene Expression, Splicing, and Protein Expression 
The most extensive high-throughput analyses for understanding hnRNP H1 function was 
conducted by Uren et al. (2016) in HeLA cells, where they identified 1086 target transcripts 
associated with hnRNP H using RIP-seq and CLIP-seq and assessed the impact of hnRNP 
H binding on gene expression and splicing on those targets using RNA-seq and protein 




prevalent component of hnRNP H binding motif. There was a strong enrichment of hnRNP 
H1 targets for spliceosome-associated genes, supporting hnRNP H as having a major role 
in the regulation of splicing. In addition, the data also supported hnRNP H regulation of 
mRNA decay (as corroborated by RNA decay assay) and polyadenylation (length of 
3’UTR was altered as a result of hnRNP H knockdown).  
To date, genome-wide characterization of hnRNP H1 RNA-interactome has only 
been performed in cell lines and not in CNS tissue. Given the ubiquitous expression of 
hnRNP H1 in the brain and brain-region specific as well as cell type specific alternative 
splicing of neural genes by hnRNP H1 previously discussed, in vivo CLIP-seq analyses in 
specific brain regions and cell types are necessary for understanding the multi-functional 
roles of hnRNP H1 in transcriptional and post-transcriptional regulation of gene expression. 
 
Dissertation Research Specific Aims 
The genetic factors underlying risk for psychostimulant addiction remain largely unknown. 
Our lab mapped and validated Hnrnph1 as a QTG for reduced MA stimulant sensitivity. 
Mice heterozygous for a 16 bp deletion in the first coding exon of Hnrnph1 also showed 
reduced MA-induced reward and reinforcement, and a decrease in MA-induced DA release. 
The combined results indicate reduced addiction liability in H1 MUT mice.  Thus, 
understanding the cellular and molecular mechanisms underlying reduced MA addiction 
liability in Hnrnph1 mutants could provide novel insight into strategies for 
psychostimulant addiction treatments as well as stimulant therapeutics.  hnRNP H1 is an 




The objective of my dissertation research is to understand the mechanism of hnRNP H1 
dysfunction in MA-induced DA release and behavior through multi-omics data integration 
including proteome, transcriptome, and hnRNP H1 RNA-interactome. These are my 
specific aims: 
Aim 1: Identify the functional variants within the 5’UTR region of Hnrnph1 underlying 
reduced sensitivity to psychostimulant effect of methamphetamine. 
Aim 2: Identify the striatal synaptosome proteome associated with decreased 
methamphetamine behavior and increased synaptic hnRNP H in Hnrnph1 mutant versus 
wild-type mice. 
Aim 3: Evaluate the effect of methamphetamine on hnRNP H RNA-binding targets and 





CHAPTER II: 5’UTR variants in Hnrnph1 support reduced 5’ UTR usage and 
hnRNP H protein for reduced methamphetamine sensitivity 
Adapted from Ruan et al., 2020, The FASEB Journal 
ABSTRACT 
We previously identified a 210 kb region on chromosome 11 (50.37-50.58 Mb, mm10) 
containing two protein-coding genes (Hnrnph1, Rufy1) that was necessary for reduced 
MA-induced locomotor activity in C57BL/6J congenic mice harboring DBA/2J 
polymorphisms. We have since shown that Hnrnph1 mutants also exhibit reduced MA-
induced reward, reinforcement, and DA release. However, the quantitative trait variants 
that modulate Hnrnph1 function at the molecular level are not known. Nine single 
nucleotide polymorphisms and seven indels distinguish C57BL/6J from DBA/2J within 
Hnrnph1, including four variants within the 5’ untranslated region. Gene-level 
transcriptome analysis of striatal tissue from 114 kb congenics versus Hnrnph1 mutants 
identified a nearly perfect correlation of fold-change in expression for those differentially 
expressed genes that were common to both mouse lines, indicating functionally similar 
effects on the transcriptome and behavior. Exon-level analysis (including noncoding exons) 
revealed decreased 5’UTR usage of Hnrnph1 and immunoblot analysis identified a 
corresponding decrease in hnRNP H protein in 114 kb congenic mice. Molecular cloning 
of the Hnrnph1 5’UTR containing all four variants (but none of them individually) 
upstream of a reporter induced a decrease in reporter signal in both HEK293 and N2a cells, 





Psychostimulant use disorders (PUDs), including MA and cocaine dependence, are a 
serious public health concern in the United States. While the opioid epidemic crisis 
continues to garner warranted attention, there has been much less focus on the recent steep 
surge in PUDs as evidenced by the steep increase in PUD-related deaths, especially MA-
related deaths (Fogger, 2019). This public health concern is particularly problematic, given 
that there are no FDA-approved treatments for PUDs. Both genetic and environmental 
factors contribute to PUDs (Pierce et al., 2018), yet genome-wide association studies to 
date have identified very few genetic factors (Jensen, 2016). One notable example was the 
identification of a genome-wide association between FAM53B and cocaine dependence in 
humans (Gelernter et al., 2014). This finding was particularly interesting in the context of 
a mouse forward genetic study of psychostimulant addiction traits that identified a trans-
expression quantitative trait locus (QTL) originating from a locus containing Cyfip2 and 
Hnrnph1 that influenced Fam53b expression and was associated with cocaine intravenous 
self-administration (Dickson et al., 2015). This is one of the first examples demonstrating 
a direct correspondence between genome-wide genetic association, functional changes in 
gene expression, and trait-relevant behaviors (cocaine self-administration) between rodents 
and humans. Thus, this example highlights the power and translational relevance of 
systems genetics in mice in the study of substance use disorder (SUD)-relevant traits.   
There are several advantages to using rodent forward genetics in studying the 
genetic basis of molecular and behavioral traits relevant to SUDs, including the ability to 




drug exposure, the sample size, the collection of the appropriate tissue at the appropriate 
time points, and the ability to both map and validate causal functional variants in vivo 
within the same animal species. While there are clear limitations to modeling the genetic 
basis of psychiatric disease traits in rodents, it is important to point out studies in which 
there have been promising successes. In addition to the translational link of Fam53b with 
cocaine addiction traits in mice and humans (Gelernter et al., 2014; Dickson et al., 2015), 
there are multiple other recent examples of forward genetic discoveries in rodents that have 
yielded a high likelihood for translation to humans. A missense SNP in Taar1 (trace amine-
associated receptor 1) was mapped in mice for the aversive properties of MA self-
administration, body temperature (Harkness et al., 2015) and toxicity (Shi et al., 2016; 
Miner et al., 2017; Reed et al., 2018) and genetic variants in TAAR1 in humans were 
associated with drug craving in methamphetamine dependence (Shi et al., 2016; Loftis et 
al., 2019) . CNIH3 (Cornichon Family AMPA Receptor Auxiliary Protein 3) was identified 
as a GWAS hit for opioid dependence in humans that was corroborated with a forward 
genetic study of morphine physical dependence in mice (Nelson et al., 2016). Whole 
genome sequencing plus QTL analysis and functional validation identified Grm2 (mGlu2 
receptor) in escalation of alcohol consumption in rats  (Zhou et al., 2013). A mouse strain 
survey correlating gene expression with behavior found a link between glyoxylase 1 (Glo1) 
and anxiety-like behavior that was confirmed via viral knockdown and overexpression 
(Hovatta et al., 2005). A cis-eQTL and copy number variant containing Glo1 was 
subsequently discovered to segregate in outbred mice and is fixed in several classical 




with anxiety-like behavior (Williams et al., 2009). Glo1 metabolizes methylglyoxal which, 
in light of mouse preclinical studies, was found to act as an agonist for the GABA-A 
receptor and exert anxiolytic-like effects (Distler et al., 2012; McMurray et al., 2016). 
Increasing methylglyoxal levels preclinically reduced alcohol drinking (McMurray et al., 
2017; de Guglielmo et al., 2018), induced a rapid antidepressant-like response (McMurray 
et al., 2018), and reduced seizures (Distler et al., 2014). To summarize, mouse forward 
genetic studies have led to the identification and/or corroboration of several promising 
therapeutic targets for SUDs and other psychiatric disorders.  
A major focus of our lab is to use discovery-based forward genetics to identify 
novel genetic factors underlying heritable differences in sensitivity to the locomotor 
stimulant response to drugs of abuse, including opioids as well as psychostimulants such 
as MA. The neurocircuitry and neurochemical mechanisms underlying drug-induced 
locomotor activity are in part shared with those that mediate the addictive properties of 
drugs of abuse (Wise and Bozarth, 1987; Di Chiara and Imperato, 1988; Deminiere et al., 
1989); thus, a reasonable hypothesis is that a subset of shared, polymorphic genetic factors 
influence both sets of complex behavioral traits. Examples from our lab that support this 
hypothesis include casein kinase 1-epsilon which influences opioid- and MA-induced 
locomotor activity (Bryant et al., 2009, 2012) and opioid conditioned place preference 
(Goldberg et al., 2017) as well as Hnrnph1 which we first mapped and validated for MA-
induced locomotor activity (Yazdani et al., 2015) and subsequently found to influence MA-
induced extracellular DA in the NAc, MA-induced reward, and MA-induced reinforcement 




With regard to Hnrnph1, QTL mapping in an F2 cross first identified a locus 
containing Hnrnph1 on chromosome 11 whereby the DBA/2J (D2J) allele was associated 
with reduced MA-induced locomotor activity (Parker et al., 2012). An interval-specific 
congenic approach was employed in C57BL/6J (B6J) mice carrying various introgressed 
regions on chromosome 11 from the DBA/2J strain (Iakoubova et al., 2001) to fine map 
the QTL. We detected a fortuitous recombination event that revealed a 210 kb region on 
chromosome 11 (50.37 - 50.58 Mb) that was necessary for reduced sensitivity in the 
locomotor stimulant response to MA (Yazdani et al., 2015). Replacement of this 
polymorphic region with the background C57BL/6J allele completely eliminated the MA-
induced behavioral phenotype, thus demonstrating that this region was necessary for 
reduced MA-induced locomotor activity (Yazdani et al., 2015). The 210 kb region contains 
two protein-coding genes – Hnrnph1 and Rufy1. Introduction of a heterozygous deletion 
within the first coding exon of each gene provided strong support for Hnrnph1 (and not 
Rufy1) as a QTG underlying reduced MA sensitivity (Yazdani et al., 2015) and we 
subsequently expanded the phenotypic repertoire of the Hnrnph1 mutants to include a 
reduction MA reinforcement, MA reward and MA-induced dopamine release (Ruan et al., 
2020a).  
Although the combined published evidence supports Hnrnph1 as a QTG for MA 
sensitivity, to date, we have only demonstrated that inheritance of the 210 kb region 
polymorphic region containing Hnrnph1 and Rufy1 is necessary for the reduction in MA-
induced behavior. In order to demonstrate that this region is also sufficient, in the present 




and we identified a founder containing a 114 kb introgressed region. Following the 
observation of reduced MA-induced locomotor activity in 114 kb congenic mice, we 
assessed the striatal transcriptome at both the gene- and exon-level and compared these 
results to the transcriptome of Hnrnph1 mutants (H1 MUT) in order to provide further 
support for Hnrnph1 as a QTG and to identify the quantitative trait variant(s) (QTV)s. 
Upon discovering decreased usage of the 5’UTR in Hnrnph1 in 114 kb congenic mice as a 
potential molecular mechanism underlying the QTL and QTG, we validated decreased 
5’UTR expression via real-time quantitative PCR (qPCR) by targeting the adjacent exon 
junction and the specific 5’UTR noncoding exon. We then identified decreased protein 
expression of hnRNP H in 114 kb congenic mice as a potential downstream functional 
consequence of reduced 5’UTR usage.  Finally, to validate candidate QTV(s), we cloned 
the 5’ UTR of Hnrnph1 containing either the individual Hnrnph1 5’UTR variants, or the 
combined set of all four 5’ UTR variants fused to a luciferase reporter gene and tested the 
effect on reporter expression in two different cell lines. The results identify a set of 5’ UTR 
variants within Hnrnph1 that likely represent the QTVs underlying molecular regulation 








Positional cloning of a 114 kb interval that is necessary for reduced MA sensitivity 
In backcrossing the congenic line “Line 4a” that captured a QTL for reduced MA-induced 
locomotor activity and contained a heterozygous introgressed region from the D2J strain 
that spanned 50Mb to 60Mb, we monitored for recombination events at rs254771403 
(50,486,998 bp, mm10). We identified a crossover event that defined 114 kb congenic 
region that influenced MA sensitivity. There are two protein coding genes within this 114 
kb region - Hnrnph1 and Rufy1 (Figure 5A). 114 kb congenic mice homozygous for the 
D2J allele within this region on an otherwise isogenic B6J background displayed no 
difference in saline-induced locomotor activity, compared to their wild-type homozygous 
B6J littermates (Figure 5B-C). In response to an acute dose of MA on Day 3, 114 kb 
congenic mice showed reduced locomotor activity relative to B6J (Figure 5D). Again, in 
response to a second dose of MA on Day 4, the 114 kb congenic mice showed reduced 
MA-induced locomotor activity compared to B6J wild-type littermates (Figure 5E). No 
genotypic difference in MA-induced locomotor activity were observed on Day 5 after the 
third MA injection (Figure 5F) which is potentially explained by a ceiling effect on 
sensitization at this dose.  
In examining changes in summed locomotor activity across days, both 114 kb and 
B6J mice showed habituation to the testing apparatus as indicated by a reduction in saline-
induced locomotor activity from Day 1 to Day 2 (Figure 5G). 114 kb congenic mice 
showed greater sensitization to repeated doses of MA from Day 3 to Day 5 (Figure 5G), 




compared to B6J wild-types. In comparing summed locomotor activity over 60 min across 
the five days, the 114 kb congenic mice showed a significant reduction in MA-induced 
locomotor activity compared to B6J wild-type littermates on Day 4 (Figure 5G). Taken 
together, these results indicate that 114 kb congenic mice are less sensitive to the locomotor 











Figure 5. MA-induced locomotor activity in the 114 kb congenic mice.     
(A): Congenic mice containing an introgressed 114 kb region on chromosome 11 from the D2J 
strain on an isogenic B6J background were identified via backcrossing and screening for a 
recombination event at rs254771403 (50,486,998 bp; mm10) while monitoring for the retention of 
polymorphic rs29383600 (50,373,006 bp; mm10) and polymorphic rs29459915 (50,484,260 bp; 
mm10), and. Mice were then backcrossed again to B6J to generate additional heterozygotes for 
intercrossing (heterozygous-heterozygous breeding) which yielded heterozygous offspring as well 
as offspring homozygous for the 114 kb region (homozygous D2J) and wild-type homozygous B6J 
littermates. Behavioral analysis and results are shown for the homozygous genotypes. The 114 kb 
region contains two protein-coding genes: Hnrnph1 and Rufy1. Mice were injected on Days 1 to 2 
with saline (i.p.; panels B and C) and on Days 3, 4, and 5 with 2 mg/kg MA (panels D, E, and F). 
Locomotor activity was video-recorded for 60 min on each day and is presented in 5-min bins over 
60 min. (B,C): No genotypic differences were observed in distance traveled in response to a saline 




p = 0.133] or Day 2 [mixed ANOVA: F(1,46)Genotype = 0.003, p = 0.958; F(11,506)Genotype x Time = 
1,29, p = 0.227]. A main effect of Sex was detected for both Days 1 and 2 [F(1,46)Day1 = 10.52, p 
= 0.002; F(1,46)Day2 = 9.83, p = 0.003]. However, there was no significant Genotype x Sex 
interaction for Day 1 or Day 2 [F(1,46)Day1 = 0.32, p = 0.576; F(1,46)Day2 = 2.32, p = 0.134]. (D): 
Locomotor activity on Day 3 in response to MA is shown in 5-min bins over 60 min. 114 kb 
congenic mice showed reduced acute MA-induced locomotor activity relative to B6J wild-type 
littermates [mixed ANOVA: F(1,46)Genotype = 3.41, p = 0.071; F(11,506)Genotype x Time = 2.80, p = 
0.002; unpaired t-test for each 5-min bin: t(48)30min = 2.17, *p = 0.035; t(48)50min = 2.05, *p = 0.045]. 
A main effect of Sex was also detected [F(1,46) = 4.32, p = 0.043], however, there was no 
significant Genotype x Sex interaction [F(1,46) = 2.74, p = 0.104]. (E): MA-induced locomotor 
activity on Day 4 is shown in 5-min bins over 60 min. 114 kb congenic mice showed reduced MA-
induced locomotor activity relative to B6J mice [mixed ANOVA: F(1,46)Genotype  = 5.40, p = 0.025; 
F(11,506)Genotype x Time = 1.96, p = 0.031; unpaired t-test for each 5-min bin: t(48)15min = 2.43, *p = 
0.019; t(48)20min = 3.10, *p = 0.003; t(48)25min = 2.90, *p = 0.006; t(48)30min = 2.22, *p = 0.031]. A 
main effect of Sex was also detected [F(1,46) = 7.33, p = 0.009] but no significant Genotype x Sex 
interaction [F(1,46) = 2.05, p = 0.159]. (F): MA-induced locomotor activity is shown for Day 5 in 
5-min bins over 60 min. 114 kb congenic mice showed no difference in MA-induced locomotor 
activity compared to B6J [mixed ANOVA: F(11,506)Genotype x Time = 0.59, p = 0.841]. A main effect 
of Sex was detected [F(1,46) = 6.09, p = 0.017], however, there was no significant Genotype x Sex 
interaction [F(1,46) = 0.39, p = 0.535]. (G): Locomotor activity summed over 60 min is shown for 
Days 1 and 2 (saline) and on Days 3, 4, and 5 (MA). In examining habituation via changes in 
locomotor activity in response to saline injections on Day 1 versus Day 2, both B6J and 114 kb 
showed similar degree of habituation [mixed ANOVA: F(1,46)Genotype = 0.47, p = 0.496; F(1,46)Day 
= 225.51, p < 2E-16; F(1,46)Genotype x Day = 1.35, p = 0.252; unpaired t-test for each day: t(50)Day 1 = 
6.34, #p = 3.26E-04; t(46)Day 2 = 6.64, #p = 1.55E-04].  In examining sensitization of MA-induced 
locomotor activity across Day 3, Day 4, and Day 5, 114 kb congenic mice showed increased 
locomotor sensitization relative to B6J [mixed ANOVA: F(1,46)Genotype = 2.74, p = 0.105; F(2,92)Day 
= 65.71, p < 2E-16; F(2,92)Genotype x Day = 5.03, p = 0.009]. Only the 114 kb congenic mice showed 
an increase in MA-induced locomotor activity across the three MA treatment days [Bonferroni’s 
multiple comparison tests (adjusted for 3 comparisons in 114 kb congenics and B6J group 
separately): Day 3 versus D4: t(50)B6J = 2.40, p = 0.120; t(46)114 kb = 2.76, *p = 0.050; Day 3 
versus D5: t(50)B6J = 2.45, p = 0.108; t(46)114 kb = 4.52, *p = 2.57E-04; Day 4 versus D5: t(50)B6J = 
0.12, p = 0.999; t(46)114 kb = 1.92, p = 0.368]. In addition, 114 kb congenic mice showed reduced 
MA-induced locomotor activity compared to B6J mice on Day 4 when compared across all five 
days [mixed ANOVA: F(4,184)Genotype x Day = 3.96, p  = 0.004; unpaired t-test for each day: t(48)Day4 
= 2.16, %p = 0.036]. A main effect of Sex was detected [F(1,46) = 9.17, p = 0.004] but there was 
no significant Genotype x Sex interaction [F(1,46) = 2.14, p = 0.150]. Data are represented as the 








Acute MA-induced locomotor activity and sensitization in 114 kb congenic mice 
Next, we examined MA-induced locomotor activity while accounting for individual 
differences in baseline locomotion in response to saline on Day 2 (Figure 6A-C), as well 
as MA-induced locomotor sensitization (Figure 6D-F), via differences in MA-induced 
locomotor activity between MA treatment days. When accounting for non-drug locomotor 
activity, we again found that 114 kb congenic mice showed less acute MA-induced 
locomotor activity relative to B6J mice (Figure 6A), as well as after repeated exposure to 
MA (Figure 6B-C). After two MA injections (comparing Day 4 versus Day 3 activity), 
114 kb congenic mice showed a significant decrease in locomotor sensitization early post-
injection (Figure 6D). After three MA injections (comparing between Day 5 and Day 3), 
114 kb congenic mice showed a significant increase in locomotor sensitization, starting at 
20 min post-MA (Figure 6E). Again, when comparing Day 5 versus Day 4, 114 kb 
congenic mice also showed significantly greater MA locomotor sensitization relative to 
B6J mice (Figure 6F). The more delayed, greater sensitization in 114 kb congenic mice 
during the later MA injections is likely due to their initially lower MA response which 






Figure 6. Normalized MA-induced locomotor activity and locomotor sensitization in 114 kb 
congenic mice.      
Mice were injected (i.p.) with saline on Days 1 to 2 and with 2 mg/kg MA on Days 3, 4, and 5. 
Locomotor activity was recorded for 60 min. (A): Day 3 – Day 2 distance traveled represents the 
acute locomotor response to MA while accounting for individual differences in non-drug, saline-
induced locomotor activity. 114 kb congenic mice showed less acute MA-induced locomotor 
activity relative to B6J wild-type littermates [mixed ANOVA: F(1,46)Genotype = 3.43, p = 0.070; 
F(11,506)Genotype x Time = 2.36, p = 0.008; unpaired t-test for each 5-min bin: t(48)25min = 2.30, 
*p = 0.033; t(48)30min = 2.18, *p = 0.035]. (B): Day 4 – Day 2 distance traveled represents the 
locomotor response to the second, repeated dose of MA while accounting for individual differences 
in non-drug, saline-induced locomotor activity. 114 kb congenic mice showed less MA-induced 
locomotor activity relative to B6J [mixed ANOVA: F(1,46)Genotype = 5.25, p = 0.027; 
F(11,506)Genotype x Time = 1.76, p = 0.058; unpaired t-test for each 5-min bin: t(48)10min = 2.15, 
*p = 0.037; t(48)15min = 2.47, *p = 0.017; t(48)20min = 2.80, *p = 0.007; t(48)25min = 3.34, *p 
= 0.002; t(48)30min = 2.24, *p = 0.030]. (C): Day 5 – Day 2 distance traveled represents locomotor 
response to the third, repeated dose of MA while accounting for individual differences in saline 
locomotor activity. No genotypic difference in locomotor activity was observed in response to the 
third dose of MA [mixed ANOVA: F(1,46)Genotype = 0.17, p = 0.680; F(11,506)Genotype x Time 
= 0.92, p = 0.523]. (D): Day 4 – Day 3 distance traveled is shown to represent locomotor 
sensitization from the first to the second MA injection. 114 kb congenic mice showed a decrease 
in locomotor sensitization during the first 15 min [mixed ANOVA: F(1,46)Genotype = 0.47, p = 
0.495; F(11,506)Genotype x Time = 3.09, p = 4.92e-5; unpaired t-test for each 5-min bin: t(48)5min 
= 2.47, *p = 0.017; t(48)15min = 2.47, *p = 0.017]. (E): Day 5 – Day 3 distance traveled is shown 
to indicate the degree of sensitization observed following the third MA injection relative to the first 




[mixed ANOVA: F(1,46)Genotype = 5.35, p = 0.025; F(11,506)Genotype x Time = 1.95, p = 0.032; 
unpaired t-test for each 5-min bin: t(48)20min = 2.30, p = *0.026; t(48)25min = 2.07, *p = 0.044; 
t(48)30min = 2.11, *p =0.040; t(48)45min = 2.27, *p = 0.028; t(48)50min = 2.80, p = 0.007]. (F): 
D5 – D4 distance traveled is shown to indicate which genotype continued to sensitize from the 
second MA injection to the third MA injection. Again, 114 kb congenic mice showed increased 
locomotor sensitization relative to B6J [mixed ANOVA: F(1,46)Genotype = 8.50, p = 0.006; 
F(11,506)Genotype x Time = 1.75, p = 0.061; unpaired t-test for each 5-min bin: t(48)5min = 2.67, 
*p = 0.010; t(48)15min = 3.28, *p = 0.002; t(48)20min  = 4.59, *p = 3.17E-05; t(48)25min = 3.43, 
*p = 0.001; t(48)35min = 2.24, *p = 0.030]. No main effect of Sex was detected for any locomotor 
sensitization measures (panels A-F) [F(1,46)Sex < 0.8, all p’s > 0.3]. Data are represented as the 
mean  S.E.M. 
 
Transcriptome analysis of the striatum identifies differential usage of the Hnrnph1 
5’UTR in 114 kb congenic mice   
To further understand the molecular mechanism of the 114 kb congenic region in reducing 
MA sensitivity, we performed both differential gene expression and differential exon usage 
analysis on RNA-seq data collected from the striatum of naïve 114 kb and their B6J wild-
type littermates. We identified 69 differentially expressed genes (p < 0.001; Table 2). 
Enrichr analysis of these 69 genes for pathway and gene ontology (GO) terms identified 
enrichment for several terms potentially related to MA-induced DA release and behavior, 
including circadian entrainment, cholinergic synapse, cAMP signaling pathway, long-term 
















Table 2. Differentially expressed genes in the striatum of 114 kb congenic mice.  
This table shows the 69 genes that are differentially expressed in the striatum of 114 kb 
congenic mice relative to the B6J wild-type littermates (p < 0.001).  
Gene logFC AveExpr t p value Adjusted p value B 
Baiap3 -0.534 4.730 -5.500 1.14E-06 0.0162 5.180 
Hap1 -0.302 7.192 -5.065 5.36E-06 0.0271 3.919 
Wdr6 -0.348 5.830 -5.047 5.72E-06 0.0271 3.856 
Zcchc12 -0.225 7.100 -4.726 1.75E-05 0.0623 2.815 
Trpc4 -0.562 3.444 -4.556 3.13E-05 0.0713 1.838 
Tmem130 -0.270 7.087 -4.545 3.26E-05 0.0713 2.237 
Prkcd -0.524 4.363 -4.523 3.51E-05 0.0713 2.076 
Trp53inp2 0.183 8.099 4.399 5.33E-05 0.0857 1.752 
Wnk1 0.123 8.451 4.347 6.35E-05 0.0857 1.578 
Scd1 0.184 7.767 4.338 6.55E-05 0.0857 1.568 
Zic1 -0.630 4.393 -4.317 7.03E-05 0.0857 1.482 
Cacng5 -0.454 3.203 -4.291 7.65E-05 0.0857 1.005 
Col6a3 -0.892 2.255 -4.259 8.51E-05 0.0857 0.249 
Kcnj2 0.201 6.042 4.259 8.53E-05 0.0857 1.378 
Ecel1 -0.187 5.713 -4.203 0.000102 0.0857 1.220 
Fos 0.994 2.801 4.201 0.000103 0.0857 0.773 
Lbhd2 -2.694 -0.765 -4.196 0.000105 0.0857 -1.978 
Magel2 -0.704 1.965 -4.186 0.000108 0.0857 0.001 
Zic2 -0.692 2.885 -4.118 0.000136 0.0986 0.386 
Osbpl8 0.115 8.486 4.099 0.000144 0.0986 0.808 
Qk 0.152 8.422 4.097 0.000145 0.0986 0.805 
Gatm 0.193 7.062 4.056 0.000166 0.1074 0.730 
Nrp2 -0.391 3.477 -4.005 0.000196 0.1127 0.423 
Itm2c -0.089 10.023 -4.001 0.000198 0.1127 0.461 
Ezr -0.170 6.308 -3.982 0.000211 0.1127 0.537 
Zic4 -0.971 1.787 -3.980 0.000213 0.1127 -0.702 
Ermn 0.240 6.924 3.978 0.000214 0.1127 0.502 
Zcchc18 -0.103 8.156 -3.954 0.000231 0.1175 0.381 
Pnmal2 -0.226 7.963 -3.925 0.000253 0.1216 0.300 
Fth1 0.169 10.805 3.922 0.000256 0.1216 0.196 
Dlx1 -0.701 3.098 -3.895 0.000279 0.1252 -0.051 
Icam5 -0.104 8.147 -3.891 0.000283 0.1252 0.195 
Sept7 0.107 8.420 3.883 0.000290 0.1252 0.162 
Pcdh8 -0.391 3.388 -3.853 0.000319 0.1337 0.027 
Ttll7 0.104 7.896 3.840 0.000332 0.1346 0.055 
Rasd1 -0.842 1.393 -3.830 0.000344 0.1346 -1.180 
Tspan2 0.175 7.668 3.824 0.000350 0.1346 0.019 
Slc22a17 -0.120 9.192 -3.810 0.000366 0.1371 -0.082 
Gpm6b 0.091 10.728 3.777 0.000406 0.1378 -0.233 
Tppp 0.091 9.176 3.775 0.000409 0.1378 -0.184 
Cadm2 0.134 7.765 3.764 0.000423 0.1378 -0.161 




Adcy1 0.111 8.611 3.761 0.000426 0.1378 -0.201 
Npas4 0.694 4.629 3.758 0.000431 0.1378 -0.052 
Rapgef4 0.146 9.876 3.744 0.000451 0.1378 -0.299 
Tro -0.103 7.983 -3.744 0.000451 0.1378 -0.233 
Grin2a 0.232 4.844 3.736 0.000462 0.1378 -0.111 
Scn5a -0.522 2.614 -3.734 0.000465 0.1378 -0.572 
Maged1 -0.152 8.935 -3.694 0.000526 0.1528 -0.410 
Kcna2 0.109 8.165 3.684 0.000543 0.1547 -0.410 
Ano3 0.105 9.169 3.668 0.000571 0.1594 -0.493 
Slit1 -0.361 4.198 -3.652 0.000601 0.1645 -0.361 
Oip5os1 0.146 6.009 3.621 0.000661 0.1747 -0.483 
Lpgat1 0.090 8.070 3.620 0.000663 0.1747 -0.589 
Ptprd 0.143 7.600 3.602 0.000700 0.1812 -0.619 
Ngb -0.792 1.543 -3.596 0.000714 0.1815 -1.419 
Rgs7bp 0.118 9.071 3.589 0.000729 0.1821 -0.716 
Camk4 0.101 9.316 3.583 0.000744 0.1825 -0.743 
Thsd7a 0.117 7.467 3.561 0.000793 0.1892 -0.728 
Hipk2 0.191 5.988 3.560 0.000798 0.1892 -0.651 
Pnck -0.209 5.758 -3.542 0.000843 0.1968 -0.686 
Camk2n1 0.106 10.768 3.519 0.000904 0.2022 -0.979 
Ret -0.589 2.081 -3.516 0.000911 0.2022 -1.307 
Zeb2 0.142 6.285 3.512 0.000922 0.2022 -0.798 
Bcas1 0.185 8.413 3.507 0.000937 0.2022 -0.920 
Samd5 0.260 3.992 3.507 0.000937 0.2022 -0.747 
S100b 0.206 7.036 3.498 0.000964 0.2033 -0.884 
Gpc3 -0.594 1.672 -3.495 0.000971 0.2033 -1.579 























Table 3. Pathway and gene ontology analysis of differential gene expression in 114 kb 
congenic mice. 
This table shows the top 5 KEGG pathways (A) and the top 5 Gene Ontology (GO) biological 
processes (B) pathways when considering the 69 differentially expressed genes (p < 0.001) between 
114 kb congenic and B6J mice 
(A): KEGG Pathways 
Name p value Overlap Genes 
Oxytocin signaling pathway 1.92E-04 5/154 
Camk4, Fos, Adcy1, Kcnj2, 
Cacng5 
Circadian entrainment 3.82E-04 4/99 Grin2a, Rasd1, Fos, Adcy1 
Cholinergic synapse 6.29E-04 4/113 Camk4, Fos, Adcy1, Kcnj2 
cAMP signaling pathway 8.10E-04 5/211 
Grin2a, Camk4, Fos, Adcy1, 
Rapgef4 
Long-term potentiation 1.71E-03 3/67 Grin2a, Camk4, Adcy1 
(B): GO Biological Processes 
Name p value Overlap Genes 
peptidyl-threonine 
phosphorylation (GO:0018107) 
1.92E-04 4/68 Pnck, Wnk1, Prkcd, Hipk2 
regulation of non-motile cilium 
assembly (GO:1902855) 
3.82E-04 2/6 Sept7, Hap1 
peptidyl-threonine modification 
(GO:0018210) 
6.29E-04 4/89 Pnck, Wnk1, Prkcd, Hipk2 
regulation of synaptic 
transmission, GABAergic 
(GO:0032228) 
8.10E-04 2/11 Npas4, Hap1 














Exon-level analysis of coding and noncoding exons (e.g., 5’UTR noncoding exons) 
identified 35 genes exhibiting differential exon usage (Table 4A-B), which is defined as 
the proportion of total normalized reads per gene that are counted within an exon bin for 
that gene. Enrichr analysis of the 35 genes for pathway analysis identified an enrichment 
of dopaminergic synapse and amphetamine addiction involving Ppp3ca, Calm2 and Mapk2 
as well as calcium signaling and long-term potentiation involving Ppp3ca and Calm2 
(Figure 7). Notably, Hnrnph1 (the first protein-coding gene within the 114 kb congenic 
interval) was one of the top genes exhibiting differential exon usage (Table 4A), providing 
direct evidence at the exon level that one or more functional variants within Hnrnph1 
regulates exon usage and ultimately underlies differences in MA behavior. Note that 
Hnrnph1 did not show a significant difference in overall gene-level transcript levels 
(log2FC = 0.016; t(14) = 0.70; p = 0.49; adjusted p = 0.99). Thus, any subsequent 
downstream functional changes that we report are not mediated by overall Hnrnph1 
transcript levels, but instead, by transcripts with alternative exons (either coding or 
noncoding; see Table 6). It should also be noted that we did not identify a significant 
difference in gene expression or in exon usage of Rufy1 (the second protein-coding gene 
within the interval), thus limiting functional effects of D2J variants at the mRNA level to 
Hnrnph1 and further supporting the candidacy of Hnrnph1 as a QTG underlying MA 






Table 4. Genes exhibiting differential exon usage in 114 kb congenic mice.  
The table shows 35 genes exhibiting differential exon usage in striatal tissue from 114 kb congenic 
mice relative to their B6J wild-type littermates (p < 0.001). Differential exon usage was detected 
using either an F-test (A) or a Simes test (B) in limma (Ritchie et al., 2015). 
(A): F-test (p < 0.001) 
Gene Fstat Fstat_P Fstat_FDR Simes_P Simes_FDR 
Ppp3ca 2.87 5.12E-07 0.0092 1.30E-09 2.30E-05 
Cdhr4, Ip6k1, Uba7, 
Gm20661, Gm20662 
1.65 1.36E-06 0.012 0.0015 1 
Hnrnph1 2.19 7.50E-06 0.045 0.0055 1 
Mrps14 4.92 2.67E-05 0.1 4.10E-05 0.19 
Pfdn5, Myg1 2.1 2.89E-05 0.1 0.028 1 
Scn3a 2.14 4.26E-05 0.13 0.002 1 
Chn2 2.53 5.58E-05 0.14 0.026 1 
Myo5b 1.89 7.13E-05 0.16 0.036 1 
Mapk9 2.33 1.20E-04 0.21 0.022 1 
Calm2 3.6 1.30E-04 0.21 0.0024 1 
Hnrnpm, March2 1.83 1.40E-04 0.21 0.014 1 
Cdc42bpa 1.75 1.40E-04 0.21 0.18 1 
Arrdc1 2.11 1.90E-04 0.26 0.21 1 
Igbp1 3.98 3.50E-04 0.43 0.014 1 
Sptbn1 1.84 3.60E-04 0.43 0.017 1 
Tm4sf1 3.64 4.30E-04 0.49 0.018 1 
Ptpn5 1.94 5.60E-04 0.6 0.2 1 
(B): Simes (p < 0.001) 
Gene Fstat Fstat_P Fstat_FDR Simes_P Simes_FDR 
Ppp3ca 2.87 5.12E-07 0.0092 1.30E-09 2.30E-05 
Tspan32 2.96 0.0013 1 2.27E-05 0.19 
Mrps14 4.92 2.67E-05 0.1 4.09E-05 0.19 
Txn2 1.59 0.048 1 4.13E-05 0.19 
Map2 1.6 0.0018 1 1.50E-04 0.53 
Map4, Mtap4 1.57 0.007 1 1.80E-04 0.54 
Slc8a3 2.88 0.0011 1 2.20E-04 0.57 
Alpk3 1.76 0.052 1 3.80E-04 0.81 
Jaml 2.74 0.006 1 4.10E-04 0.81 
Dph1, Ovca2 1.29 0.15 1 4.90E-04 0.87 
Rab21 2.69 0.15 1 5.40E-04 0.89 










Figure 7. Pathway analysis of the top genes with differential exon usage.  
We identified 35 genes showing differential exon usage between 114 kb and B6J mice (p < 0.001).  
The top 10 enriched KEGG pathways along with the five genes overlapping with each of these 
pathways are shown in the clustergram. The enriched pathways are shown in columns and input 
genes are shown in the rows and cells (in orange) in the matrix to indicate if a gene is associated 


















We previously showed that mice heterozygous for a 16-bp deletion within the first coding 
exon of Hnrnph1 (refer to as the H1 MUT mice) were less sensitive to the stimulant, 
rewarding, and reinforcing properties of MA and showed a reduction in MA-induced 
extracellular DA level in the NAc (Yazdani et al., 2015; Ruan et al., 2020a). To directly 
compare the functional effects of inheriting the deletion versus the 114 kb congenic region 
on gene expression and exon usage, we identified 21 overlapping genes that were 
differentially expressed in the striatum between 114 kb congenic mice and H1 MUT mice 
relative to their B6J wild-type littermates (Figure 8A), which was significantly greater than 
what would be expected by chance (Fisher’s exact test: p = 9.31E-23). In addition, there 
were 10 overlapping genes between H1 MUT and 114 kb congenic mice that showed 
differential exon usage, relative to their B6J littermates (Figure 8B). Again, this overlap 
was significantly greater than what would be expected by chance (Fisher’s exact test: p = 
2.96E-07). Finally, in correlating differential expression for the 21 shared differentially 
expressed genes between 114 kb congenic mice and H1 MUT mice, we found a nearly 
perfect relationship between the magnitude and direction of change in gene expression 
(Table 5 and Figure 9). These results suggest functionally similar effects of the 114 kb 







Figure 8. Overlap in differentially expressed genes and genes exhibiting differential exon 
usage between 114 kb congenic mice and H1 MUT mice.  
(A): Venn diagram showing the number of differentially expressed genes (DEGs) in 114 kb (p < 
0.001) versus H1 MUT mice (p < 0.001). The 21 DEGs that were shared between the two are 
significantly greater than what would be expected by chance (Fisher’s exact test: p = 9.31E-23) as 
it represents nearly ½ of the 48 total DEGs identified in 114 kb congenic mice. (B): Venn diagram 
shows the number of non-overlapping and overlapping genes with differential exon usage in 114 
kb congenic mice (p < 0.001) versus H1 MUT mice (p < 0.001). Ten genes showed differential 
exon usage in both the 114 kb congenic mice and the H1 MUT mice which is significantly greater 
than chance (Fisher’s exact test: p = 2.96E-07) and include Ppp3ca, Cdhr4, Hnrnph1, Mapk9, 





Table 5. Correlation of differential expression between 114 kb congenic and H1 MUT mice. 
Table showing the log2FC values for the 21 overlapping genes in the 114 kb and H1 MUT. The 






Magel2 -0.704 -0.857 
Dlx1 -0.701 -0.686 
Zic2 -0.692 -0.811 
Zic1 -0.630 -0.897 
Trpc4 -0.562 -0.786 
Prkcd -0.524 -0.528 
Wdr6 -0.348 -0.420 
Hap1 -0.302 -0.380 
Zcchc12 -0.225 -0.297 
Pnck -0.209 -0.353 
Ecel1 -0.187 -0.596 
Zcchc18 -0.103 -0.154 
Camk4 0.101 0.311 
Ano3 0.105 0.212 
Kcna2 0.109 0.247 
Osbpl8 0.115 0.129 
Thsd7a 0.117 0.303 
Rgs7bp 0.118 0.335 
Wnk1 0.123 0.220 
Cadm2 0.134 0.192 



















Figure 9. Correlation of differential expression between 114 kb congenic mice and H1 MUT 
mice.  
The direction and the magnitude of change in gene expression relative to B6J wild-type were nearly 
identical between the 114 kb congenics and H1 MUT mice for every gene [Pearson correlation: r 












































The physical positions and exon numbers comprising differential exon usage of Hnrnph1 
in 114 kb relative to B6J mice are shown in Table 6. Note that fewer normalized reads 
were mapped to the junction comprising exon 3 and exon 4 in 114 kb congenic mice versus 
B6J (log2FC = -0.484 = 1.4-fold decrease; Table 6). Additionally, a greater number of 
normalized reads mapped to the junction comprising exons 6 and 7, as well as the junction 
comprising exons 7 and 8 in the 114 kb congenic mice relative to B6J (Table 6). It is 
important to note that Hnrnph2 (homolog of Hnrnph1) did not show differential exon usage 
in our analysis (F = 1.330, Fstat p = 0.198, Fstat FDR = 1 and Simes p = 0.38, Simes FDR 
= 0.998). To validate differential exon usage of Hnrnph1, we performed qPCR with 
primers flanking those exons exhibiting significant differential exon usage. Out of the three 
exon junctions, 114 kb congenic mice showed less usage of exons 3 to 4, but no difference 
in the other two exon junctions (Figure 10A). To further validate the specific exons 
exhibiting differential usage, we designed primers to target exon 3 (5’UTR noncoding exon) 
and exon 4 (first coding exon) separately. Less usage of the 5’UTR noncoding exon was 
detected in the 114 kb congenic mice (Figure 10B), with no change in the first coding exon 
(Figure 10C). Exons 1 to 3 are noncoding exons that comprise the 5’UTR of Hnrnph1 (see 
Figure 12). Thus, we conclude that 114 kb congenic mice show a reduced number of 








Table 6. Differential exon usage of Hnrnph1 in 114 kb congenic mice.  
Table showing the four exon positions of Hnrnph1 that display differential exon usage in 114 kb 
congenic mice relative to B6J wild-type littermates with p < 0.05 using the Simes test. Exon usage 
was defined as the proportion of total normalized reads per gene that were counted within an exon 




log2FC p value FDR 
chr11:50,377,719-50,377,750 3-4 -0.484 0.018 1 
chr11:50,380,191-50,380,825 6-7 0.137 0.001 1 
chr11:50,381,598-50,382,137 7-8 0.094 0.017 1 






Figure 10. Decreased 5’UTR noncoding exon 3 usage of Hnrnph1 in striatal tissue of 114 kb 
congenic mice.  
Hnrnph1 was one of the top-ranked genes showing differential exon usage as indicated via the 
proportion of total normalized reads counted within an exon bin between 114 kb congenic mice 
versus B6J wild-type littermates. To validate differential exon usage, we conducted a set of qPCR 
experiments targeting the exon junction or the individual exons. Primer sequences, as well as the 
exon junctions or individual exons they target are provided in Supplemental Table 1. (A) Decreased 
usage of the junction comprising exons 3 and 4 was detected in 114 kb congenic mice [unpaired t-
test for each exon junction: t(13)exon 3-4 = 5.65, *p = 7.9e-5; t(6)exon 6-7 = 0.58, p = 0.585; t(6)exon 7-8 
= 0.20, p = 0.846]. (B-C) To further test specific exons, primers targeting either exon 3 or 4 of 
Hnrnph1 were used to demonstrate that 114 kb congenic mice showed decreased usage of the 5’ 
UTR noncoding exon 3 [unpaired t-test: t(13) = 3.25, *p = 0.006] but no difference in the first 









Reduced hnRNP H protein expression in the striatum of 114 kb congenic mice  
Three different antibodies for detecting and quantifying hnRNP H protein expression 
between 114 kb congenic mice and B6J wild-type litters were used and all samples 
analyzed are shown in Figure 11A. A significant decrease in hnRNP H immunoreactivity 
was detected with all three antibodies in the 114 kb congenic mice as indicated by total 
protein stain normalized densitometry values (Figure A1) that were in turn normalized to 
averaged B6J values to illustrate fold-change (p = 0.003, 0.014, 0.01; Figure 11B-D). Thus, 
Hnrnph1 variants in 114 kb congenic mice are associated with both a decrease in Hnrnph1 












Figure 11. Decrease in hnRNP H protein expression in the striatum of 114 kb congenic mice.  
The striatum (left and right whole striatum) were dissected from the mice and protein lysates were 
extracted for protein quantification of hnRNP H using three anti-hnRNP H antibodies from three 
different companies. (A): Immunoblots showing hnRNP H protein expression in the striatum of 
114 kb congenics and B6J mice. Three antibodies specific for hnRNP H were used. The hnRNP H 
antibody from Bethyl recognizes the C-terminus of the protein and the one from Santa Cruz 
recognizes the N-terminus. The epitope site for the antibody from Proteintech is unknown. (B-D): 
Quantification of the immunoblots shown in A showing a significant decrease in hnRNP H protein 
expression in the 114 kb congenic mice relative to the B6J mice when assessed with all three anti-
hnRNP H antibodies [unpaired t-test: t(10)Bethyl = 5.06, ***p = 0.003; t(10)Santa Cruz = 2.99, *p = 
0.014; t(10)Proteintech = 3.02, *p = 0.013]. The expression values for hnRNP H were normalized to 
total protein staining by ponceau S as a loading control (See Appendix Figure A1 for ponceau S 
staining images and densitometry quantification values). The normalized values were normalized 
to the average of B6J expression values to examine fold-change in expression relative to B6J wild-













 Identification of a set of 5’ UTR functional variants in Hnrnph1 that decrease 
translation using a luciferase reporter assay  
Three SNPs and one indel between D2J and B6J are located within the 5’ UTR noncoding 
exons and introns (Figure 12 and Table 7). Given that the 5’ UTR contains a promoter 
element for translational regulation, we employed a luciferase reporter system to assay the 
strength of the Hnrnph1 promoter in the presence of one or all four of the 5’ UTR variants 
in both Human Embryonic Kidney (HEK) 293T and Neuro2a (N2a) cells. We engineered 
a Hnrnph1:luc2 construct by cloning 2956 bp of the B6J Hnrnph1 promoter into the 
pGL4.17[luc2/Neo] promoter-less vector (Figures A2 and 13A). The 2956-bp promoter 
increased firefly luminescence compared to the pGL4.17[luc2/Neo] vector, and this 
increase in signal showed a cell number dependency (Figure A3). Using site-directed 
mutagenesis, we constructed 4 Hnrnph1 promoters each possessing its own D2J variant 
within the 5’ UTR (Table A1). In HEK293T cells, none of the four promoters with a single 
D2J variant showed a significant difference between the wild-type B6J Hnrnph1 promoter 
in driving luciferase expression (Figure 13B). However, when all four D2J variants were 
introduced into the promoter, there was a significant reduction in luciferase activity 
compared to the B6J promoter (p = 5.68E-11; Figure 13C). The findings were 
subsequently replicated in N2a cells (p = 1.19E-06; Figure 13D-E).  
Taken together, these results identify a set of functional 5’ UTR variants within 
Hnrnph1 that are associated with a decrease in usage of the 5’ UTR noncoding exon 3, a 







Figure 12. Hnrnph1 variants between the B6J and D2J parental strains.  
(A): Schematic representation of the position of SNPs and indels in Hnrnph1 with the exon numbers 
listed. The exon with decreased usage in 114 kb congenic mice is boxed in red. (B): Genomic 
sequence for part of the Hnrnph1 5’ UTR with positions of the three noncoding exons highlighted 









Table 7. SNPs and indels in Hnrnph1 between B6J and D2J.  
A query for Hnrnph1 genetic variants (SNPs plus indels) between the B6J and D2J parental strains 
was conducted using the Sanger database query tool (mm10, REL-1505). The variants highlighted 
in orange are located in close proximity to the 5’ UTR noncoding exon 3 and were cloned and 
tested for functional significance in the luciferase reporter assay. 
Position (mm10) dbSNP C57BL/6J DBA/2J Type 
50,377,288 rs29411274 T C* SNP; intron variant 
50,377,546 rs221962608;rs224352813 GA G* Indel; intron variant 
50,377,795 rs29475617 T G* SNP; 5'UTR variant 
50,377,937 rs257760362 G C* SNP; intron variant 
50,378,499 rs245024332 T C* SNP; intron variant 
50,379,377 rs387789478;rs233140941 GTT GT* Indel; intron variant 
50,383,262 rs13481018 C T* 
SNP; synonymous 
variant 
50,383,443 rs226185912 ATG A* Indel; intron variant 
50,383,487 rs211965589 T TA* Indel; intron variant 
50,384,116 rs13461679 G A* SNP; intron variant 
50,384,175 rs263842089 T TAGATG* Indel; intron variant 
50,384,378 rs29466249 A T* SNP; intron variant 
50,385,052 rs247364036 GTT G* Indel; intron variant 
50,385,066 rs51675672 G T* SNP; intron variant 
50,386,305 rs229280897 T t/c* SNP; 3'UTR variant 












Figure 13. Luciferase reporter assay for the Hnrnph1 promoter in HEK293T and N2a cells 
to test the functional effect of 5’ UTR variants.  
Firefly luciferase was used as a reporter to assess the activity of B6J-Hnrnph1:luc2 versus 
promoters containing individual 5’ UTR variants from the D2J strain. Renilla luciferase was used 
as an internal control reporter. (A): Schematic representation of the Hnrnph1:luc2 reporter 
construct that was transfected to HEK293T (B and C) or N2a (D and E) cells. (B): Single D2J 
variants were engineered within the 5’ UTR of the Hnrnph1 promoter and had no effect on the 
luciferase reporter signal in HEK293T cells [one-way ANOVA comparing B6J-Hnnrph1:luc2 
against the single D2J variants: F(4,50) = 3.03, p = 0.025; Dunnett’s multiple comparison test with 
comparing each of the four variants with the B6J-Hnnrph1:luc2 control group: DDunnett(T7288C) = 0.36, 
p = 0.988; DDunnett(GA7546G) = 1.88, p = 0.199; DDunnett(T7795G) = 2.11, p = 0.125; DDunnett(G7937C) = 2.14, 
p = 0.117]. Data points represent the normalized luciferase signal from 2 independent replicates. 
(C): Engineering of all four D2J variants (D2J-Hnrnph1:luc2) in the promoter of Hnrnph1 
decreased luciferase luminescence relative to B6J-Hnrnph1:luc2 in HEK293T cells [unpaired t-
test, t(34) = 9.39, *p = 5.68E-11]. Data points represent the normalized luciferase signal from 3 
independent replicates. (D): Singly engineered D2J variants within the promoter had no effect on 
luciferase reporter signal in N2a cells [one-way ANOVA comparing B6J-Hnnrph1:luc2 against the 
single D2J variants: F(4,75) = 4.42, p = 0.003; Dunnett’s multiple comparison test with comparing 
each of the four variants with the B6J-Hnnrph1:luc2 control group: DDunnett(T7288C) = 1.18, p = 0.584; 
DDunnett(GA7546G) = 2.20, p = 0.100; DDunnett(T7795G) = 0.18, p = 0.999; DDunnett(G7937C) = 1.79, p = 0.229]. 
Data points represent the normalized luciferase signal from 2 independent replicates. (E): 
Engineering all four D2J variants (D2J-Hnrnph1:luc2) within the Hnrnph1 promoter decreased 
luciferase luminescence relative to the B6J-Hnrnph1:luc2 promoter in N2a cells [unpaired t-test, 
t(46) = 5.59, *p = 1.19E-06]. Data points are normalized luciferase signal from 3 independent 

























The 114 kb region containing two protein genes (Hnrnph1, Rufy1) was not only necessary 
(Yazdani et al., 2015), but was also sufficient to cause a decrease in sensitivity to the 
locomotor stimulant response to MA (Figure 5). Our prior work strongly implicated 
Hnrnph1 and not Rufy1 as the QTG responsible for the reduction in MA-induced locomotor 
activity (Yazdani et al., 2015) and we subsequently expanded the behavioral repertoire of 
H1 MUT mice to include reduced MA-induced reinforcement, reward, and DA release 
(Ruan et al., 2020a). Our exon-level transcriptome analysis and comparative differential 
gene expression analysis between the 114 kb congenics and H1 MUT mice further supports 
Hnrnph1 as the QTG underlying the reduction in MA-induced behavior (Figure 8 and 
Table 4). Decreased usage of the 5’ UTR noncoding exon 3 of Hnrnph1 in 114 kb congenic 
mice was independently validated via qPCR (Figure 10). Approximately 13% of genes in 
the mammalian transcriptome show differences in 5’ UTR splicing of their transcripts 
(Carninci et al., 2005). Inheritance of the Hnnrph1 5’UTR variants (along with the other 
Hnrnph1 variants; Table 7) were associated with a decrease in striatal hnRNP H protein 
expression (Figure 11). We identified a set of four variants within and flanking the 5’ UTR 
that decreased reporter expression in two different cell lines (Figure 13), thus identifying 
a set of QTVs underlying molecular regulation of Hnrnph1 and likely MA behavior. 
Identification of QTGs and QTVs is extremely rare in mammalian forward genetic 
studies, in particular for behavior (Yalcin and Flint, 2012), and especially when considering 
the identification of noncoding functional variants. In the recent identification of a 




took advantage of the reduced genetic complexity of closely related C57BL/6 substrains 
(Bryant, 2011; Bryant et al., 2020) to deduce and validate an intronic variant in Gabra2 
(alpha-2 subunit of the GABA-A receptor) near a splice site that drastically reduced 
transcript and protein expression and modulated behavior (Mulligan et al., 2019). 
Correction of the single base deletion in C57BL/6J to the wild-type C57BL/6N allele via 
CRISPR/Cas9-mediated gene editing restored Gabra2 transcript and protein levels to a 
normal level, thus identifying the QTV (Mulligan et al., 2019). The vast majority of other 
examples that successfully identified both the QTG and the QTV involve functional coding 
mutations, including Cyfip2 (Kumar et al., 2015), Grm2 (Zhou et al., 2013) , and Taar1 
(Stafford et al., 2019). With regard to Hnrnph1, a human candidate gene association study 
identified a functional intronic variant in OPRM1 (mRNA target of hnRNP H) that affected 
binding to hnRNP H to regulate splicing and was associated with the severity of heroin 
addiction (Xu et al., 2014). 
Less than one-third of genes analyzed in human cell lines showed a direct 
correlation between mRNA level and protein expression (Vogel et al., 2010; Araujo et al., 
2012). Furthermore, cis-expression QTL analysis at both the mRNA and protein level in 
Diversity Outbred mice indicated the presence of genetic variants that regulate protein 
levels without affecting overall transcript levels (Chick et al., 2016). In support, our gene-
level transcriptome analysis did not identify Hnrnph1 as a differentially expressed gene; 
however, exon-level analysis identified decreased 5’UTR noncoding exon usage of 
Hnrnph1 in 114 kb congenic mice (Figure 10 and Table 6) that was associated with 




elements located in the 5’UTR and 3’UTR of genes and trans-regulatory factors that bind 
to these elements (e.g. RBPs) can perturb translation or overall protein abundance 
(Chatterjee and Pal, 2009; Vogel et al., 2010; Araujo et al., 2012; Dvir et al., 2013; Kim et 
al., 2014b). In our study, we identified an association between decreased 5’UTR usage and 
decreased hnRNP H protein expression in 114 kb congenic mice. The GC content, 
secondary structure, and length of the 5’ UTR can affect translational efficiency (Jackson 
et al., 2010; Araujo et al., 2012). Thus, the altered GC content within the 5’UTR of 
Hnrnph1 in 114 kb congenic mice could inhibit translation by changing the thermal 
stability of secondary stem loop structure (Araujo et al., 2012). Because the length of the 
5’UTR determines the amount of energy needed for the ribosome to reach the AUG start 
site (Chatterjee and Pal, 2009), a change in length of the 5’UTR in Hnrnph1 caused by the 
set of 114 kb variants could also alter protein synthesis. Also, a change in binding sites for 
RBPs to regulate translation could contribute to reduced hnRNP H protein in 114 kb 
congenic mice (Dassi, 2017; Steri et al., 2018). RBPs recognizes specific motifs in the 
5’UTRs, and thus, a change in the sequence of these motifs induced by these variants could 
alter the association of RBPs with the translation machinery at the 5’ UTR of Hnnrph1 to 
control expression. The RBPDB database (Cook et al., 2011) indicates that several RBPs 
are predicted to bind to the 5’UTR of Hnrnph1, though notably not hnRNP H itself (Table 
A3).  
The hnRNP family of RBPs act in concert to regulate RNA metabolism and gene 
expression of other RBPs (Huelga et al., 2012). Downregulation of hnRNP H protein in 




to regulate expression and in turn, alter recruitment of RBPs involved in splicing of the 
5’UTR of Hnrnph1. As an example, hnRNP A1 is predicted to bind to the 5’ UTR of 
Hnrnph1 (Cook et al., 2011) and this RBP is known to cooperate with hnRNP H in 
mediating gene splicing (Fisette et al., 2010). Thus, although Hnrnph1 is not predicted to 
be a direct target of hnRNP H, reduced hnRNP H protein could alter the expression of and 
coordination with other RBPs to regulate 5’UTR usage of Hnrnph1.  
To summarize, we provide further causal behavioral and molecular evidence for 
Hnrnph1 as a QTG for MA sensitivity by demonstrating that inheritance of a small, 114 
kb chromosomal region was not only necessary (Yazdani et al., 2015) but also sufficient to 
induce the behavioral phenotype. We provide functional evidence for a set of four QTVs 
within the 5’UTR that could plausibly reduce 5’UTR usage and the amount of hnRNP H 
protein; however, demonstrating that these four variants are sufficient alone to induce these 
functional effects on Hnrnph1 molecular regulation and behavior would require the 
generation of a mouse model containing only these four variants. The relatively subtle 
effect of the 114 kb region on behavior raises the question of whether modeling these 
variants in vivo is worth the effort – convergent evidence provides strong evidence that we 
have identified a set of QTVs underlying functional molecular and behavioral changes. 
Future studies involving cell type-specific knockdown of Hnrnph1 using the Cre-loxP 
system will efficiently and more selectively model the effects of reduced hnRNP H protein 








MATERIALS AND METHODS 
Generation of B6J.D2J 114 kb congenic mice 
All procedures involving mice were conducted in accordance with the Guidelines for 
Ethical Conduct in the Care and Use of Animals and were approved by the Institutional 
Animal Care and Use Committee at Boston University (#AN-15326). The founder 114 kb 
congenic mouse was identified by monitoring the distal single nucleotide polymorphism 
(SNP) sites of offspring generated via backcrossing heterozygous congenic mice from Line 
4a carrying one copy of a ~11 Mb introgressed interval from the D2J strain to the 
background B6J strain (Yazdani et al., 2015). We monitored for retention of the most 
proximal D2J SNP that was just upstream of Hnrnph1 (rs29383600; 50,373,006 bp; mm10) 
and this SNP defined the proximal end of the 114 kb interval. We previously genotyped 
several purported SNP markers proximal to rs29833600 that were monomorphic until 
49,873,463 bp (mm10), which was catalogued by Sanger as a B6J/D2J polymorphic marker 
and that we genotyped as homozygous for B6J (Yazdani et al., 2015). Because we were 
unable to identify any polymorphisms between 49,873,463 bp (mm10) and rs29383600, 
we defined the proximal interval of this smaller congenic with the marker rs29383600 
(50,373,006 bp). The remainder of the genome is isogenic for B6J as determined by several 
other markers on chromosome 11 and by a medium-density genotyping array containing 
882 informative SNP markers from our previous study (Yazdani et al., 2015). 
We also simultaneously monitored for the detection of a recombination event (i.e., 
the observation of a homozygous B6J genotype) at a second marker located just distal to 




at rs254771403, we then genotyped at an additional upstream proximal marker at 
rs29459915 (50,484,260 bp; mm10) that was also downstream of Rufy1 and found 
retention of the D2J allele at this locus. Thus, the new remarkably smaller congenic interval 
was conservatively defined by a region spanning proximal rs29383600 (50,373,006 bp) 
and distal rs254771403 (50,486,498 bp), yielding a 114 kb interval. Thus, we named this 
new congenic, “114 kb”.  
PCR primers were designed to amplify a ~200 bp amplicon that contained and 
flanked each SNP. The PCR products were run on a 1.5% agarose gel and visualized for 
band specificity. Single bands were excised according to their predicted fragment size and 
gel-purified (Promega Wizard SV Gel and PCR Clean-Up System, Cat A9281), and 
prepared for Sanger sequencing (Genewiz, Cambridge, MA, USA). Mice homozygous for 
the 114 kb region (referred to as 114 kb) and B6J littermates were generated via 
heterozygous-heterozygous 114 kb breeders. To avoid genetic drift, heterozygous 114 kb 
breeders were maintained by mating heterozygous male offspring with C57BL/6J females 
purchased from The Jackson Laboratory in Bar Harbor, ME, USA. Mice were SNP-
genotyped using genomic DNA extracted from tail biopsies and two Taqman SNP markers: 
rs29383600 (50.37 Mb) and rs29459915 (50.48 Mb) (ThermoFisher Scientific, Waltham, 
MA, USA). 
Methamphetamine-induced locomotor activity in 114 kb congenic mice 
Both female and male littermates (56-100 days old at the start of the experiment), were 
phenotyped for MA-induced locomotor activity. Mice were housed in same-sex groups of 




standard housing conditions. Colony rooms were maintained on a 12:12 h light–dark cycle. 
The estimated sample size required to detect a significant effect (Cohen’s d = 0.72), with 
80% power (p < 0.05) was n = 25 per genotype based on the previously published 
phenotype in the larger congenics capturing a QTL for reduced MA-induced locomotor 
activity (Yazdani et al., 2015). Mice were tested for baseline locomotor activity on Days 1 
and 2 over 60 min and then administered MA (2 mg/kg, i.p.) on Days 3, 4, and 5 and were 
video-recorded for distance traveled over 60 min using Anymaze (Stoelting Co., Wood 
Dale, IL, USA) as previously described (Yazdani et al., 2015). Data are presented in six, 
five-min bins or as the summed distance traveled over 60 min for each of the five days of 
injections.  
Transcriptome analysis followed by gene set enrichment analysis 
Striatum punches were harvested bilaterally from 114 kb congenic mice homozygous for 
the congenic region (n = 8) and B6J wild-type littermates (n = 8) and processed for total 
RNA extractions (Yazdani et al., 2015). RNA samples were bioanalyzed (RIN > 8) and 
cDNA library was prepared using the Illumina TruSeq Standard mRNA LT (100 bp paired-
end reads). The 16 samples were multiplexed and sequenced over three lanes on Illumina 
HiSeq 2500. The data is available on the NCBI GEO database under accession number 
GSE76929. FastQ files were aligned to the mouse mm10 reference genome using TopHat 
(Trapnell et al., 2012). HTSeq python framework (Anders et al., 2015) was used to compute 
the read counts per gene followed by limma (Ritchie et al., 2015) to integrate counts and 
detect differentially expressed genes. For differential analysis, a linear model was used to 




Furthermore, between-technical replicate correlation was accounted for using the 
duplicateCorrelation(), limma function (Smyth et al., 2005). An α level of p < 0.001 was 
employed.  For gene set enrichment analysis of the 69 differentially expressed genes that 
meet the significant cutoff, Enrichr (Chen et al., 2013; Kuleshov et al., 2016) was used to 
determine the enrichment of top Kyoto Encyclopedia of Genes and Genomes (KEGG) 
pathway terms and gene ontology (GO) terms.  
Differential exon usage analysis followed by gene set enrichment analysis  
For differential usage of exons using limma (Ritchie et al., 2015), reads were aligned to the 
Ensembl-annotated genome that contains extensive annotation of coding and non-coding 
exons and quantified using DEXSeq (Anders et al., 2012) with a requirement of one read 
count per exon bin and a minimum of at least 10 reads across all replicates. Similar to 
differential analysis, for each gene, a linear model was used to detect differential exon 
usage between genotypes with “Cage” included as a covariate and between-technical 
replicate correlation was accounted for using the duplicateCorrelation() limma function 
(Smyth et al., 2005). Differential exon usage was defined as the proportion of total 
normalized reads per gene that are counted within an exon bin for that gene. Statistical 
significance was evaluated using gene-level tests, including an F test that reflects a 
consensus signal across a gene and is highly powered to detect differential exon usage 
when more than one signal is observed across multiple exons per gene. We also report the 
results from a Simes multiple testing procedure that assesses all exons within a gene which 
is more powered to detect differential exon usage when a single strong signal is observed. 




significant genes exhibiting differential exon usage between the 114 kb and B6J were 
analyzed for pathway enrichment using Enrichr (Chen et al., 2013; Kuleshov et al., 2016) 
for KEGG pathway enrichment analysis. A clustergram was used for visualization of the 
overlapping genes of the top enriched pathways.  
Real-time quantitative PCR (qPCR) validation 
For qPCR validation of exon usage, oligo-dT primers were used to synthesize cDNA from 
total RNA using the same samples that were used in RNA-seq analysis using SYBR Green 
(ThermoFisher Scientific, Waltham, MA, USA; Cat# 4309155). The qPCR primers used 
for exon usage in Hnrnph1 are shown in Table A2.  Each sample was run in triplicate, 
averaged, and normalized to its own expression level using GAPDH as a housekeeping 
gene. Differential exon usage was reported as the fold-change in 114 kb congenic mice 
relative to B6J littermates using the 2-(∆∆CT
) method (Schmittgen and Livak, 2008). 
SDS-PAGE and Western blot 
Whole striata (left and right sides) were homogenized using a hand-held homogenizer in 
RIPA buffer supplemented with Halt protease and phosphatase inhibitor cocktail (Thermo 
Fisher Scientific, Waltham, MA, USA; Cat# 78840) followed by sonication. 30 g of 
protein was heated in a 70°C water bath for 10 min before loading into a 4 – 20% Criterion 
TGX precast Midi protein gel (Bio-Rad, Hercules, CA, USA; Cat# 5671094) for SDS-
PAGE followed by wet transfer to a nitrocellulose membrane. After the transfer, all 
membranes were stained with ponceau S solution (0.1% ponceau S in 1% (v/v) acetic acid) 




membranes were then imaged and densitometry analysis for total protein per lane was 
quantified in ImageJ2 (Rueden et al., 2017). The membrane was then blocked with 5% 
milk for 1 h and probed with primary antibodies. hnRNP H protein expression was 
evaluated using three different antibodies: 1) C-term specific hnRNP H antibody 
(1:100,000, Bethyl, Montgomery, TX, USA; Cat #A300-511A); 2) N-term specific hnRNP 
H antibody (1:20,000, Santa Cruz, Dallas, TX, USA; Cat# sc-10042); and 3) hnRNP H1 
antibody (1:10,000, Proteintech, Rosemont, IL, USA; Cat# 14774-1-AP). The secondary 
used for the Bethyl and Proteintech antibodies was donkey anti-rabbit HRP (1:10,000, 
Jackson ImmunoResearch Laboratories, West Grove, PA; Cat# 711-035-152) and the 
secondary used for the Santa Cruz one was bovine anti-goat HRP (1:10,000, Jackson 
ImmunoResearch Laboratories, West Grove, PA; Cat# 805-035-180). All membranes were 
imaged via enhanced chemiluminescence photodetection. For quantification analysis of 
protein expression, total protein stains were used as loading controls in normalization for 
immunoblotting quantification (Aldridge et al., 2009; Gilda and Gomes, 2013). 
Cell culture and transfection 
HEK-293T cells were grown in DMEM, high glucose with L-glutamine (Gibco, Waltham, 
MA, USA; Cat# 11965-092), supplemented with 10% fetal bovine serum (Gibco, Waltham, 
MA, USA; Cat# 26140-079), and 1% penicillin-streptomycin (Gibco, Waltham, MA, USA; 
Cat# 15140-122). N2a neuron-like cells were grown in 1:1 ratio of DMEM, high glucose 
with L-glutamine (Gibco, Waltham, MA, USA; Cat# 11965-092) to Opti-MEM (GibCO, 
Waltham, MA, USA; Cat# 31985-070), supplemented with 5% fetal bovine serum (Gibco, 




MA, USA; Cat# 15140-122). Cells were split every 3 to 4 days and were grown at 37C in 
an atmosphere of 5% CO2. 
For HEK293T, cells were seeded in 6-well plate at a density of 2.5 x 105 cells per 
well 24 hours prior to transfection and would be about 90% confluent at the time of 
transfection. For N2A (given they grow faster than HEK293T cells), cells were seeded in 
6-well plate at a density of 2 x 105 cells per well. A suspension of plasmids, Lipofectamine 
3000 and P3000 reagents (ThermoFisher Scientific, Waltham, MA, USA; Cat# L3000008) 
in Opti-MEM medium was pre-incubated at room temperature for 15 min before being 
added to each well of the 6-well plates. The cells were co-transfected with 1 g of the 
experimental firefly luciferase construct and 0.2 g internal pRL control plasmid 
expressing Renilla luciferase driven by the CMV promoter (Promega, Madison, WI, USA; 
Cat# E2261). 24 hours after transfection, HEK293T cells were detached with 0.25% of 
Trypsin-EDTA (ThermoFisher Scientific, Waltham, MA, USA; Cat# 25200056) and 
counted and re-seeded at a density of 2.5 x 104 cells per well in 96-well plate. N2a cells 
were re-seeded at a density of 2 x 104 cells per well in 96-well plate. Cells were allowed to 
grow for approximately 48 h before measurement of luciferase activity as described below. 
Luciferase reporter assay 
We cloned the B6J Hnrnph1 promoter sequence (Chr11: 50,375,375 to 50,378,330; mm10) 
starting at 2956 bp upstream of the annotated transcription start site for Hnrnph1. This 
sequence was amplified from B6J genomic DNA extracted from spleen tissue using iProof 
High-Fidelity PCR kit (BIO-RAD, Hercules, CA, USA; Cat# 172-5330) with the following 




primers respectively: sense (5’-GATTCTCGAGGCTCCCGTGATCAGATACAG-3’) and 
anti-sense (5’-GTAAAGCTTCGTCCCTTCGGTGGTCCTGGC- 3’). The sequence was 
subsequently cloned into the multiple cloning site of pGL4.17[luc2/Neo] (Promega, 
Madison, WI, USA; Cat# E6721) with restriction enzymes XhoI and HindIII, placing the 
Hnrnph1 promoter was inserted upstream of firefly luciferase luc2 coding sequence. 
To identify variants within Hnrnph1 between D2J and B6J mice, we used the whole 
genome sequence dataset (35, 36) and the online Sanger variant query tool (REL-1505 - 
GRCm38) to identify a total of 16 variants including three SNPs and one idel 
(insertion/deletion) located in the 5’UTR of Hnrnph1 (see Table 7). To replace B6J variants 
with D2J variants within the 5’UTR of Hnrnph1, we conducted site-directed mutagenesis 
using the B6J Hnrnph1:luc2 construct as a template (Agilent QuikChange II, Santa Clara, 
CA, USA; Cat# 200521) to generate four luciferase reporter lines, each containing a single 
D2J variant. To introduce the three SNPs and the single indel all together into the 5’ UTR 
of Hnrnph1, multi-site directed mutagenesis was performed by using the GA7546G:luc2 
construct with rs221962608 SNP variant as the template (Agilent, Santa Clara, CA, USA; 
Cat# 200514). The mutagenic primers are provided in Table A1. 
To account for background fluorescence signal, untransfected cells were used to 
subtract out background signal from the 96-well plate. Negative control cells were 
transfected with the promoter-less plasmid pGL4.17[luc2/Neo]. The Dual-Glo luciferase 
assay system (Promega, Madison, WI, USA; Cat# E2920) was used to measure luciferase 
activity. The growth medium was removed first and cells were then washed with PBS. Cell 




cells by shaking the plate on rocker for 15 min. 20 l of lysate from each well was 
transferred to wells of white opaque 96-well microplate (Corning, Corning, NY, USA; Cat# 
3610). Dual-Glo LARII reagents (100 l) were added into each well and the firefly 
luminescence was measured with SpectraMax i3x microplate reader after 15 min. An equal 
amount (100 l) of Stop & Glo reagent was then added to the wells and Renilla 
luminescence was measured after 15 min. 
Firefly and Renilla luciferase signal values were subtracted from the average 
background signal first. The background-adjusted firefly luciferase activity (FLA) for each 
sample was normalized to the background-adjusted internal control Renilla luciferase 
activity (RLA) to correct for differences in transfection efficiency and cell death. Relative 
luciferase activity for each experimental construct is expressed as the fold increase over 
the B6J Hnrnph1:luc2 control: 








Experimental design and statistical analyses 
All data are presented as means of replicates from each experiment ± S.E.M. For 
experiments in which two conditions were compared, a two-tailed unpaired t-test was used 
to analyze the data unless otherwise specified. For the behavioral experiments in which 
multiple factors were evaluated, ANOVA was used and significant interactions were 
deconstructed along the relevant factor to examine main effects and group differences 




which multiple factors were evaluated, ANOVA was used and significant interactions were 
deconstructed with Dunnett’s post hoc test for multiple comparisons. Statistical α level for 
t-test, ANOVA, and post-hoc tests were set to 0.05. The data comprising MA-induced 
locomotor activity were analyzed in R (http://www.R-project.org/). All other data analyses 




CHAPTER III: A mutation in Hnrnph1 that decreases methamphetamine-induced 
reinforcement, reward, and DA release and increases synaptosomal hnRNP H and 
mitochondrial proteins 
Adapted from Ruan et al., 2020, Journal of Neuroscience 
ABSTRACT 
Individual variation in the addiction liability of amphetamines has a heritable genetic 
component. We previously identified Hnrnph1 as a quantitative trait gene underlying 
decreased MA-induced locomotor activity in mice. Here, we showed that mice (both 
females and males) with a heterozygous mutation in the first coding exon of Hnrnph1 (H1 
MUT) showed reduced MA reinforcement and intake and dose-dependent changes in MA 
reward as measured via conditioned place preference. Furthermore, H1 MUT mice showed 
a robust decrease in MA-induced extracellular DA in the NAc with no change in baseline 
extracellular DA, striatal whole tissue DA, DA transporter protein, DA uptake, or striatal 
MA and amphetamine metabolite levels. Immunohistochemical and immunoblot staining 
of midbrain dopaminergic neurons and their forebrain projections for tyrosine hydroxylase 
did not reveal any major changes in staining intensity, cell number, or forebrain puncta 
counts. Surprisingly, there was a two-fold increase in hnRNP H protein in the striatal 
synaptosome of H1 MUT mice with no change in whole tissue levels. To gain insight into 
the mechanisms linking increased synaptic hnRNP H with decreased MA-induced DA 
release and behaviors, synaptosomal proteomic analysis identified an increased baseline 
abundance of several mitochondrial complex I and V proteins that rapidly decreased at 30 




synaptosomal mitochondrial proteins in wild-type mice showed a rapid increase. We 
conclude that H1 MUT decreases MA–induced extracellular DA in the NAc, reward, and 
reinforcement and induces dynamic changes in basal and MA-induced synaptic 







Addiction to psychostimulants including MA is a major public health concern in the United 
States, with an estimated 535,000 individuals currently meeting the criteria for MA 
dependence (Lipari et al., 2016). Despite the prevalence of MA addiction, there is currently 
no FDA-approved treatment, in part because the neurobiological mechanisms underlying 
MA addiction are still not clear. Variation in sensitivity to the locomotor stimulant response 
to psychostimulants is a heritable trait and can sometimes predict differences in drug self-
administration in rodents (Hooks et al., 1991; Yamamoto et al., 2013) because shared 
neurocircuits and neurochemical mechanisms underlie these behaviors. We recently used 
QTL mapping, positional cloning and gene editing via Transcription Activator-like 
Effector Nucleases (TALENs) to identify Hnrnph1 as a quantitative trait gene for MA 
sensitivity in mice (Yazdani et al., 2015). Hnrnph1 encodes an RBP that is expressed 
throughout the brain, and is a part of a subfamily of hnRNPs that includes hnRNP H1, 
hnRNP H2 and hnRNP F that possess structurally unique quasi-RNA recognition motifs 
(Honoré et al., 1995). hnRNP H1 regulates all aspects of RNA metabolism, including pre-
mRNA splicing through binding at specific intronic sites, mRNA stability and translational 
regulation via binding to the 5’UTR and 3’UTR, and poly-adenylation control (Chou et al., 
1999; Arhin et al., 2002; Katz et al., 2010; Witten and Ule, 2011; Wang et al., 2012; Song 
et al., 2017). 
We previously demonstrated that Hnrnph1 polymorphisms and heterozygous 
deletion in the first coding exon of Hnrnph1 affect behavioral sensitivity to acute MA-




unknown. Additionally, the neurobiological mechanism(s) underlying the mutational 
effects of Hnrnph1 on MA-induced behaviors remain to be established. Hnrnph1 mRNA 
is ubiquitously expressed throughout the adult mouse brain (Lein et al., 2007). While the 
protein expression of hnRNP H1 appears to be nuclear-restricted, studies assessing hnRNP 
H1 protein in the brain are limited (Kamma et al., 1995; Honore et al., 1999; Van Dusen et 
al., 2010). With regard to CNS function, hnRNP H family proteins are described as master 
regulators of neuron and oligodendrocyte differentiation via alternative splicing control 
(Wang et al., 2007; Grammatikakis et al., 2016b). Whole-exome sequencing identified 
coding variants in human HNRNPH1 and HNRNPH2 (located on the X chromosome) 
associated with severe neurodevelopmental disorders (Bain et al., 2016; Pilch et al. 2018), 
implicating a crucial role of the hnRNP H protein family in neurodevelopment.  
The purpose of the present study was three-fold. First, in order to expand beyond 
MA locomotor stimulant sensitivity, we examined the effect of the Hnrnph1 mutation on 
oral MA reinforcement and intake via operant-conditioning and MA reward via 
conditioned place-preference (CPP). This mutation comprises a small, frameshift deletion 
in the first coding exon of Hnrnph1 (H1 MUT) that causes reduced MA-induced locomotor 
activity (Yazdani et al., 2015). To gain insight into the neurobiological mechanisms 
underlying behavioral differences in MA sensitivity, we examined drug-induced 
extracellular DA level via in vivo microdialysis, DA content of striatal tissue, and DA 
clearance from striatal tissue. Second, because we previously implicated Hnrnph1 
polymorphisms in dopaminergic neuron development, we assessed the effect of H1 MUT 




pathway via immunoblotting and immunohistochemistry. Finally, to gain insight into 
neural dysfunction in H1 MUT mice at the protein level that could underlie behavioral and 
neurochemical deficits, we examined the synaptosomal proteome of the striatum between 








































Characterization of Hnrnph1/2 and hnRNP H protein expression in H1 MUT mice 
Hnrnph1 mutant mice (H1+/- or H1 MUT) were generated using TALENs targeting the 
first coding exon of Hnrnph1 (exon 4, UCSC Genome Browser). Deletion of a small region 
in the first coding (exon 4) in Hnrnph1 leads to a premature stop codon and transcription 
of a truncated mRNA message. The mice were genotyped using a restriction enzyme based 
assay (Figure 14A; Yazdani et al., 2015). Gene expression via qPCR with primers specific 
for exons 6 – 7 (not targeting the deleted exon 4) detected a 50% increase of Hnrnph1 
transcript in the H1 MUT (heterozygous for deletion) relative to WT (Yazdani et al., 2015) 
and a 1.5-fold increase in the H1-/- (homozygous for deletion) (Figure 14B) with no 
change in gene expression of Hnrnph2 (Figure 14C, Yazdani et al., 2015). At the protein 
level, there was no change in hnRNP H protein expression in H1 MUT or H1-/- embryonic 
stage brain tissue homogenate (Figure 14D-G). Because hnRNP H1 and H2 have 96% 
amino acid sequence homology, there is no commercially available antibody that can 
differentiate the two proteins. Quantitative analysis of protein peptide from an hnRNP H 
immunoprecipitation mass spectrometry study identified no difference in peptide level 
unique to hnRNP H1 between the H1 MUT mice compared to that of WT (Figure 15A-B). 
Because we previously detected a decrease in transcription of exon 4 in the H1 MUT mice 
(Yazdani et al. and Figure 14B), we hypothesized that there would be a decrease in the 
level of Peptide 3 (GLPWSCSADEVQR) which contains amino acid residues encoded by 
the deleted region in exon 4 of Hnrnph1. Indeed, there was a decrease in the level of Peptide 




B). No genotypic difference was observed in unique peptides associated with hnRNP H2 
(Figure 15C-D).  
 
Figure 14.  Hnrnph1 whole brain mRNA and hnRNP H whole body protein expression in 
WT, H1 MUT, and H1-/- mice. H1-/- mice and WT littermates were generated by 
intercrossing H1 MUT and H1 MUT.  
Embryos were harvested at E12 for genotyping using a restriction enzyme-based assay. (A): A PCR 
amplicon capturing the deleted region was digested with BstNI. WT mice had two copies of two 
BstNI restriction sites, and thus, restriction digest produced three fragments (58 bp, 157 bp, and 
153 bp) corresponding to two bands on the gel. H1-/- mice had two copies of a single BstNI 
restriction sites, and thus, restriction digest produced two fragments (153 bp and 198 bp). H1 MUT 
mice possessed one copy of each of the two BstNI restriction sites and one copy of a single BstNI 
restriction site, and thus, restriction digest produced 5 fragments (58 bp, 153 bp, 153 bp, 157 bp, 




increase in the transcript level Hnrnph1 in H1 MUT and H1-/- mice. The 1.5-increase in Hnnph1 
transcript level in H1 MUT mice replicated our previously observation (Yazdani et al. 2015). The 
> 2-fold increase in Hnrnph1 transcript level in H1-/- with two copies of the mutation provides 
further functional support for increased expression of the mutant transcript (one-way ANOVA, 
F(2,9) = 2.55, p = 0.133; pairwise comparison between WT versus H1-/-: t(6) = -2.82 , *p = 0.031). 
(C): There was no genotypic difference in Hnrnph2 transcript level. (D-G): Protein expression of 
hnRNP H in WT, H1 MUT, and H1-/- mice. There was no significant genotypic difference in 
hnRNP H protein expression using an antibody targeting the C-terminus of hnRNP H (D-E) or the 
N-terminus of hnRNP H (F-G) (one-way ANOVA, C-terminus: F(2,9) = 0.89, p = 0.440; N-
terminus: F(2,9) = 1.64, p = 0.250). n = 4 per genotype. 
 
 
Figure 15.  Quantification of hnRNP H1 and hnRNP H2 protein peptide sequences from mass 
spec of hnRNP H immunoprecipitates from H1 MUT and WT striatum.  
A separate cohort of mice were used for this study. Co-immunoprecipitation was used to pull down 
hnRNP H and associated proteins. Using the “Similarity” function in the Scaffold software, 
peptides exclusive to hnRNP H1 or hnRNP H2 were identified and quantified. (A): A list is shown 
for the peptides that are unique to hnRNP H1. (B): Quantification of peptides unique to hnRNP H1. 




WT mice (unpaired t-test for each individual peptide, Peptide 1: t(4) = -0.45, p = 0.673; Peptide 2: 
t(4) = -1.39, p = 0.236; Peptide 3: t(4) = -1.94, p = 0.125; Peptide 4: t(4) = -0.85, p = 0.445; Peptide 
5: t(4) = -1.06, p = 0.351; Peptide 6: t(4) = 0.46, p = 0.672, Peptide 7: t(4) = 2.21, p = 0.091, Peptide 
8: t(4) = -1.07, p = 0.346; ). Amino acids PWSCS within this peptide are encoded by the deleted 
region (GCCCTGGTCCTGCTCC) in exon 4 of Hnrnph1 in the H1 MUT mice. (C): Table 
outlining the peptides that are unique to hnRNP H2. (D): Quantification of hnRNP H2 unique 
peptides. No significant change in unique peptides of hnRNP H2 was observed between WT and 
H1 MUT mice (unpaired t-test for each individual peptide, Peptide 1: t(4) = -0.83, p = 0.454; 
Peptide 2: t(4) = 0.86, p = 0.441; Peptide 3: t(4) = 1.56, p = 0.197; Peptide 4: t(4) = 0.95, p = 0.396; 
Peptide 5: t(4) = -0.516, p = 0.633; Peptide 6: t(4) = -0.07, p = 0.950) 
 
Oral MA self-administration 
We previously demonstrated a robust reduction in sensitivity to the locomotor stimulant 
response to MA in H1 MUT mice (Yazdani et al., 2015). To more directly test MA-induced 
motivated behaviors, we investigated MA reinforcement and intake in H1 MUT mice using 
an oral MA self-administration paradigm as conducted previously in C57BL/6J mice 
(Szumlinski et al., 2017). This study showed that mice allocated the majority of their nose-
poking behavior toward the MA-reinforced hole, indicating drug reinforcement. H1 MUT 
mice presented fewer active nose-pokes at the 160, 200, 300 and 400 mg/L MA doses 
compared to WT mice (Figure 16A), with no difference in non-specific, inactive nose-
pokes across a range of MA concentrations (80-400 mg/L) (Figure 16B). Consistent with 
their lower level of MA reinforcement, H1 MUT mice also consumed less MA (intake; 
mg/kg/day) at the 200, 300 and 400 mg/L concentrations (Figure 16C). No interactions 
between Sex and Genotype were observed for any measure during self-administration 
testing. The genotypic differences in high-dose MA intake did not relate to bitter taste 
sensitivity as quinine intake in the home cage was equivalent between H1 MUT and WT 







Figure 16. Oral MA self-administration in H1 MUT mice.  
H1 MUT mice were less sensitive than WT to the reinforcing effect of MA. H1 MUT and WT mice 
were provided access to 80, 120, 160, 200, 300 and 400 mg/L of MA for a time period of five days 
per dose. (A): The average total active nose-pokes emitted during five, 1 h, sessions varied as a 
function of MA Dose with H1 MUT showing less active nose pokes at MA doses 160, 200, 300, 
and 400 mg/l (mixed effects ANOVA, F(1,41)Genotype = 6.33, p = 0.02; F(5,205)Dose = 23.93, p < 
0.0001; F(5,205)Genotype x Dose  = 1.58, p = 0.166; unpaired t-tests for 80 and 120 mg/L, p’s > 0.65; 
for 160-400 mg/L, p’s < 0.03; unpaired t-test at each dose for WT versus H1 MUT: for 160-400 
mg/L, *p’s < 0.03). (B): The average total inactive nose-pokes emitted during the five, 1 h, sessions 
varied as a function of MA Dose with no genotypic difference between H1 MUT and WT (mixed 
effects ANOVA, F(1,41)Genotype = 0.76, p = 0.39; F(5,205)Dose = 5.84, p < 0.0001; F(5,205)Genotype x 
Dose  = 1.27, p = 0.28). (C): H1 MUT mice consuming less MA than WT mice at 200, 300, and 
400mg/l doses of MA (mixed effects ANOVA, F(1,41)Genotype = 6.85, p = 0.01; F(5,205)Dose = 52.11, 
p < 0.0001; F(5,205)Genotype x Dose  = 4.47, p < 0.0001; unpaired t-tests for 80 -160 mg/L, p’s > 0.12; 
for 200 - 400 mg/L, *p’s < 0.03). n = 23 (10 females, 13 males) for H1 MUT and n = 22 (9 females, 
13 males) for WT. 
 
The blunted escalation of oral MA intake observed at high MA concentrations (≥ 
200 mg/L) in H1 MUT mice initially trained to respond for 80 mg/L MA prompted us to 
determine if the Hnrnph1 mutation would blunt the acquisition of oral MA self-
administration when 200 mg/L MA served as the reinforcer. However, we were unable to 
detect any genotypic difference in MA intake and active nose-pokes when mice were 
trained at this higher MA concentration (data not shown; refer to Ruan et al., 2020a). These 
results indicate that the Hnrnph1 mutation interferes with the transition from low to high-
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dose MA self-administration, without altering the reinforcing effects of MA during 
acquisition. 
MA-conditioned reward 
To further investigate why H1 MUT mice showed less oral self-administration of MA, we 
assessed MA reward via CPP. When mice were tested in a MA-free state (Day 8), the 
genotypic difference in the time spent in the MA-paired side between Day 8 and varied 
with MA doses (Figure 17A). H1 MUT mice showed lower CPP to 0.5 mg/kg MA but 
higher CPP to 2 mg/kg MA compared to the WT mice (Figure 17A;). Similar non-
significant effects were observed during drug state-dependent CPP whereby H1 MUT mice 
exhibited lower and higher CPP at 0.5 mg/kg and 2 mg/kg MA doses, respectively (Figure 
17B). No sex differences or interactions were observed for any measure during MA-CPP 
testing. The dose-dependent difference in CPP indicates that H1 MUT showed a reduced 
sensitivity to the rewarding effect of low-dose MA and that a higher MA dose was required 








Figure 17. MA-induced CPP in H1 MUT mice.  
H1 MUT mice were less sensitive than WT to the rewarding effect of MA. (A): Genotypic 
differences in the time spent in the MA-paired side between Day 8 and 1 (preference, s) were 
observed at 0.5 mg/kg and 2 mg/kg MA doses. H1 MUT mice showed lower preference at 0.5 
mg/kg and higher preference at 2 mg/kg in comparison to WT (two-way ANOVA, F(2,121)interaction 
= 3.92; p = 0.023; F(1,121)Genotype = 0.07, p = 0.788; F(2,121)Dose = 6.15, p = 0.003; unpaired t-test; 
0.5 mg/kg: t(45) = -2.13, p = 0.039; 2 mg/kg: t(45) = 2.18, p = 0.036). (B): In examining state-
dependent CPP following a challenge dose of MA that was the same dose administered during 
training, a similar pattern of results (although no significant) was observed with H1 MUT showing 
lower and higher preference at 0.5 and 2 mg/kg, respectively, compared to WT wo-way ANOVA, 
F(2,121)interaction = 1.86; p = 0.160; F(1,121)Genotype = 0.23, p = 0.634; F(2,121)Dose = 2.08, p = 0.129. 
n = 24 (16 females, 8 males), 22 (14 females, 8 males) and 16 (9 female, 7 males) at 0, 0.5 and 2 
mg/kg MA for H1 MUT; n = 23 (9 female, 14 males), 23 (12 female, 11 males) and 19 (7 female, 
12 males) at 0, 0.5 and 2 mg/kg MA for WT.  
 
We also identified significant genotypic differences in MA-induced locomotor 
activity in the confined one-half of the CPP box during CPP training on Days 3 and 5 (data 
not shown; refer to Ruan et al., 2020a). H1 MUT mice traveled less distance at 60 min 
post-2 mg/kg MA injection on Day 3 and 5 (data not shown; refer to Ruan et al., 2020a). 
During state-dependent CPP (following the two previous MA exposures) on Day 9 when 
mice had twice as much open access space, we observed a decrease in MA-induced 
locomotor activity in H1 MUT mice (data not shown; refer to Ruan et al., 2020a). This 
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the CPP divider and floor textures in response to a single, acute MA dose of 2 mg/kg 
(Yazdani et al., 2015). Furthermore, note that we later demonstrate replication of reduced 
MA-induced locomotor activity in H1 MUT mice using the same three-day protocol from 
the original publication (Yazdani et al., 2015) prior to tissue harvesting for mass 
spectrometry analysis (see Figure 24 and later description of the results). There was no 
genotypic difference in the striatal level of either MA or its metabolite amphetamine at 30 
min i.p. post injection of MA (Figure 18). Thus, differences in transport or metabolism of 
MA are unlikely to explain the decrease in MA-induced behavior in H1 MUT mice at 30 
min post-MA. 
 
Figure 18. Concentration of MA and amphetamine in the striatum at 30 min post-MA 
injection in H1 MUT mice.  
On Days 1 and 2, mice were injected (i.p.) with saline and placed into apparatus for 1 h. On Day 3, 
mice were injected (i.p.) with 2 mg/kg MA and placed into apparatus for 30 min followed by 
subsequent removal of the striatum. (A): No genotypic difference was detected in the striatal 
concentration of MA. (B): Also, no genotypic difference was detected in the striatal concentration 
of amphetamine. Unpaired t-test, t(14) = -0.72, -0.22, p = 0.480, 0.826 for MA and amphetamine 


































































MA-induced extracellular DA in NAc of H1 MUT mice 
Because H1 MUT mice showed reduced MA self-administration and reward, we next 
examined basal extracellular DA and MA-elicited extracellular DA using in vivo 
microdialysis in the NAc, a brain region and neurochemical event that are necessary for 
MA reinforcement and reward (Prus et al., 2009; Keleta and Martinez, 2012; Bernheim et 
al., 2016). Linear regression analysis of no net-flux in vivo microdialysis in the NAc 
indicated no significant change in either DA release/reuptake (data not shown; refer to 
Ruan et al., 2020a) or basal extracellular DA content or (data not shown; refer to Ruan et 
al., 2020a). Following administration of 0.5 mg/kg MA (i.p.), WT mice exhibited an 
increase in extracellular DA whereas H1 MUT mice showed a decrease in extracellular DA 
below baseline (Figure 19A). Administration of 2 mg/kg MA (i.p.) induced an increase in 
DA within the NAc of both genotypes but H1 MUT mice again showed markedly lower 
MA-induced extracellular DA levels, in particular from 100 to 180 min post-MA (Figure 
19B). Consistent with the genotypic differences in extracellular DA levels, for both the 0.5 
and 2 mg/kg MA doses, H1 MUT mice also showed a lower level of 3,4-






Figure 19. In vivo microdialysis of MA-induced extracellular DA in NAc of H1 MUT mice.   
H1 MUT mice showed blunted MA-induced DA and DOPAC levels compared to WT. Mice were 
probed on the contralateral side, perfused with artificial cerebrospinal fluid (aCSF), and 
administered a MA challenge of either 0.5 mg/kg or 2 mg/kg (i.p., black arrow) after a 1 h baseline 
period. (A-B): The capacity of MA to elevate DA in the NAc was blunted in the H1 MUT mice, in 
a manner that varied with the dose of MA administered. (A): The 0.5 mg/kg MA dose elicited an 
increase in extracellular DA in in WT but not in H1 MUT mice, with H1 MUT mice exhibiting 
significantly lower extracellular DA levels than WT mice at all time-points post-injection (mixed 
effects ANOVA, F(1,25)Genotype = 18.57, p < 0.0001; F(11,275)Time = 1.63, p = 0.09; F(11,275)Genotype 
X Time = 4,71, p < 0.0001; unpaired t-tests for time = -60 to 0 min, t(25) < 0.60, p’s > 0.60; for time 
= 20 to 180 min, t(25) > 2.25, *p’s < 0.033). (B): The 2 mg/kg MA dose elicited an increase in 
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rise was distinct between H1 MUT and WT mice.  H1 MUT mice exhibited lower DA levels 
compared to WT mice during the first 20 min post-injection, as well as during the second half of 
testing (mixed effects ANOVA, F(1,31)Genotype = 6.41, p = 0.02; F(11,341)Time = 8.29, p < 0.0001; 
F(11,341)Genotype X Time = 5.58, p < 0.0001; unpaired t-tests, for time -60 to 0 and 40 min, t(31) < 1.5, 
p’s > 0.15; for time 20, 60-180 min, t(31) > 2.0, * p’s < 0.05). (C-D): MA dose-dependently reduced 
NAc extracellular DOPAC levels; however, irrespective of MA Dose or Sex, this reduction was, 
overall, greater in H1 MUT versus WT mice. (C): 0.5 mg/kg MA induced a lowering of 
extracellular DOPAC, relative to baseline levels, with H1 MUT mice exhibiting significantly lower 
DOPAC 80 min post-injection (mixed effects ANOVA, F(1,28)Genotype = 1.50, p = 0.23; 
F(11,308)Time = 13.33, p < 0.0001; F(11,308)Genotype X Time = 2.76, p = 0.002; unpaired t-tests, for all 
times but 160 min, t(28) < 1.90, p’s > 0.08; for time = 160 min, t(28) = 2.37, * p = 0.03). (D): 2 
mg/kg MA induced a lowering of extracellular DOPAC in both genotypes; however, the effect was 
amplified in H1 MUT mice. Relative to WT animals, H1 MUT mice exhibited lower DA levels 
during the first 20 min post-injection, as well as during the second half of testing (mixed effects 
ANOVA, F(1,25)Genotype = 24.09, p < 0.0001; F(11,275)Time = 29.04, p<0.0001; F(11,275)Genotype X 
Time = 10.42, p < 0.0001; unpaired t-tests, for time -60 to 0 and 40 min, t(25) < 1.6, p’s > 0.10; for 
time 20, 60-180 min, t(25) > 2.0, *p’s < 0.05). n=13 (7 females, 6 males) at 0.5 and n=17 (10 
females, 7 males) at 2.0 mg/kg MA for H1 MUT; n=14 (8 females, 6 males) at 0.5 mg/kg MA and 
17 (10 females, 7 males) at 2 mg/kg MA for WT. 
 
In examining glutamate levels, no net flux microdialysis study revealed no 
difference in basal extracellular level of glutamate (data not shown; refer to Ruan et al., 
2020a). Acute administration of 0.5 mg/kg or 2 mg/kg MA did not induce much effect on 
extracellular glutamate levels, nor was there any genotypic differences in glutamate levels 
(data not shown; refer to Ruan et al., 2020a). To summarize, H1 MUT mice showed a 
significantly blunted MA-induced DA release in the NAc in the absence of any significant 
difference in baseline DA levels and in the absence of any significant differences in 
glutamate neurotransmission.  No sex differences or interactions were observed. These 
results point toward a MA-induced deficit in DA release as a plausible functional 





To further investigate the possible causes of the decreased capacity of MA to 
increase extracellular DA in H1 MUT mice, we quantified basal striatal tissue levels of 
biogenic amines in drug-naïve H1 MUT and WT mice. No genotypic difference was 
detected in the amount of DA and DOPAC (Figure 20A), or in the levels of other biogenic 
amines, including HVA, 3-MT, 5-HT, etc. (Figure 20A). We also tested whether H1 MUT 
impacts the function of DAT by examining DAT-mediated DA uptake in synaptosomes 
prepared from whole striatal tissue. However, no difference in basal DAT function was 
detected (Figure 20B). In addition, there was no change in the protein level of DAT in the 
total striatal brain lysate in H1 MUT compared to WT mice (Figure 20C-D). An increase 
in DAT protein level was detected in the female mice (Figure 20C-D). There was also no 






Figure 20. DA content and uptake and DAT levels in the striatum of H1 MUT mice.  
No changes in DA or in DAT were detected at baseline in the striatum of H1 MUT mice compared 
to WT mice. (A) Measurement of biogenic amine content in the striatum showed no difference in 




of other biogenic amines unpaired t-test, DA: t(14) = -0.30, p = 0.766; DOPAC: t(14) = -0.93, p = 
0.372). n = 8 per genotype. (B) DAT-mediated DA uptake in the striatum of H1 MUT mice. 
Striatum was harvested at 2 h post-saline or MA injection for DA uptake assay, based on the time 
course of the microdialysis data. There was no genotypic difference in the rate of DA uptake in 
response to saline (SAL) or MA (two-way ANOVA, F(1,14)interaction = 0.01, p = 0.911; F(1,14)Genotype 
= 0.02, p = 0.903; F(1,14)Treatment = 0.26, p = 0.619). n = 4 per group. (C-D): Immunoblot for DAT 
level in the striatum. Representative immunoblot for DAT shown in (C) with quantification shown 
in (D). There was no change in DAT protein level in the striatum of H1 MUT relative to WT mice 
(unpaired t-test, t(23) = 0.32, p = 0.750). WT: n = 14 and H1 MUT: n = 11. There was a main effect 
of Sex that was explained by females showing a higher level of DAT compared to that of male 
mice (two-way ANOVA, F(1,21)Sex = 5.74, p = 0.026, F(1,21)Genotype = 0.12, p = 0.730; 
F(1,21)interaction = 0.07, p = 0.800; unpaired t-test, females versus males t(23) = 2.53, *p = 0.019.) 
Females: n = 13 and Males: n = 12. (E): Immunoblot showing DAT protein level the striatal 
synaptosome at 30-min post saline (SAL) or MA treatment. (F): The striatal synaptosome of H1 
MUT mice did not show any change in DAT relative to WT mice after SAL or MA treatment (two-
way ANOVA, F(1,20)Genotype = 0.031, p = 0.86; F(1,20)Treatment = 0.037, p = 0.85; F(1,20)interaction = 
1.24, p = 0.28). WT SAL: n = 5, WT MA: n = 6, H1 MUT SAL: n = 6, and H1 MUT MA: n = 7. 
 
TH expression in the mesolimbic and nigrostriatal brain regions of H1 MUT mice 
In our previous transcriptome analysis of congenic mice that captured Hnrnph1 
polymorphisms and decreased MA behavioral sensitivity, we identified a decrease in 
expression of Nurr1 (Nr4a2), a transcription factor critical for dopaminergic neuron 
development (Yazdani et al., 2015). Thus, we hypothesized that dysfunctional mesolimbic 
and nigrostriatal DA pathways at the neuroanatomical level could underlie decreased MA-
induced behaviors and DA release in H1 MUT mice.  We tested this hypothesis by 
examining changes in the number of neurons and the number of projections from neurons 
in the dopaminergic mesolimbic and nigrostriatal pathways, which mediate reward and 
motor activity, respectively (Adinoff 2004). Diagrams outlining the different brain regions 
assessed are presented in Figure A4. We first examined co-expression of hnRNP H (there 
are currently no commercially available antibodies for differentiating between hnRNP H1 




of DA; Daubner et al., 2011). Results showed that hnRNP H and TH were co-expressed in 
the same midbrain TH neurons of the ventral tegmental area (VTA) and substantia nigra 
pars compacta (SNc) at a similar level in both genotypes (Figure 21A). hnRNP H 
immunostaining was primarily nuclear whereas TH immunostaining was cytoplasmic. We 
next examined expression of TH in the dopaminergic neurons of the mesolimbic and 
nigrostriatal circuit (Figures 21 and 22). TH DAB immunohistostaining in the VTA and 
SNc of the midbrain (Figure 21B) indicated no significant genotypic differences in TH 
optical density (OD) (Figure 21C). There was also no genotypic difference in the number 
(Figure 21D) or diameter (Figure 21E) of TH-positive neuron of the VTA and SNc. 
Immunoblot analysis indicated no significant difference in TH protein level in the midbrain 











Figure 21. TH levels in the midbrain of H1 MUT mice.  
No difference in TH level was detected in the VTA between H1 MUT and WT mice. (A): 
Immunofluorescent staining of hnRNP H (magenta) and TH (green) was conducted in coronal 
midbrain sections (Bregma: -3.28 mm to -3.64 mm) containing the VTA dopaminergic neurons in 
adult H1 MUT and WT mice. Higher magnification images in panels (i) and (ii) demonstrate 
nuclear expression of hnRNP H across all TH-positive dopaminergic neurons that we examined. 
Scale bars represent 200 μM (top) and 20 μM (bottom). (B): Representative image showing 
immunohistochemical DAB staining of TH in coronal sections of the midbrain region (Bregma: -
3.28 mm to -3.64 mm). Scale bars represent 1 mm. (C-E): Immunohistochemical DAB staining of 
TH in the midbrain regions revealed no genotypic difference between the H1 MUT and WT mice 
in  (C) TH optical density (unpaired t-test, VTA: t(13) = -1.29, p = 0.220; SNc: t(13) = -0.75, p = 
0.466; WT: n = 7 and H1 MUT: n = 8), in (D) number of TH-positive cells (unpaired t-test, t(14) = 
0.02, t = 0.985; n = 8 per genotype), or in (E) the diameter of TH-positive cells (t(14) = 0.88, p = 
0.395; n = 8 per genotype). (F-G): Immunoblot for TH protein level in the midbrain. Representative 
immunoblot for TH shown (F) and quantification (G).  There was no change in TH protein level in 
the midbrain region of H1 MUT relative to WT mice (unpaired t-test, t(18) = 0.67, p = 0.510; n = 
10 per genotype).  
 
TH DAB immunostaining in the striatum indicated no change in TH OD in the 
dorsal striatum between H1 MUT and WT mice (Figures 22A-C). However, a small, but 
statistically significant increase in TH OD was observed in the ventral striatum (which 
includes the NAc) of the H1 MUT mice (Figures 22D-F). To measure TH-positive puncta 
as an indirect estimate of the number of DA terminals in the striatum, we performed 
stereology under higher magnification (Figure A5A) and detected no difference in the 
number of TH-positive puncta between the H1 MUT and WT mice in the dorsal striatum 
or in the ventral striatum (Figure A5B). Immunoblot analysis indicated no significant 
difference in TH protein level in the whole striatum (Figures 22G-H). Taken together, 
analysis of the dopaminergic mesolimbic and nigrostriatal DA circuit did not provide 
strong evidence for changes in the expression of TH within cell bodies or terminals or 
changes in the number of TH-positive terminals that could explain behavioral differences 





Figure 22. TH levels in striatum of H1 MUT mice.  
No difference in TH level was detected in the striatum between the H1 MUT versus WT mice. (A-
F): Representative images showing immunohistochemical DAB staining on coronal sections of 
striatum (Bregma: 1.18 mm to 0.86 mm). A-C: dorsal striatum. D-F: ventral striatum which 
includes NAc. Scale bars represent 1 mm. Optical density (OD) analysis revealed a nonsignificant 
increase in TH OD in the dorsal striatum (unpaired t-test, t(13) = 2.07, p = 0.10) and a small but 
significant increase in TH intensity in the ventral striatum (unpaired t-test, t(13) = 2.30, *p = 0.040) 
of H1 MUT compared to WT mice. WT: n = 8 and H1 MUT: n = 7.  (G-H): Immunoblot for TH 
protein level in the striatum. Representative immunoblot for TH shown in (G) with quantification 
shown in (H).  There was no change in TH protein expression in the striatum of H1 MUT compared 






An important message gleaned from the above results is that the behavioral and 
neurochemical deficits exhibited by H1 MUT mice appear to manifest only under the 
influence of MA. In further support of this notion, a screen of WT and H1 MUT mice in a 
behavioral test battery (data not shown; refer to Ruan et al., 2020a) did not detect any 
genotypic differences in sensorimotor-gating, anxiety-like behaviors, depressive-like 
behaviors, or in sensorimotor coordination. The null results from this behavioral battery, 
combined with the lack of genotypic differences in saline-induced locomotion/response to 
a novel environment, and in various indices of basal DA transmission in the striatum argue 
for an active, MA-induced cell biological mechanism linking Hnrnph1 dysfunction to MA 
behavior. 
MA-induced changes in total and synaptic level of hnRNP H  
The above neuroanatomical studies failed to support a neuroanatomical hypothesis of 
reduced neurodevelopment of DA projection pathways that could underlie reduced MA-
induced DA release and behavior in H1 MUT mice. Thus, to further explore the possibility 
of a synaptic, MA-induced cell biological mechanism that could underlie H1 MUT 
behavior, we next examined changes in the synaptic localization of hnRNP H which is 
potentially relevant for understanding how H1 MUT could alter MA-induced DA release. 
Surprisingly, we identified a two-fold increase in hnRNP H protein level in the striatal 
synaptosome of H1 MUT mice, regardless of treatment (Figures 23A-B). In contrast, there 
was no significant genotypic difference in hnRNP H protein level in bulk striatal tissue in 
response to saline or MA (Figures 23C-D), indicating a change in localization rather than 





Figure 23. MA-induced changes in hnRNP H protein expression in striatal tissue and striatal 
synaptosomes of H1 MUT mice.  
An increase in hnRNP H protein level was detected in the striatal synaptosome of H1 MUT versus 
WT mice but no change in hnRNP H protein from total striatal tissue. (A-B): Representative 
immunoblot for hnRNP H protein level in the striatal synaptosome at 30min post-saline (SAL) or 
post-MA treatment (A) and quantification (B). A genotypic difference in hnRNP H protein level 
was detected in the striatal synaptosome of H1 MUT and WT mice. Collapsing across Treatment, 
an increase in hnRNP H protein was noted in the striatal synaptosome of H1 MUT versus WT mice 
regardless of Treatment (two-way ANOVA, F(1,27)Genotype = 24.36, p = 3.63E-5; F(1,27)Treatment = 
0.23, p = 0.636; F(1,27)interaction = 0.41, p = 0.528; WT (n = 15) versus H1 MUT (n = 16): unpaired 
t-test, t(29) = -5.51, *p = 2.176E-5). This finding was subsequently validated in multiple 
replications. (C-D): Representative immunoblot for total hnRNP H protein level in the striatum at 
30-min post-SAL or post-MA (C) and quantification (D). There was no change in total striatal level 
of hnRNP H relative to WT mice after SAL or MA treatment (two-way ANOVA, F(1,20)Genotype = 






To identify changes in the levels of other synaptic proteins that could 
mechanistically link the robust increase in synaptic hnRNP H with decreased MA-induced 
DA release and behavior, we examined genotypic differences in the synaptosomal 
proteome in the striatum of H1 MUT and WT mice treated with MA versus saline using 
LC-MS/MS. At the behavioral level, H1 MUT showed reduced MA-induced locomotor 
activity only in response to MA on Day 3 (Figure 24C). In contrast, no difference in 
locomotor activity was detected between WT and H1 MUT in response to saline (Figures 
24A-B).  
 
Figure 24. MA-induced locomotor activity in H1 MUT and WT mice that were used for 
harvest of striatal synaptosome for proteomic analysis.  
On Days 1 and 2, mice were injected (i.p.) with saline (SAL) and placed into apparatus for 1 h. On 
Day 3, mice were injected (i.p.) with 2 mg/kg MA and placed into apparatus for 30 min followed 
by immediate sacrifice and removal of the striatum. (A-B): Locomotor activity on Day 1 (A) and 
Day 2 (B) for 1 h in 5-min bin.  No genotypic difference in total distance traveled was observed in 
response to a SAL injection (i.p.) on Day 1 or Day 2 (mixed effects ANOVA, Day 1: F(1,12)Genotype 
= 2.40, p = 0.147; F(1,12)Treatment = 0.203, p = 0.660; F(1,12)Genotype x Treatment = 0.17, p = 0.684;  
F(11,132)Time = 1.89, p = 0.046; F(11,132)Genotype x Treatment x Time = 1.19, p = 0.301; Day 2: 
F(1,12)Genotype = 1.27, p = 0.283; F(1,12)Treatment = 0.466, p = 0.508; F(1,12)Genotype x Treatment = 0.21, p 
= 0.656;  F(11,132)Time = 0.45, p = 0.930; F(11,132)Genotype x Treatment x Time = 1.32, p = 0.219). (C): 
Locomotor activity on Day 3 for 30 min in six, 5-min bins. In response to MA (2 mg/kg, i.p.), H1 
MUT showed less distance traveled compared to WT (mixed effects ANOVA, F(1,12)Genotype = 8.54, 
p = 0.013; F(1,12)Treatment = 77.42, p = 1.4E-6; F(1,12)Genotype x Treatment = 5.85, p = 0.032;  F(5,60)Time 
= 1.83, p = 0.120; F(5,60)Genotype x Treatment x Time = 1.23, p = 0.305; unpaired t-test for WT versus H1 
MUT post MA at each 5-min bin, t(6) = -1.63, -1.67, -2.44, -2.46, -2.41, -3.01, p = 0.154, 0.147, 




Overall, proteomic analysis for the main effect of Genotype identified a highly 
enriched upregulation of mitochondrial proteins in the H1 MUT striatal synaptosome 
regardless of treatment (Figure 25A). Enrichment analysis for the set of top differentially 
expressed proteins (absolute log2FC > 0.2; p < 0.05) between H1 MUT and WT mice 
revealed a highly significant enrichment for mitochondrial respiratory chain complex I 
assembly (Table 8). In examining MA-induced changes in synaptic proteins in H1 MUT 
versus WT mice, we again identified an enrichment for alterations in metabolic processes 
involving components of mitochondrial complex I and V (Figures 25B and A6, Table 9). 
Interestingly, in response to MA, there was a decrease in the level of mitochondrial proteins 
in the H1 MUT mice, but an increase in the WT mice (Figure 26). The findings were 
independently validated with a separate cohort of mice, which also pointed to a trending, 
non-significant pattern of an increase in expression of all three mitochondrial proteins in 
saline-treated H1 MUT mice and a trending, non-significant decrease in all three 






Figure 25. Proteomic analysis of the striatal synaptosome in H1 MUT mice.  
On Days 1 and 2, mice were injected (i.p.) with saline (SAL) and placed into apparatus for 1 h. On 
Day 3, mice were injected (i.p.) with 2 mg/kg MA and placed into the apparatus for 30 min and 
then whole striatum was rapidly harvested via free form dissection. Locomotor activity for all three 
days is shown in Figure 20. The LIMMA package was used for differential analysis with Genotype 
and Treatment as factors. A ranked list was generated from the analysis and the fgsea R package 
was used to perform pre-ranked analysis, with proteins filtered for absolute log2FC > 0.2 and p < 
0.05. (A): Proteomic analysis was performed to identify differences in protein abundance in the 
striatal synaptosome of H1 MUT versus WT mice. The volcano plot shows the top differentially 
expressed proteins in the H1 MUT versus WT striatal synaptosome. Proteins that are part of the 
mitochondrial respiratory complex I are circled in orange. (B): Proteomic analysis was performed 
to examine Genotype x Treatment interactions in protein abundance in the striatal synaptosome of 
H1 MUT versus WT mice. This analysis accounted for baseline differences by examining the 
difference of the difference between the H1 MUT and WT in response to MA: (H1 MUTMA – H1 
MUTSAL) – (WTMA – WTSAL). The volcano plot shows the top differential expressed proteins 
between the H1 MUT versus WT striatal synaptosome in response MA. Proteins that are part of 
the mitochondrial respiratory complex I are circled in orange. Network and pathway analysis in 
Figure 21-1 also detected an enrichment of proteins involved in metabolic processes in the H1 MUT 










Table 8. Differentially expressed proteins in H1 MUT vs WT. 
GO Term p value FDR Proteins 
mitochondrial respiratory 
chain complex I assembly 
2.1E-12 1.4E-09 
SAMM50, NDUFB10, NDUFAF6, 
NDUFB3, NDUFA1, NDUFAF2, 
NDUFV3, NDUFV1 
Complex I biogenesis 1.7E-11 1.6E-09 
NDUFB10, NDUFAF6, NDUFB3, 
NDUFA1, NDUFAF2, NDUFV3, 
NDUFV1 
Respiratory electron transport 2.3E-11 1.6E-09 
NDUFB10, NDUFAF6, NDUFB3, 




Table 9. Differentially expressed proteins in [H1 MUT (MA) – H1 MUT (SAL)] – [WT(MA) – 
WT(SAL)]. 
GO Term p value FDR Proteins 
Metabolic pathways 4.2E-10 1.7E-08 
NDUFB10, NDUFB3, ATP5A1, 
MBOAT2, HSD17B4, ATP5F1, 
ATP5O, AGPAT1, UGT8, GANAB, 
MTHFD1L, ACOX1, AGPS, 
NDUFS1, ALDH18A1 
Parkinson's disease 3.6E-09 7.0E-08 
NDUFB10, NDUFB3, ATP5A1, 
NDUFS1, VDAC1, ATP5F1, 
ATP5O 
mitochondrial ATP synthesis 
coupled proton transport 
4.1E-06 1.2E-3 











Figure 26. Protein expression profiles of select mitochondrial proteins in the striatal 
synaptosome of H1 MUT and WT mice from the proteomic dataset.  
The protein abundance for the mitochondrial proteins are shown for the four groups: WT (SAL), 
H1 MUT (SAL), WT (MA) and H1 MUT (MA). Opposing Genotype x Treatment effects on protein 
levels are shown for the mitochondrial complex I components (A-C) and complex V ATPase 
subunits (D-F). MA administration induced a decrease in protein expression of these subunits in 







Figure 27. Immunoblots of select mitochondrial proteins in the synaptosome of H1 MUT and 
WT mice.  
Three mitochondrial proteins (NDUFS2, ATP5A, and ATP5F1) were selected for independent 
validation of mass spectrometry results in a separate sample cohort via immunoblot. (A): 
Immunoblots for NDUFS2, ATP5A1 and ATP5F1. (B-D): Quantification of protein expression of 
three select mitochondrial proteins. All three proteins show the same trend as the mass spectrometry 
results depicted in Figure 9 where an increase in expression was detected in SAL-treated H1 MUT 
versus SAL-treated WT mice (unpaired t-test, NDUFS2: t(6) = -1.39 p = 0.107; ATP5A1: t(6) = -








Here, we extend a role for Hnrnph1 in MA reinforcement and reward (Figure 28). A 
heterozygous frameshift 16 bp deletion of the first coding exon of Hnrnph1 reduced MA 
oral operant self-administration and MA-induced CPP (Figures 16-17) and induced a 
robust reduction in MA-induced DA release in the NAc (Figure 19). This DA anomaly 
occurred without any differences in 1) basal extracellular DA; 2) basal DA content within 
striatal tissue (Figure 20A); 3) DA uptake (Figure 20B); 4) the number or staining of 
midbrain DA neurons within the mesolimbic and nigrostriatal dopaminergic circuits 
(Figure 21) or 5) any robust changes in the number of forebrain striatal puncta originating 
from these neurons (Figure 22). The combined results suggested an alternate mechanism 
underlying the decrease in MA-induced extracellular DA level and behavior in H1 MUT 
mice. In further support of a MA-induced cell biological mechanism, there was no effect 
of H1 MUT on spontaneous locomotion, anxiety- and depressive-like behaviors, or 
sensorimotor function. 
H1 MUT mice showed less MA-CPP at 0.5 mg/kg but greater CPP at 2 mg/kg than 
WT mice (Figure 17). One interpretation is that MA-CPP exhibits an inverted U-shaped 
dose-response curve (Uhl et al., 2014) in WT and that H1 MUT shifts this curve to the right, 
yielding reduced sensitivity to positive and negative reinforcing effect of MA at lower 
versus higher doses. Consistent with this interpretation, H1 MUT mice exhibited blunted 
operant oral MA reinforcement. The combined data are consistent with H1 MUT mice self-
administering less MA because they are less sensitive to the physiological and 




H1 MUT mice exhibited a blunted DA response to 0.5 and 2 mg/kg MA. This effect 
on MA-induced extracellular level could not be explained by alterations in total DA levels 
(Figure 20A), or in DAT levels or function at the presynaptic membrane (Figures 20B-F). 
An alternative explanation to DAT dysfunction is that the Hnrnph1 mutation somehow 
decreases MA binding to DAT, limiting its entry into presynaptic dopaminergic neuronal 
terminals and decreasing DA release. Future studies are necessary to examine MA binding 
to DAT in H1 MUT mice.  
Our findings support a dopaminergic mechanism underlying reduced MA reward 
and reinforcement in H1 MUT mice. Nevertheless, we acknowledge the potential 
involvement of additional neurotransmitter systems and brain regions. We did not identify 
any difference in basal or MA-induced changes in extracellular glutamate levels in the NAc 
of H1 MUT mice. While MA reward is generally attributed to an increase in DA release in 
the NAc (Segal and Kuczenski, 1997; Adinoff, 2004), MA also increases release of 
norepinephrine and serotonin by targeting their respective transporters that could modulate 
the locomotor stimulant and/or rewarding response to psychostimulants such as MA 
(Haughey et al., 2002; Rothman et al., 2001; Zaniewska et al., 2015). Future studies are 
warranted to address these other neurotransmitters in MA-induced behavioral dysfunction 
in H1 MUT mice as well as the possibility that H1 MUT has a pleiotropic influence on 
behavioral (e.g., cognitive, antidepressant) and neurochemical responses to drugs targeting 
other membrane transporters such as NET and SERT. For example, phosphorylation of the 
RBP hnRNP K increases expression of SERT protein via changes in binding to the distal 




The two-fold increase in hnRNP H protein in the striatal synaptosome of H1 MUT 
mice with no change in total hnRNP H protein was surprising. This finding was observed 
in multiple replication studies and suggests a redistribution of hnRNP H protein to the 
synapse in H1 MUT mice. We performed LC-MS/MS analyses on striatal synaptosomes 
following 2 mg/kg MA (i.p.) to further understand the effect of increased synaptosomal 
hnRNP H on global changes in protein expression and the underlying cell biological 
mechanisms. We identified a higher abundance of several mitochondrial proteins, in 
particular, complex I of the mitochondrial respiratory chain in H1 MUT mice. The 
mammalian complex I consists of 38 nuclear DNA-encoded subunits (Sharma et al., 2009) 
and our proteomic analysis identified 8 out of the 38 subunits that showed higher 
expression in H1 MUT mice (Figures 25-27). Proteomics has been widely used to study 
the effects of MA on protein expression in the brain tissues of animals (Liao et al., 2005; 
Faure et al., 2009; Bosch et al., 2015). Iwazaki et al. (2006) used two-dimensional gel 
electrophoresis proteomics and found that a single low dose of MA (1 mg/kg) 
administration in rats induced differential expression of proteins involved in 
mitochondria/oxidative metabolism. Furthermore, chronic exposure of 1 mg/kg MA 
induced locomotor sensitization and neurotoxicity along with a downregulation of 
numerous striatal proteins indicating mitochondrial dysfunction and  an oxidative response 
(Iwazaki et al., 2007; Chin et al., 2008).  
Recent studies showed postsynaptic dendritic mitochondrial fission and fusion 
processes mediate cellular and behavioral plasticity, spine and synapse formation, and 




et al., 2018). Dynamin-related protein (Drp1), a GTPase involved in mitochondria fission, 
has been shown to regulate addiction-relevant behavior during early cocaine abstinence 
(Chandra et al., 2017), with inhibition of mitochondrial fission blunting cocaine-seeking 
and locomotor sensitization. While the results of our synaptosomal proteome dataset did 
not reveal any mitochondrial fission and fusion mediators, it is still possible that changes 
in mitochondrial proteins in the post-synaptic dendrites contribute to behavioral differences. 
Future studies will isolate potential pre- versus postsynaptic mechanisms.  
Most mitochondrial proteins are nuclear-encoded and must be transported to 
mitochondria for organelle-coupled translation (Williams et al., 2014). RBPs play a critical 
role in targeting mRNAs to membrane-bound organelles such as mitochondria. RBPs 
interact with mRNAs and chaperone them toward mitochondrial outer membranes where 
they are translated (Gerber et al., 2004; García-Rodríguez et al., 2007; Eliyahu et al., 2010; 
Gehrke et al., 2015). RBPs recognize and bind mitochondria-targeting RNA elements to 
form higher-order units called mRNA ribonucleoprotein (RNP) complexes consisting of 
mRNAs and associated RBPs (Béthune et al., 2019; Rossoll and Bassell, 2019). The robust 
increase in hnRNP H protein in the striatal synaptosome accompanied by the increase in 
several complex I subunits suggests a novel function for hnRNP H in targeting mRNAs 
encoding for subunits of mitochondrial complex I to the mitochondria, thus, regulating 
local translation (Figure 28). Once the mRNAs are transported nearby the mitochondria, 
hnRNP H could coordinate with other RBPs to form an RNP complex to stabilize mRNAs 
to the mitochondrial membrane where translational activators initiate translation. An 




mitochondrial components of the F1F0 ATPase and localizes to the outer mitochondrial 
membrane (García-Rodríguez et al., 2007). Future studies involving CLIP-seq will identify 
target mRNAs bound to hnRNP H and determine the degree of enrichment for mRNAs 
encoding mitochondrial complex I subunits. 
Mitochondria are abundant at the synapse where they generate ATP for Ca2+ 
buffering, vesicle release, and recycling (Vos et al., 2010; Devine and Kittler, 2018). 
Mitochondria consist of five oxidative phosphorylation complexes (I through V) (Mimaki 
et al., 2012; Sharma et al., 2009). Complex I is the first enzyme of the respiratory chain 
and initiates electron transport continuing to complex II through IV to generate redox 
energy for Complex V to produce ATP. The increase in Complex I subunits in H1 MUT 
mice could increase Complex I activity and synaptic ATP production to support vesicle 
fusion, DA release, and DA transport back into the cells via DAT and Na+/K+ ATPase to 
counteract MA-induced DA release. We found a Genotype by Treatment effect on protein 
levels of F0F1 ATP synthase subunits (Atp5a1, ATP5f1 and Atp5o) of Complex V (Figure 
26) in the synaptosomal proteome whereby MA decreased these ATP synthase subunits in 
H1 MUT mice which could decrease ATP production in response to MA in H1 MUT mice 
and affect extracellular DA levels.  
Besides binding and targeting RNAs to the mitochondria for translation, hnRNP H, 
like other RBPs, could bind and target proteins via its glycine-rich domain in an activity-
dependent manner (Tiruchinapalli et al., 2008). In an animal model for frontotemporal 
dementia, ploy(GR) aggregates (resulting from hexanucleotide repeats in C9ORF72) bind 




through the proteasome pathway, thus disrupting mitochondrial function (Choi et al., 2019). 
The higher level of synaptosomal hnRNP H protein in H1 MUT mice could increase 
binding to mitochondrial complex I and V proteins (e.g., via the glycine-rich domain) to 
prevent degradation, yielding higher protein levels at baseline (Figures 25 and 26). MA 
administration could then decrease hnRNP H-protein interactions in H1 MUT mice, thus 
decreasing synaptic mitochondrial proteins and synaptic function.   
Taken together, the opposing effects of MA treatment on synaptic abundance of 
mitochondrial complex I proteins between H1 MUT and WT mice could represent a 
mechanism underlying blunted MA-induced extracellular DA level in the NAc of H1 MUT 
mice. Future studies will focus on the interaction between hnRNP H and mRNA encoding 
mitochondrial complex I and V subunits at the protein-RNA and protein-protein level (pre- 
and postsynaptically) and determine whether disruption of such interactions can alter ATP 





Figure 28. Proposed model linking increased synaptic mitochondria with a decrease in MA-
induced DA release and behaviors.  
Compared to WT mice, H1 MUT mice showed reduced MA-induced extracellular DA in the NAc 
and reduced sensitivity to the locomotor stimulant, rewarding, and reinforcing effects of MA. In 
addition, H1 MUT mice show an increase in hnRNP H protein in the striatal synaptosome, with no 
change in total hnRNP H. This increased localization of synaptosome hnRNP H is associated with 
an increase in complex I mitochondrial proteins. RBPs such as hnRNP H chaperone mRNAs to 
membrane-bound organelles such as the mitochondria for translation and subsequent assembly in 
the mitochondria. In the absence of MA, hnRNP H binds to mRNA transcripts encoding 
mitochondria proteins and transports them to the surface of the mitochondria. MA administration 
disrupts hnRNP H-RNA interactions which results in fewer mitochondrial mRNAs being 










MATERIAL AND METHODS 
Mice 
Experimental mice were generated by mating H1 MUT males with C57BL/6J females 
purchased from The Jackson Laboratory in Bar Harbor, ME USA (for studies in Boston 
University) or in Sacramento, CA USA (for studies in UC Santa Barbara).  Offspring were 
genotyped as previously described (Yazdani et al., 2015). Unless otherwise indicated, both 
female and male littermates (56-100 days old at the start of the experiment), were used in 
the studies. Mice were housed in same-sex groups of 3-5 in standard mouse cages and 
housed within ventilated racks under standard housing conditions. All procedures 
conducted in mice were approved by the Boston University, UC Santa Barbara and 
Virginia Commonwealth University Animal Care and Use Committees. All experiments 
were conducted in strict accordance with the Guide for the Care and Use of Laboratory 
Animals. Colony rooms were maintained on a 12:12 h light–dark cycle.  
Genotyping of H1 MUT and H1-/- mice 
The genotyping protocol for the H1+/- or H1 MUT  mice is published in Yazdani et al. 
(2015). For genotyping of H1-/- embryo tissue, an Hnrnph1 forward primer 
(GATGATGCTGGGAGCAGAAG) and reverse primer (GGTCCAGAATGCACAGATT 
G) were designed to target upstream and downstream of the deleted region in exon 4 of 
Hnrnph1. Genomic DNA was used to amplify a 204-bp PCR product using DreamTaq 
Green PCR Mastermix (ThermoScientific) followed by overnight restriction enzyme digest 




Hnrnph1 and Hnrnph2 RT-qPCR for mouse embryo tissue 
Oligo-dT primers were used to synthesize cDNA from total RNA to examine mRNA 
expression and qPCR for evaluating gene expression were performed using Taqman SYBR 
Green (ThermoFisher Scientific Cat# 4309155). The primer sequences used for evaluating 
expression of Hnrnph1 (targeting exons 6 and 7 were ACGGCTTAGAGGACTCCCTTT 
and CGTACTCCTCCCCTGGAAGT. The primer sequences used for quantifying 
expression of Hnrnph2 (targeting exons 1 and 2) were TAGCCGTTTGAGGGAAGAAG 
and CCCTGTTAGAGTTTCTTCCAGGTA. The house keeping gene used was Hprt 
(targeting exons 7 and 9) with following primer sequence: GCTGGTGAAAAGGACCTC 
T and CACAGGACTAGAACACCTGC. 
Oral MA self-administration 
The procedures for MA operant-conditioning were similar to those recently described 
(Lominac et al., 2016). Testing was conducted in operant chambers equipped with 2 nose-
poke holes, 2 cue lights, a tone generator, and a liquid receptacle for fluid reinforcement 
(Med Associates Inc.). Mice were not water-restricted at any point during oral MA self-
administration procedures. The vehicle for MA was filtered tap water. Under a fixed-ratio 
1 (FR1) schedule of reinforcement, mice were trained daily to self-administer MA during 
1 h sessions where a single active nose poke response resulted in delivery of 20 μl of liquid 
MA into the receptacle, with a 20s illumination of the cue light, and the sounding of the 
tone. During the 20s period, further responding resulted in no programmed consequences. 
Inactive hole responses were recorded but had no consequences, serving to gauge the 




poke 80 mg/l MA, with the concentration of MA progressively increased over weeks (120, 
160, 200, 300 and 400 mg/l MA; five days per dose). Upon the completion of each daily 
session, the volume of MA remaining in the receptacle was determined by pipetting and 
was subtracted from the volume delivered to calculate MA intake (Lominac et al., 2016).  
Conditioned place preference (CPP) 
Mice were trained for 1 h each day in Plexiglas activity boxes within sound-attenuating 
chambers (40 cm length x 20 cm width x 45 cm tall; divided into two sides with different 
plastic floor textures for CPP). Mice were recorded from above using infrared cameras 
(Swan) and tracked with ANY-maze (RRID:SCR_014289). The CPP paradigm was 
described in Kirkpatrick and Bryant (2015). On training Days 2-5, mice were injected with 
either saline (Days 2 & 4) or MA (Days 3 & 5; saline, 0.5 or 2 mg/kg, i.p.) and confined to 
either the saline- or MA-paired side for 1 h.  
Stereotaxic surgery 
The procedures to implant indwelling microdialysis guide cannulae bilaterally over the 
NAc of mice were described previously (Lominac et al., 2014, 2016). Mice were 
anesthetized under 1.5–2% isoflurane with 4% oxygen as a carrier gas, mounted in a Kopf 
stereotaxic device with tooth and ear bars adapted for mice. The mouse skull was exposed, 
leveled, and holes were drilled based on coordinates from Bregma for the NAC (AP: +1.3 
mm, ML: ±1 mm, DV: −2.3 mm), according to the mouse brain atlas of Paxinos and 
Franklin (2001). The guide cannulae were lowered bilaterally such that the tips of the 




application and the guide cannulae were secured to the skull with dental resin. Post-surgery, 
mice were injected subcutaneously (s.c.) with warm saline and 250 μl of 2.5 mg/ml 
Banamine (Henry Schein Animal Health) and allowed to recover on a heating pad. Post-
operative care was provided for four days, during which mice were injected with 250 μl of 
2.5 mg/mL Banamine s.c. daily for the first two days. Mice were allowed a minimum 1-
week recovery prior to in vivo microdialysis assessments. 
In vivo microdialysis & HPLC analysis 
Conventional microdialysis was conducted using a within-subjects design to examine 
saline and acute MA-induced DA release (0.5 or 2 mg/kg, i.p.), using procedures similar 
to those described previously (Lominac et al., 2014, 2016). Microdialysis probes were 
inserted unilaterally and perfused with artificial cerebrospinal fluid for 3 h (2 μl/min), 
allowing for neurotransmitter equilibration. For DA no net-flux analysis, DA was infused 
at 0, 2.5 nM, 5 nM, and 10 nM, and dialysate was collected in 20-min intervals for 
1h/concentration. On a subsequent day, mice were probed on the contralateral side, and 
following the 3 h equilibration period and 1 h of baseline dialysate collection, mice were 
injected i.p. with either 0.5 or 2.0 mg/kg MA and dialysate was collected in 20-min 
intervals for 3 h post-injection. HPLC analysis of DA was conducted as described 
previously (Lominac et al., 2014). Cannulae placement was determined on Nissl-stained 





Quantification of baseline monoamine neurotransmitters 
Drug-naïve striatum were harvested from H1 MUT and WT littermates and flash-frozen 
on dry ice. The dissected tissue was sent to Vanderbilt University Neurotransmitter Core 
for the quantification of monoamine neurotransmitters using HPLC wth electrochemical 
detection. 
DAT-mediated DA uptake 
SAL or MA (2.0 mg/kg) was administered interperitoneally in a volume of 10 ml/kg. After 
2 h post-administration (2 h was chosen based on the microdialysis results), mice were 
decapitated, and DAT-specific [3H]DA uptake from synaptosome preparations was 
conducted as described previously (Kivell et al., 2014).  Mice were rapidly decapitated, 
and striatal regions were dissected from the brain and collected in 10 volumes (wt/vol) of 
prechilled 0.32 M sucrose buffer (0.32 M sucrose in 5 mM HEPES, pH 7.5). The striatal 
tissue was homogenized and centrifuged at 1000 x g for 15 min at 4˚C. The supernatant 
was centrifuged at 12,000 x g for 20 min, and the pellet was suspended in 0.32 M sucrose 
buffer. Striatal synaptosomes (30 µg) were incubated in a total volume of 0.3 ml of Krebs-
Ringer-HEPES (KRH) buffer consisting of 120 mM NaCl, 4.7 mM KCl, 2.2 mM CaCl2, 
10 mM HEPES, 1.2 mM MgSO4, 1.2 mM KH2PO4, 5 mM Tris, 10 mM D- glucose, pH 7.4 
containing 0.1 mM ascorbic acid, and 0.1 mM pargyline at 37˚C for 10 min with or without 
DAT- specific blocker GBR12909 (50 nM). Following incubation, 5 nM [3H]DA (63.2 
Ci/mmol-dihydroxyphenylethylamine [2,5,6,7,8-3H]; PerkinElmer) and further incubated 
for additional 5 min. Uptake of DA was terminated with the addition of 500 nM DAT 




filters on a Brandel Cell Harvester (Brandel Inc.), and washed rapidly with 5 ml cold PBS. 
Radioactivity bound to the filter was counted using a liquid scintillation counter. DAT 
mediated [3H]DA uptake was determined by subtracting total accumulation of [3H]DA 
(absence of GBR12909) and in the presence of GBR12909. Uptake assays were performed 
in triplicates.  
Immunohistochemistry 
For immunohistochemistry (IHC), drug-naïve H1 MUT and WT mice were anesthetized 
with pentobarbital, and transcardially perfused with phosphate buffered saline (PBS) 
followed by 4% paraformaldehyde in PBS at room temperature. Next, brains were 
dissected and processed for tyrosine hydroxylase (TH) 3-3’-diaminobenzidine (DAB) IHC 
and analysis as previously described (Burke et al., 1990; Hutson et al., 2011), or double 
immunofluorescent IHC for hnRNP H and TH colocalization. For DAB IHC, coronal slices 
were blocked with 4% normal goat serum and then incubated for 48 h at 4°C with anti-
hnRNP H (1:50,000, Bethyl Cat# A300-511A, RRID:AB_203269) or tyrosine hydroxylase 
(TH) (1:500, Santa Cruz Cat# sc-14007, RRID:AB_671397), and processed for DAB 
staining and analyzed as previously described (Hutson et al., 2011). For co-staining studies 
with hnRNP H and TH, tissues were blocked with superblock (ThermoFisher Scientific 
Cat# 37515), and incubated with anti-hnRNP H (Santa Cruz Cat# sc-10042, 
RRID:AB_2295514) and TH (1:500, Santa Cruz Cat# sc-14007, RRID:AB_671397) for 
48 hours at 4°C. Next, tissues were incubated with donkey anti-rabbit Alexa Fluor 488 
(1:500, Molecular Probes Cat# A-21206, RRID:AB_141708) and donkey anti-goat Alexa 




coated with ProLong Diamond Antifade Mountant (ThermoFisher Scientific Cat#P36961), 
mounted onto slides, and imaged on the Leica SPE Confocal microscope.  
TH puncta quantification in the striatum 
Entire coronal slices of rostral, medial, and caudal striatum were imaged at 40x 
magnification using a Nikon Eclipse 600 microscope. A 225,000 µm2 grid was overlaid 
onto these images using Image J and every 3rd field of view within the striatum was graded. 
Number of puncta within a field of view was graded in ImageJ by subtracting out 
background signal, creating binary images from these files, and then counting puncta 
meeting roundness and diameter criteria (roundness <0.6, diameter 1-45 µm). Averages 
puncta densities for ventral, dorsal, and total striatum were calculated. Grading of the 
puncta was performed in Image J. The image was duplicated into a 1,000,000-pixel area 
followed by brightness/contrast adjustment and background subtraction. The threshold was 
set to 106. A binary image was then generated for puncta measurement. Roundness was 
set to 0.6-1 and size was set to 5 – 200 pixels. 
Dissection of mouse brain regions: striatum and midbrain 
Live, rapid decapitation was used to avoid the effects of anesthesia or CO2 asphyxiation 
on gene expression. Immediately followed live-decapitation using large, sharpened shears 
with an incision just posterior from the ears, the mouse brain was removed quickly with 
forceps and transfer to a cold surface. The striatum has a somewhat darker appearance than 
the surrounding cortex. To dissect the dorsal and ventral striatum, fine-tip forceps were 




removed to reveal the striatum. To dissect the midbrain, a razor blade was used to make a 
rostral cut where the cerebral aqueduct begins and another caudal cut just before the start 
of the cerebellum.  
Methamphetamine-induced locomotor activity followed by tissue harvesting  
On Days 1 and 2, all mice received a SAL injection (10 ml/kg, i.p.) and were recorded for 
locomotor activity in Plexiglas chambers (40cm length x 20 cm width x 45 cm height) for 
1 h. On Day 3, mice receive either saline or MA (2 mg/kg, i.p.; Sigma Aldrich) and were 
recorded for locomotor activity for 30 min and the whole striatum was harvested as 
described above at 30 min post-injection. Whole striata (left and right sides) were flash 
frozen in ethanol/dry ice bath and stored at -80oC for long-term storage. Four cohort of 
animals were run in this behavioral paradigm for tissue collection: 1) hnRNP H 
immunoprecipitation followed by mass spec; 2) synaptosome mass spec and hnRNP H 
immunoblot; 3) validation studies for mitochondrial protein immunoblots; 4) measurement 
of MA concentration in MA-treated striatal tissues. The mice that were used for hnRNP H 
immunoprecipitation were all MA-treated on Day 3.  
Quantification of MA metabolites MA-treated whole striatal tissue 
Whole striata (left and right sides) were flash frozen in ethanol/dry ice bath and stored at -
80oC. Tissue were then shipped on dry ice to University of Utah Health Science Center for 
MA and amphetamine metabolite quantification as previously described (Slawon et al., 




Preparation of synaptosomes 
Striatal tissue collection from saline- or MA-treated mice was performed as described 
above. The tissues were subsequently processed to obtain synaptosomes using a Percoll 
(Sigma Aldrich Cat# 1644) gradient fractionation method, which was adapted from 
Dunkley et al. (Dunkley et al., 2008). Whole striata (left and right hemisphere) were placed 
in 1 ml sucrose homogenization buffer (2 mM HEPES, pH7.4, 320 mM Sucrose, 50 mM 
EDTA, 20 mM DTT) supplemented with protease and phosphatase inhibitor 
(ThermoFisher Scientific Cat# 78440). The brain tissues were lightly homogenized using 
a handheld motorized pestle. The homogenate for each sample was then centrifuged for 2 
min at 3000 rcf and the supernatant (S1) was collected. The pellet (P1) was then 
resuspended in 500 μl of sucrose homogenization buffer and re-spun for 3 min at 3000 rcf. 
The supernatant (S1’) was collected and combined with S1 and then centrifuged for 15 min 
at 9200 rcf. The supernatant S2 was then removed and the pellet (P2) was re-suspended in 
500 μl of sucrose homogenization buffer and loaded onto a Percoll density gradient 
consisting of 23%, 10%, and 3% Percoll (1 ml each) in Polycarbonate centrifuge tubes (13 
x 51 mm; Beckman Coulter Cat# 349622). The gradients were then centrifuged for 15 min 
at 18,700 rcf. The distinct band between the 10% and 23% Percoll was collected as the 
synaptosome. The synaptosome fraction was then washed to 5 mL with 1X HBM buffer, 
pH 7.4 (140 mM NaCl, 5 mM KCl, 5 mM NaHCO3, 1.2 mM NaH2PO4, 1 mM MgCl2-
6H2O, 10 mM glucose, 10 mM HEPES) to dilute out the Percoll by centrifuging for 12 min 
at 18700 rcf. The pellet was then re-suspended in 100 μl of HBM buffer to yield the final 




of 30 μg of synaptosome was loaded per sample for SDS-PAGE and Western blotting as 
described below. 
SDS-PAGE and Western Blot 
Brain tissues were homogenized using hand-held homogenizer in RIPA buffer with HaltTM 
Proteatase & Phosphotase inhibitor cocktail (ThermoFisher Scientific Cat# 78840). For 
each sample, 30 μg of protein was heated in a 70oC water bath for 10 min prior to loading 
into  into a 4-15% Criterion TGX precast Midi protein gel (Bio-Rad) for SDS-PAGE 
followed by wet transfer to nitrocellulose membrane. The membrane was then blocked 
with 5% milk for 1 h and probed with primary antibodies. For evaluating TH expression in 
brain tissues, overnight incubuation of the membrane at 4°C with anti-TH (1:50,000, Santa 
Cruz Cat# sc-14007, RRID:AB_671397) was performed followed by 1 h incubation with 
donkey anti-rabbit HRP (1:10,00, Jackson ImmunoResearch Labs Cat# 711-035-152, 
RRID:AB_10015282). For evaluating hnRNP H protein expression in mouse embryo 
tissues and in striatal synaptosome, the following antibodies were used:  hnRNP H (C-term: 
1:50,000, Bethyl Cat# A300-511A, RRID:AB_203269; N-term: 1:50,000, Santa Cruz Cat# 
sc-10042, RRID:AB_2295514) followed by 1 h incubation with the appropriate secondary 
antibodies. For vadilation of mitochondrial protein expression following MA treatment, 
the following priamry antibodies were used: ATP5A1 (1:2000, Abcam Cat# ab14748, 
RRID:AB_301447); ATP5F1 (1:5000, Proteintech Cat# 15999-1-AP, 
RRID:AB_2258817); and NDUFS2 (1:5000; abcam ab192022). We used the following 




anti-GAPDH (1:20,000; Millipore Cat# MAB374, RRID:AB_2107445), and PSD95 
(1:10,000, Cell Signaling Technology Cat# 3450, RRID:AB_2292883).  
Mouse brain tissue processing for SDS-PAGE and DAT immunblotting was 
modified from Staal et al., 2007. Briefly, tissue  was triturated using a 20-22 gauge needle 
in RIPA buffer (10 mM Tris, pH 7.4, 150 mM, NaCl, 1 mM EDTA, 0.1% SDS, 1% Triton 
X-100) supplemented with HaltTM Proteatase & Phosphotase inhibitor cocktail 
(ThermoFisher Scientific Cat# 78840). 30 μg of protein of each sample was allowed to 
rotate at room temperature prior to SDS-PAGE instead of heating the sample at high 
temperature. For evaluating DAT expression in whole striatal tissue and striatal 
synaptosome, we conducted overnight incubation anti-DAT (1:2000; Millipore Cat# 
MAB369, RRID:AB_2190413) followed by 1 h incubation with goat anti-rat (1:500, 
Jackson ImmunoResearch Labs Cat# 112-035-003, RRID:AB_2338128).  
All processed membranes were imaged via enhanced chemiluminescence photo-
detection. Densitometry analysis in Image J was used for quantification. 
hnRNP H immunoprecipitation 
Following the three-day locomotor paradigm assessing acute locomotor sensitivity in H1 
MUT versus WT mice as described above, striata were dissected from the mice at 30 min 
post-injection of MA or saline. Striatum was dissected from WT or H1 MUT mice and 
frozen on dry ice and stored at -80oC.  Striatal tissues were then homogenized using a 
microcentrifuge pestle in ice-cold RIPA buffer (50 mM Tris-HCl, pH 6.8, 150 mM NaCl, 
5 mM EDTA, 1% Triton X-100, 0.1% SDS, 0.5% sodium deoxycholate) supplemented 




78840) and incubated overnight at 4oC with gentle agitation.  Lysates were centrifuged at 
10,000 rpm for 15 min at 4oC, and the supernatant fraction was saved for protein 
quantification via BCA assay. 1 mg of striatal lysates was pre-cleared for 1 h with 80 ul 
Protein G Sepharose coated beads (ThermoFisher Scientific Cat# 101243) and then 
centrifuged at 4oC for 5 min at 1000 rpm.  The pre-cleared lysates (supernatant) were then 
incubated overnight with 10 μg of rabbit anti-hnRNP H (Bethyl Cat# A300-511A, 
RRID:AB_203269) or control normal rabbit IgG antibody (Millipore Cat# NI01-100UG, 
RRID:AB_490574).  The next day, 80 μl of Protein G Sepharose coated beads were added 
to the antibody-lysate mixture, and incubated for an additional 2 h.  The beads were then 
washed 4 times in 1 ml lysis buffer, resuspended and centrifuged for 1 min at 1000 rpm 
each time. The beads were eluted by adding 60 μl of non-reducing SDS buffer and heating 
at 95oC for 10 min. hnRNP H immunoprecipitates were eluted in non-reducing SDS buffer 
as described above.  50 μl of each sample was separated by SDS-PAGE at 100 V for 30 
min (~2 cm) on a Novex Bolt 4-12% Bis-Tris gel.  The gel was then washed 3 times in 
deionized H2O and stained with Simply Blue Coomassie SafeStain (ThermoFisher 
Scientific Cat# LC6060).  The gel was then cut at ~160 kDa to exclude the prominent non-
reduced IgG band.  Individual gel lanes were then separately excised and stored in pre-
washed microcentrifuge tubes at 4oC prior to shipping to the UMass Worchester 
Proteomics and Mass Spectrometry facility for analysis by OrbiTrap liquid 





TMT Labeling, High pH reverse phase HPLC fraction, followed by LC-MS/MS 
Following the three-day locomotor paradigm assessing acute locomotor sensitivity in H1 
MUT versus WT mice as described above, striata were dissected from the mice at 30 min 
post-injection. Synaptosomes were isolated following the procedure outlined above for 
proteomic characterization. Samples were resuspended in 8 M urea for 30 min, followed 
by the addition of 5 mM DTT for 1 h. Lodoacetamide was then add to the samples that 
were incubated in the dark for 30 min. The urea concentration was diluted below 1 M with 
the addition of 50 mM of ammonium bicarbonate. The samples were then digested with 
trypsin (50:1, protein to enzyme ratio) overnight at 37oC and terminated with the addition 
of formic acid to 1%. The samples were desalted with a C18 tip. Peptide was determined 
by Pierce Quantitative Colorimetric Assay (ThermoFisher Scientific Cat# 23275), then 100 
μg of peptide was resuspended in 0.1 M triethylammonium bicarbonate (TEAB) and 
incubated with the TMT plex isobaric labeling for 1 h at room temperature. To quench the 
reaction, 5% hydroxylamine was added to each sample and incubated for 15 min. Each 
sample was combined at equal amount and cleaned with C18 tips. One mg of labeled 
peptides was fractioned using a Waters XBridge BEH C18 (3.5μm, 4.6 ×250mm) column 
on an Agilent 1100 HPLC system. 48 fractions were collected and combined to 12 fractions 
and then dried. A C18 Acclaim PepMap 100 pre-column (3μm, 100 Å, 75μm × 2cm) 
hyphenated to a PepMap RSLC C18 analytical column (2μm, 100 Å, 75μm × 50cm) was 
used to separate peptide mixture. LC-MS/MS analyses were completed using an EASY 
nLC 1200 system coupled to a Q Exactive HF-X mass spectrometer. Full MS spectra were 




50 ms and a scan range of 350 to 1650 m/z. MS2 scans were performed at 45,000 resolution 
and using 32% total normalized collision energy. Source ionization parameters were 
optimized with the spray voltage at 2.1 kV, dynamic seclusion was set to 45 s.   
Proteomics Data Analysis and Pathway Enrichment Results 
The acquired data was searched by MaxQuant against the UniProt mouse proteome data 
base with standard settings (fragment ion mass tolerance of 20ppm, maximum missed 
cleavage of 2, oxidation as variable modification, false discovery was 1%, only protein 
groups identified with at least 2 or more peptides). The intensity data were filtered and 
normalized using R (RRID:SCR_001905) and the LIMMA package (RRID:SCR_010943) 
was used for differential analysis with Genotype and Treatment as factors. A ranked list 
was generated from the analysis and the fgsea R package was used to perform pre-ranked 
analysis, with proteins filtered for absolute log2FC > 0.2 and p < 0.05. Enrichment results 
for the comparisons were visualized using Cytoscape (RRID:SCR_003032) and 
EnrichmentMap (RRID:SCR_016052), with nodes representing pathways and edges 
representing overlap genes. Pathways were clustered and annotated with themes using 
AutoAnnotate (Reimand et al., 2019).  
Experimental design and statistical analyses 
Characterization of Hnrnph1/2 gene expression and hnRNP H protein expression in H1 
MUT mice: For gene expression analysis of Hnrnph1/2 via qPCR, each sample was run in 
triplicate and averaged. Differential gene expression was reported as the fold-change in H1 
MUT and H1-/- relative to WT littermates using the 2-(∆∆CT




2001). To examine genotypic differences in transcript and protein expression among WT, 
H1 MUT and H1-/-, one-way ANOVA was conducted. To examine genotypic difference 
in level of peptides unique to either hnRNP H1 or hnRNP H2, two-tailed unpaired t-test 
was performed for each peptide with the exception of Peptide 3 for hnRNP H1, where we 
employed a one-tailed unpaired t-test based on a priori results published in Yazdani et al. 
(2015) indicating a decrease in exon 4 usage of Hnrnph1 in the H1 MUT versus WT. Thus, 
we hypothesized that Peptide 3, which is encoded by part of exon 4, would also be 
decreased in the H1 MUT mice. 
Oral self-administration: To determine the effects of the H1 MUT upon MA reinforcement 
and intake, an operant-conditioning procedure was employed and the data for the mean 
number of active nose-pokes, inactive nose-pokes and MA intake compared between WT 
and H1 MUT mice. This comparison was evaluated using mixed model ANOVA with the 
between-subjects factors of Genotype and Sex and the within-subjects factor of MA 
concentration (80, 120, 160, 200, 300 and 400 mg/L). In a follow-up study, WT and H1 
MUT mice were trained to self-administer the 200 mg/L MA concentration over the course 
of 14 days. The data for this study were analyzed using mixed model ANOVA with 
Genotype and Sex as between-subjects factors and Day as the repeated measure (Day 1 to 
14). To interrogate potential genotypic differences in bitter tastant sensitivity, the dose-
response function for quinine intake was determined in a separate cohort of mice and the 
data were analyzed using a mixed model ANOVA with between-subjects factors of 
Genotype and Sex and repeated measures on the Quinine Concentration factor (0.003, 0.01, 




In vivo microdialysis: To relate genotypic differences in behavior to changes in 
extracellular DA and glutamate within the NAc, we conducted a series of in vivo 
microdialysis experiments. The first series of experiments employed no net-flux 
microdialysis procedures and the ensuing dose-response data were analyzed by linear 
regression to determine the extraction fraction/clearance of the neurotransmitter 
(determined by the slope of the regression) and the basal neurotransmitter content 
(determined by x=0 from the regression). The extraction fraction and content were 
analyzed by an univariate ANOVA with the between-subjects factors of Sex and Genotype.  
The second series of experiments examined the time-course of MA-induced changes in 
extracellular DA, DOPAC and glutamate. The average baseline neurotransmitter content 
for the 60 min prior to MA injection was analyzed using an univariate ANOVA along the 
between-subjects factors of Genotype and Sex. Mice were slated to receive one of two MA 
doses (0.5 mg/kg and 2.0 mg/kg) and the data for each neurotransmitter were expressed as 
a percent change from the average baseline and analyzed using a mixed model ANOVA 
with Genotype and Sex as between-subjects factors and repeated measures on the Time 
factor (12, 20-min, bins), separately for each MA dose.  
Conditioned place preference (CPP): To examine genotypic differences in MA reward, we 
assessed MA-CPP by quantifying the change in time spent on drug-paired side on Day 8 
minus Day 1 or on Day 9 minus Day 1. Preference was analyzed using a three-way 
ANOVA with Genotype, Sex, and Treatment (saline, 0.5 mg/kg MA, and 2 mg/kg MA) as 
between-subjects factors. Because this analysis indicated genotype and dose-dependent 




differences in MA-CPP. To assess potential genotypic differences in MA-induced 
locomotor activity in the smaller arena containing the textured floor that comprised the 
MA-CPP side (Days 2, 3, 4, and 5) as  well as in the entire arena (Days 1, 8 and 9), we 
analyzed distance traveled in 5-min bin using a mixed effects ANOVA with Genotype, Sex, 
and Treatment (saline, 0.5 mg/kg, or 2 mg/kg MA) as between-subjects factors and 
repeated measures on Time (12, 5-min bins), separately for each day. Two-tailed unpaired 
t-tests were used to determine the sources of main effects of Genotype and Treatment and 
interactions with Time.   
Behavioral test battery: To determine the effects of Genotype upon sensorimotor function 
and affect, WT and H1 MUT mice were subjected to a behavioral test battery consisting of 
PPI, the novel object test, marble-burying, light-dark shuttle-box, Porsolt swim test, and 
motor coordination on a rotarod. The data generated from these assays were analyzed using 
two-tailed unpaired t-tests. 
Quantification of DA content and MA metabolites and DAT-mediated DA uptake: To 
determine whether there was a genotypic difference in DA content at baseline and MA 
metabolite after MA injection, a two-tailed unpaired t-test was performed. In examining 
whether there in an MA-induced change on DAT-mediated DA uptake between WT and 
H1 MUT mice, a two-way ANOVA with Genotype and Treatment (saline and MA) as 
between-subjects factors was used. 
MA-induced locomotor activity assessment prior to tissue collection for mass spectrometry:  
To replicate the reduction in MA-induced locomotor activity in H1 MUT mice that we 




distance traveled in 5 min-bin, separately for Days 1, 2, and 3 via mixed effects ANOVA 
with Genotype, Sex, and Treatment (saline and 2 mg/kg MA) as between-subjects factors 
and Time as the repeated-measures factor. Two-tailed unpaired t-tests were used to 
determine sources of the main effects of Genotype and interactions with Time.  
Immunoblotting and IHC: To examine the effect of Genotype on TH protein expression 
via immunoblotting and IHC, two-tailed unpaired t-test was performed on loading control-
normalized data between WT and H1 MUT. To determine whether there was an effect of 
Sex on DAT protein expression, two-way ANOVA with Genotype and Sex as between-
subjects factors was conducted. Two-tailed unpaired t-tests were used to determine sources 
of the main effects of Sex and interactions with Genotype. To examine MA-induced 
changes in protein expression including DAT, hnRNP H and mitochondrial proteins, two-
way ANOVA with Genotype and Treatment as between-subjects factors was conducted. 
For hnRNP H expression in the synaptosome, the significant main effect of Genotype was 
followed up with two-tailed unpaired t-tests to examine differences between WT and H1 
MUT.  
For all behavioral studies, we used an effect size of Cohen’s d = 0.9 to guide our 
sample size based on genotypic differences in MA-induced locomotor activity at 30 min 
post-MA in our previously published data from H1 MUT mice (Yazdani et al., 2015). We 
used G*Power 3 (Faul et al., 2007) to calculate a sample size of n = 16 per genotype 
required for 80% power (p < 0.05). All behavioral studies utilized both male and female 
mice. All data are presented as means of replicates from each experiment ± SEM. In 




t-test was used to analyze the data unless otherwise specified. For experiments in which 
multiple factors were evaluated, ANOVA was used and significant interaction was 
deconstructed along the relevant factor to examine main effects and group differences 
followed-up using t-tests. Statistical p value threshold for t-test and ANOVA was set to 
0.05. The data comprising oral self-administration in vivo microdialysis were analyzed in 
SPSS (Version 21). All other data were analyzed in R (RRID:SCR_001905).  
Data and Code Availability 
All related data and materials are available upon request. The mass 
spectrometry proteomics data are available in MassIVE under proteome exchange 



























CHAPTER IV: The dynamic, methamphetamine-induced hnRNP H interactome 




The genetic factors underlying risk for psychostimulant addiction remain largely unknown. 
We previously identified Hnrnph1 as a QTG with a set of 5’UTR functional variants 
underlying reduced MA behavioral sensitivity and hnRNP H protein expression. Mice with 
a heterozygous frameshift deletion in the first coding exon (containing the first RNA 
recognition motif) of Hnrnph1 (H1 MUT) showed reduced MA-induced behaviors and 
DArelease. H1 MUT also showed a two-fold increase in synaptosomal localization of 
hnRNP H and proteomic evidence for mitochondrial dysfunction. To inform the 
mechanism linking hnRNP H dysfunction with reduced methamphetamine-induced DA 
release and behavior, we surveyed RNA targets of hnRNP H via cross-linking 
immunoprecipitation coupled with high-throughput sequencing (CLIP-seq) in striatal 
tissue at baseline and at 30 min post-MA (2 mg/kg, i.p.). hnRNP H mostly bound introns 
of target mRNA transcripts, confirming its role in splicing. MA treatment induced opposite 
changes in hnRNP H binding to mRNAs between H1 MUT versus WT, including 3’UTR 
targets in mRNAs enriched for synaptic proteins involved in DA release and 
psychostimulant-induced excitatory synaptic plasticity. RNA-binding, transcriptome and 
spliceome analyses triangulated on an upregulation of Cacna2d2 transcript and decreased 
3’UTR usage in response to MA in H1 MUT mice. Cacna2d2 codes for a presynaptic, 




behavior. Our study provides new insight into the rapid methamphetamine-induced cell 
biological adaptations that are regulated by hnRNP H and likely other RNA-binding 
proteins working in concert to modulate synaptic transmission. (Yazdani et al., 






















MA is a highly addictive psychostimulant with strong abuse potential and neurotoxic 
effects on the central nervous system (Kish, 2008; Galbraith, 2015; Yazdani et al., 2015). 
In the United States, the drug overdose death rate involving psychostimulants increased 
nearly 5-fold from 2012 through 2018 and continues to rise (Hedegaard et al., 2020). There 
are currently no FDA-approved treatments for MA dependence. Understanding the cell 
biological mechanisms and adaptations underlying MA’s psychostimulant properties will 
inform new therapeutic avenues. MA-induced DA release in the striatum is mediated 
through displacement of DA from synaptic vesicles through VMAT2 and the reverse 
transport of DA into the synapse through the DAT (Fleckenstein and Hanson, 2003; 
Siciliano et al., 2014). This increased DA release induced by MA contributes to the abuse 
potential of MA (Baumann et al., 2002). However, the rapid cell biological adaptations 
following MA administration, and their consequences on neurotransmission are not fully 
understood.  
Genetic factors play a major role in risk for developing substance use disorders, 
including addiction to psychostimulants such as MA (Goldman et al., 2005; Ducci and 
Goldman, 2012). We identified Hnrnph1 as a QTG for MA stimulant sensitivity in mice 
(Yazdani et al., 2015) and have since identified a set of quantitative trait variants within 
the 5’UTR associated with both decreased hnRNP H protein and MA-induced behavior 
(Ruan et al., 2020a).  Furthermore, mice heterozygous for a 16 bp deletion within the first 
coding exon of Hnrnph1 (H1 MUT) showed reduced sensitivity to MA-induced locomotor 




ventral striatum (Ruan et al., 2020a). Synaptosomal proteomic analysis of the striatum 
following MA administration identified opposite changes in the localization of several 
mitochondrial proteins in H1 MUT compared to WT mice, suggesting synaptic 
mitochondrial dysfunction as  a cell biological mechanism underlying reduced MA-
induced DA release and addiction-related behaviors (Ruan et al., 2020a).  
RBPs such as hnRNP H1 (coded by Hnrnph1) regulate each step of the RNA life 
cycle from processing to localization to degradation (Darnell, 2013; Hentze et al., 2018). 
In human genetic studies, coding mutations in HNRNPH1 and the gene paralog HNRNPH2 
are associated with severe neurodevelopmental disorders comprising mental retardation 
and intellectual disability (Pilch et al., 2018; Reichert et al., 2020). Increasing evidence 
links RBPs to substance use disorders, including FMRP and the family of hnRNPs (Bryant 
and Yazdani, 2016). Deletion of FMRP disrupts DA neuron development and alters 
psychostimulant-induced neuroplasticity and behavior (Fulks et al., 2010; Fish et al., 2013; 
Smith et al., 2014). Alternative splicing of exon 2 and transcriptional regulation of Oprm1 
(mu opioid receptor, MOR) is mediated through the binding of hnRNP H and recruitment 
of other hnRNPs to its intronic AGGG sequence (Xu et al., 2014). Translation repression 
of MOR is mediated through binding of hnRNP H and F at its 5’UTR (Song et al., 2012). 
Song et al. also demonstrated that morphine can increase expression of hnRNP K and 
poly(C)-binding protein 1 to upregulate MOR expression through binding of the two RBPs 
to its 5’UTR (Song et al., 2017). Thus, RBPs are critical for regulating RNA metabolism 




Hnrnph1 codes for an RBP that is expressed throughout the brain and belongs to 
the hnRNP H/F subfamily of hnRNP RBPs that engage in several aspects of RNA 
processing including pre-mRNA splicing, mRNA stability, transcriptional and translational 
regulation, and polyadenylation control (Honoré et al., 1995; Arhin et al., 2002; Han et al., 
2010; Geuens et al., 2016; Uren et al., 2016). During cellular stress, RBPs including hnRNP 
H (Markmiller et al., 2018; Wall et al., 2020), hnRNP A1 (Guil et al., 2006), and hnRNP 
K (Fukuda et al., 2009) localize to stress granules in the cytoplasm to sequester mRNAs 
from being translated. The highly dynamic formation of stress granules induced by cellular 
stress suggests that the interaction of hnRNP H with its RNAs can change rapidly in 
response to environmental stimuli, including stress-induced signaling. Based on the 
multifunctional role of hnRNP H and our observations of reduced MA-induced DA release 
and behavior in H1 MUT mice (Yazdani et al., 2015; Ruan et al., 2020), we hypothesized 
that acute MA treatment would alter hnRNP H binding to transcripts coding for proteins 
that control MA-induced dopaminergic synaptic transmission, including those regulating  
DA release and clearance (Joffe et al., 2014), intracellular release of calcium (Uramura et 
al., 2000), and formation of reactive oxidative species (Hedges et al., 2018). We further 
hypothesized that disruption of this RBP in H1 MUT mice would impact basal gene 
expression, splicing, and function of its target RNAs and that acute MA treatment would 
perturb hnRNP H-RNA interactions differently in H1 MUT versus WT mice.  
To address these critical questions, we dissected the in vivo mRNA targets of 
hnRNP H at baseline and in response to acute, systemic MA administration by assessing 




conducted parallel bulk RNA-seq from the same samples which allowed us to determine 
the relationship between hnRNP H binding and transcriptional regulation in H1 MUT 
versus WT mice. This 2 x 2 design permits the ability to identify baseline differences in 
RNA-binding targets as a function of H1 MUT as well as the dynamic, MA-induced 
hnRNP H interactome and how this is also affected by H1 MUT. Genotype x Treatment 
interactions in the MA-induced interactome could reveal the dysregulated dynamic, 
downstream changes in cell biological signaling that lead to functional reductions in MA-


















H1 MUT mice showed reduced MA-induced locomotor activity relative to WT  
H1 MUT and WT mice were subjected to a 3-day behavioral protocol to assess MA-
induced locomotor activity prior to tissue collection on Day 3. Performing CLIP 
specifically in the striatum required a large quantity of tissue. For this reason, we pooled 
striata (left and right) from four mice (2 females and 2 males per pooled sample) for each 
condition (Tables A4 and A5). The data reported here represent the averaged locomotor 
activity from four mice per replicate for each of the four conditions listed. On the saline 
(SAL)-treated Days (Day 1 and Day 2), both WT and H1 MUT mice showed no significant 
difference in locomotor activity (Figure 29A-B). On Day 3, after an acute dose of MA at 
2 mg/kg, H1 MUT mice showed reduced locomotor activity compared to WT (Figure 29C) 
(Yazdani et al., 2015; Ruan et al., 2020a). Importantly, there was no significant genotypic 
difference in response to SAL on Day 3 (Figure 29C), indicating that the genotypic 
difference was specific to MA treatment. The striatum was harvested from each mouse at 





Figure 29. MA-induced locomotor activity in H1 MUT versus WT mice.  
On Days 1 and 2, mice were injected (i.p.) with saline (SAL) and placed into testing apparatus for 
1 h. On Day 3, mice were injected (i.p.) with 2 mg/kg methamphetamine (MA) and placed into 
testing apparatus for 30 min followed by immediate sacrifice and removal of the striatum. (A-B): 
Locomotor activity on Day 1 (A) and Day 2 (B) for 1 h in 5-min bins. There was no genotypic 
difference in total distance traveled in response to SAL on Day 1 or Day 2 [Day 1: F(11,616)Genotype 
x Treatment x Time = 0.841, p = 0.599; Day 2: F(11,616)Genotype x Treatment x Time = 1.181, p = 0.296]. (C): 
MA-induced locomotor activity on Day 3 for 30 min in 5-min bins. 30 min post MA injection, mice 
were sacrificed and striatum from each mouse was dissected and harvested. H1 MUT showed less 
locomotor activity compared to WT [F(5,280)Genotype x Treatment x Time = 7.354, p = 1.70e-06]. There 
was also a significant decrease in total distance traveled in H1 MUT relative to WT in response to 
SAL on Day 3 at 0 – 5 min bin F(1,30) = 6.687, %p = 0.015; and a significant decrease in distance 
traveled in H1 MUT relative to WT in response to MA on Day 3 at 10 – 15 min bin [F(1,30) = 
5.163, *p =0.030, 15 – 20 min bin [F(1,30) = 5.259, *p = 0.029], 20 – 25 min bin [F(1,30) = 5.187, 
*p = 0.030], and 25 – 30 min bin [F(1,30) = 5.895, *p = 0.021]. No effect of Sex or interaction of 
Sex with other factors was detected for any of the measure reported. n = 8 per Sex per Genotype 
per Treatment. 
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hnRNP H binding sites contain G-rich binding motifs, with enrichment in the intronic 
regions 
To our knowledge, there are no in vivo CLIP studies reported for hnRNP H in whole brain 
tissue or in specific brain regions. Accumulating evidence from our lab indicates a role of 
hnRNP H in MA addiction liability (Ruan et al., 2020). Defining a set of RNA targets 
regulated by hnRNP H would inform key mechanisms modulating these MA-induced 
behavioral responses. To identify the in vivo hnRNP H targets, we performed CLIP in the 
striatum of H1 MUT versus mice, both at baseline (SAL) and in response to MA with an 
antibody specific for hnRNP H. We previously validated the antibody to be specific for the 
C-terminus of hnRNP H via immunoabsorption with a blocking peptide for the epitope 
(Ruan et al., 2018). Here, we show that the antibody was able to specifically pull down 
hnRNP H at approximately 50 kDa with no signal detected at this size using rabbit IgG 
(Figure A7A; Lane 6 versus Lane 3). In addition, it is important to note that we used 
stringent lysis and wash conditions according to the CLIP protocols previously reported 
(Van Nostrand et al., 2016). We subsequently determined that 20 g of hnRNP H antibody 
was the optimal amount needed by visual inspection of the band intensity at 50 kDa which 
was greater at 20 g versus 10 g antibody but similar at 20 and 30 g antibody (Figure 
A7B).  
Performing CLIP with anti-hnRNP H antibody in H1 MUT and WT mice followed 
by RNase digestion and radiolabeling of nucleic acid across four different RNase 
concentrations indicated RNA-specific pulldown. As expected, treatment with increasing 




from left to right, Lanes 3 – 6), with higher concentrations of RNase more readily digesting 
the RNA into smaller fragments. As we decreased the concentrations of RNase used for 
RNA fragmentation, a higher level of RNA was detected (Figure 30A; from left to right, 
Lanes 3 – 6), indicating the hnRNP H CLIP was RNA-dependent. Longer incubation of 
CLIP samples with RNase resulted in lower amount of RNA, providing further support that 
hnRNP H CLIP was RNA-dependent, with 3-min digestion time being the most optimal 
(Figure A7C). Negative controls included immunoprecipitation (IP) from uncrosslinked 
sample (Lane 1) and IP using rabbit IgG from WT striatal tissues (Lane 2). No RNA was 
detected in the negative control samples (Figure 30A; Lanes 1 and 2), indicating the need 
for UV-crosslinking for RNA pull down and demonstrating the specificity of hnRNP H 
pull down. We chose a region approximately 30 – 70 nucleotides in size (50 – 80 kDa) for 
RNA extraction in order to capture the targets of hnRNP H in vivo (Figure 30A). We 
collected 3 replicates of CLIP samples from pools of striata of 4 mouse brains per condition 
(Table A5). For the negative control, we performed IgG mock IP from pools of striatum 
of 4 mouse brains per condition. The cDNA libraries generated from the CLIP samples of 
the IgG IPs did not yield any detectable PCR bands using gel electrophoresis, even after 
28 PCR cycles (Figure A8A). However, for the CLIP samples, DNA bands corresponded 
to the correct size of the cDNA library (> 150 bp) were detected after 18 PCR cycles. For 
this reason, none of the four IgG cDNA libraries were subjected to sequencing. To account 
for differences in RNA abundance, we subjected the same samples used in CLIP for total 










Figure 30. hnRNP H binding sites in untreated saline WT mice are enriched for introns and 
G-rich binding motifs.  
eCLIP-seq revealed transcriptome-wide striatal target RNAs associated with hnRNP H in untreated 
saline WT mice. Peak calling of both uniquely and multi-mapped reads was performed using 
CLAM (Zhang and Xing, 2017). (A): CLIP and 32P labeling of hnRNP H-bound RNA. CLIP 
conditions are shown for each lane: no crosslinking, IgG mock IP, and four different RNase If 
concentrations from high to low. An increasing amount of RNA was pulled down as the 
concentration of RNase If was decreased. The scissors denote the region above the molecular 
weight of hnRNP H (50 kDa) that was isolated for sequencing. The region runs from 50 to 80 kDa, 
which corresponds to 30 to 70 bp for RNA length. The larger bands observed above 100 kDa could 
represent very long RNAs that are resistant to digestion or large hnRNP H-associated protein-
protein complexes bound to RNAs. (B): hnRNP H binds primarily to introns of target RNAs. More 
than 60% of hnRNP H CLIP sites are intronic. The pie chart shows the relative distribution of CLIP 
sites in 5’UTR, coding sequences (CDS), introns, and 3’UTR. Proximal introns indicate less than 
200 (proximalx200_intron) or 500 (proximalx500_intron) nucleotides from the 5’ or 3’ splice sites 
with the remainder annotated as distal introns. Unannotated exons are referred to as “other exons”. 
(C): Poly-G runs is the prevalent component of the hnRNP H binding motif. De novo motif 
discovery of hnRNP H CLIP sites was performed using Homer (Heinz et al., 2010). (D): hnRNP 
H RNA-binding targets containing G-rich motifs in their binding sites are most highly enriched for 
“presynaptic depolarization and calcium channel opening” pathway. Pathway enrichment analysis 
of hnRNP H RNA-binding targets with the poly-G motif was performed in WebGestalt (Liao et al., 
2019) using the over-representation analysis methods. The top 10 pathways with FDR > 0.05 are 
shown, sorted from high to low enrichment ratio. The hnRNP H RNA-binding targets containing 
G-rich motifs associated with these pathways are listed in Table A7.  
 
To define the targets of hnRNP H, we first focused the analysis on the WT_SAL 
(WT treated with SAL) condition. Specific sites of hnRNP H were identified using 
Peakcaller subcommand in CLAM (Zhang and Xing, 2017) to perform peak calling 
throughout the whole genome. The peak calling process was done on a gene-by-gene basis 
by breaking down each gene into 100 nucleotide bins and looking for enrichment of 
mapped reads over control (or total RNA-seq mapped reads) and specifying a negative-
binomial model on observed read counts. Importantly, CLAM can call peaks using the 
combination of uniquely- and multi-mapped reads for inclusion of RNA binding sites that 
are repetitive elements (Zhang and Xing, 2017). We then annotated the peaks to their 




gene in the intron is shown in Figure A9. hnRNP H  was shown to bind to Oprm1 for 
transcriptional and translation regulation (Song et al., 2012; Xu et al., 2014). hnRNP H-
associated peaks were defined as significantly enriched (p < 0.05 and peak signal intensity 
> 1.5) in CLIP samples over input RNA-seq samples. Analysis of the peaks across the gene 
subregions revealed enriched binding of hnRNP H in introns, comprising about 70% of 
total distribution (Figure 30B). This finding is consistent with previous characterization of 
hnRNP H in HeLa cells (Huelga et al., 2012; Uren et al., 2016), supporting successful 
isolation of hnRNP H-bound RNAs in mouse striatal tissue.  
De novo motif discovery of significant hnRNP H-associated binding sites using the 
Homer database (Heinz et al., 2010) detected the top over-represented motif to be G-rich 
(Figure 30C). Closer examination of the highly enriched motifs around hnRNP H CLIP 
sites in 5’UTR, coding region sequence (CDS), introns, and 3’UTR detected these poly-G 
run to be more prevalent in intronic regions (Table A6). Previous individual and genome-
wide studies of hnRNP H-RNA interactions in cultured cells identified binding sites 
containing the tetramer (T/G)GGG (Lefave et al., 2011; Uren et al., 2016), poly-G runs of 
various lengths (Katz et al., 2010; Russo et al., 2010), or poly-G stretches interspersed or 
terminated by A (Huelga et al., 2012). Our data supports poly-G tracts as a prevalent 
component of the hnRNP H binding motif, with particular enrichment of the motif in the 
intronic regions. These poly G-stretches in the introns have been shown to enhance hnRNP 
H binding (Han et al., 2005) and the length of the poly-G tracts  was shown to positively 
correlate with splicing (Katz et al., 2010).  The consistency of our CLIP-seq findings on 




results and supported our experimental protocol and analyses for successful isolation of 
hnRNP H-associated targets in mouse striatal tissue. To determine whether these hnRNP 
H binding targets harboring the G-rich motif share any common biological and molecular 
pathways, we performed pathway enrichment analysis and found these targets to be most 
enriched for “presynaptic depolarization and calcium channel opening,” comprising of 
subunits of calcium channels encoded by Cacna1a, Cacnb4, Cacna1e, Cacng4, Cacna1b, 
Cacng2, and Cacnb2 (Table A7), all of which are important for neurotransmission 
(Dolphin, 2012).  Another RBP that binds to mRNA transcripts that encode for ion 
channels is FMRP (Darnell et al., 2011). Our findings implicate another RBP, hnRNP H, 
in binding to introns of calcium channel subunit transcripts to post-transcriptionally 
regulate gene expression at the level of splicing to adaptively modulate neurotransmission 
(Table A8). 
hnRNP H regulates gene networks important for synaptic function 
To determine whether hnRNP H regulates a subset of targets in the striatum, pathway and 
gene ontologies (GO) analyses were performed to examine the biological and molecular 
functions of hnRNP H targets. Gene sets along with the associated genes are organized into 
an enrichment map network as depicted in Figure 31. Gene sets are connected to one 
another depending on the number of shared genes, where groups of highly related gene sets 
are clustered together. The enrichment map network revealed a clear overrepresentation of 
gene sets related to synaptic function (Figure 31). The top five enriched gene sets include 
transmission across chemical synapse, neuronal system, axon guidance, muscle contraction, 




hnRNP H post-transcriptionally regulates pre-mRNAs and mRNAs encoding for proteins 
for modulating synaptic function that plausibly contribute to the neural mechanism 
underlying hnRNP H dysfunction in reducing acute response to MA. 
 
 
Figure 31. hnRNP H RNA-binding targets in untreated saline WT mice are enriched for 
synaptic function.  
A list containing all hnRNP H targets meeting the CLAM peak signal threshold cutoff of greater 
than 1.5 was used as the input for gene ontology and pathway analysis using g:Profiler (Raudvere 
et al., 2019). The top 10 gene ontology (molecular function, cellular component and biological 
process) as well Reactome and WikiPathways were selected for visualization and clustering of 
gene-set enrichment as a network in the EnrichmentMap Cytoscape App (Merico et al., 2010). 
Gene sets are organized into a network enrichment map as shown. Each square (node) represents a 
gene set and each edge represents mutual overlaps. The five nodes indicated in asterisk represent 
the top five most enriched gene sets by p-value. A majority of gene sets are annotated for synaptic 






Hnrnph1 mutation and MA treatment induce changes in targets of hnRNP H  
In order to test the hypothesis that hnRNP H, like other RBPs, can respond to cellular 
stimuli, we examined both baseline and MA-induced changes in hnRNP H1-RNA 
interactions to identify targets of hnRNP H1 that could comprise neurobiological 
mechanisms of the acute behavioral response and potentially the long-term cellular 
adaptations occurring from repeated drug exposure. To date, dynamic RNA-protein 
interaction studies that examine the effect of exposure to drugs of abuse such as MA on 
changes in RNA-binding are lacking.  We also want to determine whether the heterozygous 
16-bp deletion (part of the first RNA recognition motif in Hnrnph1) affects hnRNP H1 
binding that can account for the difference in acute behavioral response observed between 
H1 MUT and WT. Thus, in addition to examining MA perturbation on the hnRNP H RBP 
interactome, we also examined differential RNA binding in H1 MUT mice versus WT and 
its potential interaction with drug treatment. Comparing changes in binding across the 
subregions of the mRNA transcript would tell us whether MA and the Hnrph1 mutation 
impact splicing function (via binding to introns) or mRNA stability and/or translation (via 
binding to 3’UTRs). 
In using the 2 x 2 design to analyze the read distribution separately across the 
3’UTR, introns, CDS, and 5’UTR for each of the four conditions, we again discovered 
over-representation of binding sites for intronic regions of the mRNA transcripts across all 
four conditions (Figure 32A). In comparison to the hnRNP H binding events at steady state 
(those detected in WT_SAL), changes in hnRNP H binding at 3’UTR and introns due to 




5’UTR than would be expected by chance (Table A9). The variation detected for the 
proportion of intronic binding across the four conditions indicated signaling events shifted 
the binding of hnRNP H to its intronic targets that can disrupt splicing of mRNA transcripts. 
In response to MA, WT mice showed an increase in the percentage of 3’UTR binding sites 
whereasH1 MUT mice showed the exact opposite, namely, a decrease in the percentage of 
3’UTR binding sites in response to MA. The shift in the proportion of binding events at 
the 3’UTR suggested that MA-induced signaling events altered hnRNP H-dependent post-
translational regulation at the level of mRNA stability, polyadenylation site usage, and 
translation. Thus, the binding interaction of these 3’UTRs and intronic targets to hnRNP H 
warranted further investigation. 
The opposite change in the percentage of 3’UTR targets between H1 MUT and WT 
in response to MA prompted us to look more closely at the hnRNP H RNA-interactome. 
By plotting changes in hnRNP H-associated CLIP peaks in the WT against H1 MUT in 
response MA relative to SAL, a negative correlation was identified (Figure 32B). An 
hnRNP H CLIP peak with increased binding in the WT in response to MA was more likely 
to show decreased binding in the H1 MUT. This negative correlation potentially indicates 
that the heterozygous deletion in the H1 MUT exerts a dominant negative effect on hnRNP 
H1 function, especially in response to MA. Thus, the hnRNP H shift in binding depends 
on both MA and Genotype and those CLIP peaks that show Genotype x Treatment 





Our CLIP-seq dataset defined more than 1000 mRNAs transcripts responsible for 
Genotype and MA effects (Figure A10A-B). To narrow on the list to those that are most 
relevant for the neural mechanisms driving reduced MA-induced dopamine release and 
behavior in H1 MUT mice, we focused on the ones that show Genotype x Treatment 
interaction. These targets are enriched for pathways associated with psychostimulant-
induced synaptic plasticity including “amphetamine addiction,” “long-term potentiation,” 
and “dopaminergic synapse” (Figure 32C and Table A10A). The targets are found to be 
in cellular components of “ATPase complex”, “myelin sheath,” “neuron spine”, and 
“nuclear chromatin”, all of which are involved in the cellular adaptations underlying 
exposure to drug of abuse (Figure 32D and Table A10B). Furthermore, the enrichment 
map network of top over-represented pathways and GO terms for these targets revealed 
clustering of nodes associated with synaptic function (Figure A10C). The post-
transcriptional regulation of the mRNA transcripts for these targets (most of which are 
important for synaptic transmission in response drugs of abuse) by hnRNP H to could be 
part of the neural mechanisms responsible for driving the MA phenotypic difference 










Figure 32.  hnRNP H RNA-binding targets showing a Genotype x Treatment interaction are 
enriched for pathways and cellular components involved in drug-evoked synaptic plasticity.  
CLIP-seq analysis revealed transcriptome-wide striatal RNA targets associated with hnRNP H in 
untreated SAL or MA-treated H1 MUT versus WT mice.  Peak calling in CLAM (Zhang and Xing, 
2017) was performed separately for each of the four conditions. For differential analysis, peak 
calling was also performed using CLAM (Zhang and Xing, 2017) on the merged bam file across 
all conditions followed by read counts against the identified peaks and differential analysis of peak 
intensity. (A): In comparison to untreated saline WT mice (WT_SAL), only the percentages of 
hnRNP H binding events associated with 3’UTR and introns were significantly different from those 
detected in WT_SAL (See chi-square tests in Table A7). The percentage that comprised 3’UTRs 
varied between Genotype and Treatment with an increase in response to MA versus SAL in WT 
mice and a decrease in response to MA versus SAL in H1 MUT mice (chi-square test: *p < 0.001). 
All of the intron binding events (including distal introns and proximal introns) also varied 
significant from WT_SAL (chi-square test: all p’s < 0.001, with the exception of MUT_SAL vs 
WT_SAL where p = 0.453 for proximalx200_intron).  The relative distribution of hnRNP H 
binding sites over the gene elements for each of the four conditions in the 2 x 2 (Genotype x 
Treatment) experimental design is shown. WT_MA = WT treated with MA; MUT_SAL = H1 MUT 
treated with SAL; and MUT_MA = H1 MUT treated with MA. (B): An hnRNP H CLIP peak with 
increased binding in WT mice in response to MA is more likely to show decreased binding in H1 
MUT mice. The plot shows a negative correlation between log2FC(WT_MA vs WT_SAL) and 
log2FC(MUT_MA vs MUT_SAL) (Pearson’s correlation coefficient r = -0.034, p < 2.2e-16). The 
hnRNP H CLIP peaks showing Genotype x Treatment interaction (highlighted in magenta) showed 
a much stronger negative correlation (Pearson’s r = -0.692, p < 2.2e-16). Each data point 
corresponds with a hnRNP H-associated CLIP peak. (C): Strong enrichment scores for the 
“amphetamine addiction”, “alcoholism”, “long-term potentiation”, and “dopaminergic synapse” 
pathways were detected for those hnRNP H RNA-binding targets showing decreased binding to 
hnRNP H in the H1 MUT versus WT in response to MA relative to SAL. The hnRNP H RNA-
binding targets associated with these pathways are listed in Table A10A. GSEA analysis was 
performed in WebGestalt (Liao et al., 2019) on a ranked list (based on log2FC) of hnRNP H targets 
showing Genotype x Treatment interaction. (D): Strong enrichment for “ATPase complex”, 
“myelin sheath”, “neuron spine” and “nuclear chromatin” cellular components were detected for 
those hnRNP H RNA-binding targets showing decreased binding to hnRNP H in the H1 MUT 
versus WT in response to MA relative to SAL. The hnRNP H RNA-binding targets associated with 
these cellular components are listed in Table A10B. 
 
3’UTR and intronic targets of hnRNP H show consistent enrichment for pathways 
involved in excitatory and psychostimulant-induced synaptic plasticity  
Hnrnph1 binding events comprising the intron and 3’UTRs both showed Genotypic and 
MA-induced changes compared to the untreated WT_SAL condition (Figure 32A). We 




at the introns and 3’UTRs are potential mechanistic targets that warrant further 
investigation and validation. We subsetted the hnRNP H-interactive CLIP peaks into 
separate subgenic regions (5’UTR, 3’UTR, intron, or CDS). Subsetting the binding events 
allowed us to characterize the impact of changes in binding on specific types of hnRNP H-
dependent post-transcriptional regulation by MA and the Hnrnph1 mutation. Do the 3’UTR 
and intron targets also show this dominant negative relationship in their association to 
hnRNP H in response to MA between H1 MUT and WT? Which subset of subgenic targets 
are enriched for pathways associated with the synaptic functions that we previously 
identified? 
We examined binding of hnRNP H across transcripts by plotting normalized 
log2CPM (counts per million) mapped reads to subgenic regions (Figure 33). The row of 
each heatmap represents a binding site sorted by p value from smallest to largest, where 
those with a p-value of less than 0.01 are shown in the heatmap. Interestingly, a distinct 
pattern was observed for the 3’UTR targets with opposing changes in the dynamics of 
hnRNP H binding in response to MA treatment between WT and H1 MUT. In response to 
MA relative to SAL, hnRNP H showed increased 3’ UTR binding in WT but decreased 3’ 
UTR binding in H1 MUT. Again, this was the same dominant negative relationship that 
was observed previously reported in Figure 32B. In plotting log2FC[WT_MA – WT_SAL] 
versus log2FC[MUT_MA – MUT_SAL] for each of these subgenic regions separately, a 
negative correlation was also detected for 3’UTR as well as 5’UTR, CDS, and introns. 
However, this dominant negative association with hnRNP H was most pronounced for the 




administration (WT_SAL versus MUT_SAL), increased binding of hnRNP H to these 
3’UTR targets was detected.  
 
Figure 33.  3’UTR targets showed opposing changes in binding to hnRNP H between H1 MUT 
and WT in response to MA.  
Genotype x Treatment-associated hnRNP H CLIP peaks, divided into 4 gene elements: 5’UTR, 
3’UTR, intron, and CDS. Heatmaps show normalized log2CPM (count-per-million) read counts for 
significant peaks demonstrating a Genotype x Treatment interaction (p < 0.05). The interaction is 
expressed as (MUTMA – MUTSAL) – (WTMA – WTSAL). Relative to WT mice, a broad increase in 
binding of hnRNP H to the 3’UTR regions of RNA-binding targets under SAL (or basal) condition 




To gain additional mechanistic insight into the 3’UTR targets showing a Genotype 
x Treatment interaction in binding, we performed separate KEGG pathway enrichment 
analysis for each type of subgenic binding site. Interestingly, only the 3’UTR targets 
showed significant enrichment for pathways associated with psychostimulant-induced 
synaptic plasticity (Table 10), whereas the 5’UTR and CDS targets did not show 
significant enrichment for any pathways. Some of these 3’UTR targets, including Gnas, 
Prkcb, Gria2, Grin2a, and Calm2 are involved in “dopaminergic synapse” and other 
3’UTR targets including Atp6v1b2, Atp60C, Slc6a1, Slc1a3, and Slc1a2 are involved in 
“synaptic vesicle cycling.” Closer examination of targets linked to “synaptic vesicle 
cycling” (Figure A11A) and “dopaminergic synapse” (Figure A11B) pointed to an 
opposing change in hnRNP H binding as a function of Genotype and MA treatment, just 
as we previously observed in the heatmap for 3’UTR targets in Figure 33. The binding of 
RBPs to 3’UTRs of transcripts provides a rapid means for mRNA translation at sites 
distance from the cell body such as  the synapse (Mayr, 2017; Harvey et al., 2018). Thus, 
in response to MA exposure, hnRNP H could plausibly regulate rapid changes in levels of 
proteins coded by genes involved in synaptic function via changes in 3’UTR binding to 
mRNA transcripts. Intronic targets also showed very similar enriched pathways as those 
found for 3’UTR targets, thus implicating hnRNP H in splicing of transcripts coding for 
proteins involved in synaptic function as well (Table 11). Thus far, our CLIP-seq data 
provided evidence for hnRNP H interacting with G-rich motifs within mostly introns and 
3’UTRs of mRNAs to drive post-transcriptional gene regulation in response to MA. 









Table 10. KEGG Enrichment analysis of dynamic hnRNP H 3’UTR targets.  
The table shows those 3’UTR RNA targets responding to the interaction of Genotype and 
Treatment. The interaction is expressed as (MUTMA – MUTSAL) – (WTMA – WTSAL) with p < 0.01. 
Pathway Adjusted p RNA targets 
Long-term potentiation 1.36E-06 
Braf, Prkcb, Grm5, Ppp3r1, Hras, Gria2, Gnaq, 
Grin2a, Calm2 
Glutamatergic synapse 5.69E-06 
Gnas, Prkcb, Slc38a1, Grm5, Ppp3r1, Gria2, Gnaq, 
Grin2a, Slc1a3, Slc1a2 
Long-term depression 7.15E-05 Gnas, Braf, Prkcb, Hras, Gria2, Gnaq, Ppp2r1b 
Salivary secretion 2.87E-04 Gnas, Prkcb, Atp1b1, Atp1b2, Gnaq, Calm2, Vamp2 
Dopaminergic synapse 9.51E-04 
Gnas, Prkcb, Ppp2r5b, Gria2, Gnaq, Ppp2r1b, 
Grin2a, Calm2 
Aldosterone synthesis and 
secretion 
9.51E-04 Gnas, Prkcb, Pde2a, Atp1b1, Atp1b2,  Gnaq, Calm2 
Amphetamine addiction 9.51E-04 Gnas, Prkcb, Ppp3r1, Gria2, Grin2a, Calm2 
Gastric acid secretion 1.24E-03 Gnas, Prkcb, Atp1b1, Atp1b2, Gnaq, Calm2 
Synaptic vesicle cycle 1.31E-03 Atp6v1b2, Slc6a1, Slc1a3, Atp6v0c, Vamp2, Slc1a2 














Table 11. KEGG Enrichment analysis of dynamic hnRNP H intronic targets.  
The table shows those intronic RNA targets responding to the interaction of Genotype and 
Treatment. The interaction is expressed as (MUTMA – MUTSAL) – (WTMA – WTSAL) with p < 0.01. 




Prkag2, Itpr1, Prkcb, Rock1, Cacnb2, Plcb1, Adcy5, Cacng2, 
Ryr2, Ppp1cb, Ppp3ca, Kcnj4, Camk1d, Ppp3r1, Cacna2d4, 
Cacna2d3, Cacna1d, Ppp1r12c, Camk4, Elk1, Camk2a, 
Map2k2, Cacna1c, Cacnb4, Gnas, Cacng8, Prkag1, Ppp3cb, 




Itpr1, Prkcb, Gria1, Grin2b, Plcb1, Grin2a, Ppp1cb, Ppp3ca, 
Ppp3r1, Camk4, Camk2a, Map2k2, Cacna1c, Grin2d, Gria2, 




Itpr1, Prkcb, Gria1, Grin2b, Plcb1, Adcy5, Grm4, Grin2a, 
Slc1a3, Ppp3ca, Gng7, Dlgap1, Ppp3r1, Grik5, Cacna1d, 
Cacna1c, Grin2d, Gria2, Gnas, Ppp3cb, Adcy6, Cacna1a, 




Itpr1, Prkcb, Gria1, Ppp1r1b, Grin2b, Plcb1, Mapk10, 
Adcy5, Grin2a, Ppp1cb, Ppp3ca, Gng7, Ppp2cb, Kif5c, 
Cacna1d, Mapk14, Camk2a, Cacna1c, Gria2, Gnas, Scn1a, 





Atp2b2, Cacnb2, Plcb1, Adcy5, Cacng2, Scn7a, Slc8a1, Ryr2, 
Ppp1cb, Cacna2d4, Cacna2d3, Ppp2cb, Cacna1d, Mapk14, 
Scn4b, Camk2a, Cacna1c, Atp1a2, Cacnb4, Gnas, Cacng8, 




Prkcb, Gria1, Ppp1r1b, Grin2b, Adcy5, Grin2a, Ppp1cb, 
Ppp3ca, Ppp3r1, Cacna1d, Camk4, Camk2a, Cacna1c, 




Itpr1, Prkcb, Gria1, Grin2b, Plcb1, Nos1ap, Adcy5, Ryr2, 
Grin2a, Gng7, Cacna1h, Cacna1d, Camk2a, Cacna1c, 




Itpr1, Atp2b2, Rock1, Prkce, Pde2a, Plcb1, Slc8a3, Adcy5, 
Mef2d, Slc8a1, Ppp1cb, Ppp3ca, Ppp3r1, Slc8a2, Cacna1d, 
Insr, Gna13, Map2k2, Cacna1c, Atp1a2, Mef2b, Ednra, 






Cacnb2, Sgcd, Cacng2, Slc8a1, Ryr2, Cacna2d4, Ctnna2, 
Cacna2d3, Cacna1d, Dag1, Cacna1c, Cacnb4, Itgb8, 




Itpr1, Prkcb, Atp2b2, Plcb1, Pde1a, Slc8a3, Htr2c, Slc8a1, 
Ryr2, Grin2a, Ppp3ca, Ppp3r1, Slc8a2, Cacna1h, Cacna1d, 
Camk4, Camk2a, Cacna1c, Chrna7, Grin2d, Ednra, Gnas, 






Cacna2d2 as candidate hnRNP H target for reduced MA-induced behavior and 
dopamine release in H1 MUT mice  
To explore whether the mRNA transcript(s) mediating reduced MA-induced behavior 
would also show functional changes in expression and/or splicing in response to Treatment 
and Genotype, in addition to a shift in mRNA-bind, we next sought to determine what the 
functional consequences of this change in binding were on mRNA transcript levels, and to 
parse direct effects on bound transcripts from indirect and downstream effects. To integrate 
striatal hnRNP H binding with gene expression and alternative splicing, we analyzed the 
transcriptome of striatal tissue from the same samples used in CLIP-seq. We performed 
both gene- and exon/intron-level transcriptome analysis to identify differentially expressed 
genes (Figure A12) and genes showing evidence for alternative splicing, namely genes 
showing significant differential exon or intron usage. Cacna2d2 was the only gene that was 
identified across all three sets of analysis, including its identification as a binding target of 
hnRNP H, as a differentially expressed gene (Genotype x Treatment), and as a gene 
demonstrating differential exon/intron usage (Genotype x Treatment; Figure 34A). 
Cacna2d2 showed an increase in expression in H1 MUT mice in response to MA and a 
decrease in WT mice (Figure 34B). A total of 19 genes showed a Genotype x Treatment 
interaction in differential gene expression (Figure 34B) with 6 of them (including 
Cacna2d2) overlapping with hnRNP H targets identified in CLIP-seq (circled in red in 
Figure 34B and listed in Table A11) – a 30% overlap in binding targets and differential 
expression is much greater than would be expected by chance (Fisher’s exact test p = 




in synapse formation and synaptic transmission (Zhang et al., 2017). Interestingly, hnRNP 
H has been shown to bind to Malat1 in multiple studies (Uren et al., 2016; Arun et al., 2020; 
Scherer et al., 2020) and we previously identified a trans-eQTL for Malat1 that originates 
within the Hnrnph1 behavioral QTL for reduced MA-induced locomotor activity (Yazdani 
et al., 2015). The other overlapping hnRNP H targets and differential expressed genes 
include Mir124, Gtf2e2, Unc13, and Camta1 (Figure 34A-B). It is possible that one or 
more of these differentially expressed and spliced mRNA transcript(s) contribute to the 






Figure 34. Cacna2d2 is the only convergent target showing a Genotype x Treatment-induced 
change in hnRNP H1 binding, gene expression and alternative splicing.  
Differential gene expression (DE) for the interaction of Genotype and Treatment [MUTMA – 
MUTSAL) – (WTMA – WTSAL)] was performed using limma (Ritchie et al., 2015) and edgeR 
(Robinson et al., 2009). Differential exon and intron usage analysis (alternatively spliced; AS) for 
interaction of Genotype and Treatment [MUTMA – MUTSAL) – (WTMA – WTSAL)] was performed 
using Aspli (Mancini et al., 2020). (A): Venn diagram comparing RNA-binding targets of hnRNP 




AS genes were then compared with the hnRNP H targets that comprised the Genotype x Treatment 
interactions. Cacna2d2 is the only RNA-binding target of hnRNP H that was both a DE gene and 
an AS gene. Only the top overlapping and non-overlapping hnRNP H targets and AS genes are 
indicated. Out of the 19 DE genes, Cacna2d2, Elfn1, Calb2, and Zic1 are putative targets of Malat1 
while Camta1 and Pcdh8 are putative targets of Mir124a. (B): Volcano plot of genes showing a 
Genotype x Treatment interaction between in H1 MUT and WT mice in response to MA The 
interaction is expressed as (MUTMA – MUTSAL) – (WTMA – WTSAL). Cacna2d2 is circled in red. 
The five overlapping hnRNP H targets and DE genes are circled in purple. (C): hnRNP H 
preferentially binds to the 3’UTR of Cacna2d2. Visualization of reads by Integrative Genome 
Browser (Thorvaldsdóttir et al., 2013) for the hnRNP CLIP peak at the 3’UTR of Cacna2d2. Scale 
of the plot height is in counts to million (CPM). (D): A G-rich motif is detected at the hnRNP H 
CLIP peak at the 3’UTR of Cacna2d2. De novo motif discovery of the binding site was performed 
in MEME (Bailey et al., 2009). (E): Interaction plots showing binding of hnRNP H to the 3’UTR 
of Cacna2d2 (left), differential usage of the 3’UTR (middle), and differential gene expression of 
Cacna2d2 (right) as a function of Genotype and Treatment. The increase in binding of hnRNP H 
to the 3’UTR of Cacna2d2 is associated with decreased usage of the 3’UTR and increased gene 
expression of Cacna2d2 in the H1 MUT. The interaction plots are generated from CLIP-seq and 
RNA-seq data showing average values with standard deviation of the means, with n = 3 per 
condition.  
 
Cacna2d2 codes for the voltage-dependent calcium channel subunit 22. Our 
CLIP analysis shows that hnRNP H binds to the 3’UTR of Cacna2d2 and thus could 
plausibly regulate polyadenylation site selection, mRNA stability at the 3’UTR, and 
ultimately CACNA2D2 protein levels (Figure 34C). Three putative isoforms, harboring 
different 3’UTR lengths, have been annotated by GENCODE so far. The MEME suite tools 
(Bailey et al., 2009) identified G-rich motifs (canonical binding motifs for hnRNP H) 
within the 3’UTR of Cacna2d2 (Figure 34D). Corresponding to this binding was the 
detection of an alternate usage event at the 3’UTR with a Genotype x Treatment interaction 
(log2FC = -1.37, p = 0.033). Here, 3’UTR usage is defined as to the number of normalized 
reads mapped to the 3’UTR portion of Cacna2d2. For WT mice, we observed a decrease 
in hnRNP H binding in response to MA treatment, which was associated with increased 




MUT mice, we observed increased binding of hnRNP H which correlated with decreased 
3’UTR usage, and an overall increase in gene expression. This identification of Cacna2d2 
implicated calcium signaling as a potential mechanism underlying the reduced MA-
induced behavior and dopamine release in the H1 MUT mice. This, interaction of hnRNP 
H with the 3’UTR implicates a role in translational regulation, perhaps at the level of 
polyadenylation site selection. Figure 35 illustrates a putative model of hnRNP H-
Cacna2d2 interaction at the 3’UTR. 
 
Figure 35. Schematic showing the putative interaction between hnRNP H-mediated 
selection of polyadenylation site in Cacna2d2.  
Predicted Cacna2d2 mRNA isoforms are shown on top (obtained from UCSC Genome Browser). 
Three polyadenylation sites are present within the 3’UTR of Cacna2d2 that distinguish isoforms 
containing 3’UTR of different lengths. We propose that binding of hnRNP H to pA-2 and pA-3 
within the 3’UTR of Cacna2d2 blocks the transcripts from being selected as polyadenylation sites 
and promotes the usage of pA-1 instead. The interaction of hnRNP H with Cacna2d2 promotes the 
generation of the isoform containing a short 3’UTR (or decreased 3’UTR usage as defined in our 
alternative splicing analysis). In response to acute MA and changes in signaling associated with 
MA entering the pre-synaptic neurons, there is a shift in binding of hnRNP H to Cacna2d2. It is 






We identified the genome-wide hnRNP H interactome in vivo in the mouse striatum in WT 
mice (isogenic C57BL/6J), both at baseline and in response to MA treatment. Most of the 
striatal hnRNP H targets were enriched for pathways and biological functions critical for 
excitatory synaptic transmission and psychostimulant addiction (Figures 31 and 32C-D). 
The posttranscriptional operon theory proposed by Keene and Tenebaum (2002) states that 
mRNAs bound by an RBP are often functionally related because these mRNAs shared 
sequence elements that are recognized by a given RBP and thus, are post-transcriptionally 
regulated as a group. For hnRNP H, the core motifs in most target mRNAs are G-rich 
sequences (Figure 30), consistent with previous characterization of hnRNP H binding sites 
(Russo et al., 2010; Lefave et al., 2011; Huelga et al., 2012; Uren et al., 2016). Interestingly, 
most target mRNAs containing these G-rich motifs code for subunits of pre-synaptic 
calcium channels (Figure 30D and Table A8). In dissecting the binding sites into different 
gene subregions, many of the 3’UTR targets are involved in psychostimulant-induced pre-
synaptic neurotransmitter release and post-synaptic plasticity (Table 10). Furthermore, 
several of the 3’UTR targets showed opposite changes in binding to hnRNP H in response 
to MA in H1 MUT (decreased 3’ UTR binding) versus WT mice (increased 3’UTR 
binding). The likely regulation of protein levels by hnRNP H binding to 3’UTR targets 
(e.g., regulation of repression, stability via differential 3’UTR usage, etc.) warrants further 
investigation. Together, CLIP-seq analysis shows a MA-induced difference in association 
of hnRNP H with target mRNA transcripts that code for synaptic proteins between the WT 




plausibly reflect rapidly regulated proteins that contribute to reduced MA-induced 
extracellular DA and behavior in H1 MUT mice.  
hnRNP H is primarily localized to the nucleus of neurons in adult mice (Kamma et 
al., 1995; Van Dusen et al., 2010; Ruan et al., 2020a). RBPs binding to 3’UTRs in the 
nucleus determines cytoplasmic localization and translation of mRNA transcripts 
(Guramrit et al., 2015). For example, She2p must first bind to the 3’UTR of ASH1 mRNA 
in the nucleus  before the transcript  localizes to the cytoplasm (Niednery et al., 2014). 
Binding of hnRNP H to 3’UTRs of mRNAs in the nucleus could recruit other proteins 
necessary for mRNA export to the cytoplasm for translation. We previously discovered 
that the H1 MUT mice, while showing no change in protein at the total striatal tissue level, 
showed a robust, two-fold increase in hnRNP H protein in the striatal synaptosome (Ruan 
et al., 2020a). Here, the H1 MUT genotype affected overall RNA binding in the striatum 
(Figure 32). Thus, differential binding of hnRNP H to its synaptic targets in H1 MUT mice 
is likely partially explained by the two-fold increase in the overall level of synaptic hnRNP 
H (Ruan et al., 2020) where it regulates translation of targets via their 3’UTRs, which, in 
turn would explain the high degree of enrichment of RNA-binding targets related to 
synaptic function as a function of Genotype (Figure 32). Our study demonstrates rapid 
plasticity of the RBP-mRNA interactome whereby exogenous cellular stimuli, such as 
acute MA acting on presynaptic terminals and synaptic vesicles, can induce rapid changes 
in binding of hnRNP H to mRNAs. Several RBPs have been shown to differentially alter 
their RNA-binding activity in response to arsenite-induced cellular stress, with distinct 




Much like these stress-responsive RBPs identified in vitro, hnRNP H also showed 
differential RNA binding to its targets in response to MA treatment in vivo. 
In agreement with previous studies (Huelga et al., 2012; Uren et al., 2016), our 
CLIP analysis of hnRNP H identified thousands of RNA-binding targets. Thus, a major 
challenge is to narrow down the list of targets that functionally contribute to decreased 
MA-induced extracellular DA level and behaviors in H1 MUT mice. Incorporating parallel 
transcriptome and spliceome datasets with CLIP targets from the same samples facilitates 
identification of functional, gene regulatory consequences of RNA binding (Chen and 
Keleş, 2020; Hwang et al., 2020; Li et al., 2020), that in turn, could modulate the cell 
biological response. In our final comparative analysis, we triangulated on the dynamic MA-
induced interactome with the MA-induced transcriptome and spliceome (Figure 6) to 
associate differential hnRNP H binding with transcriptional regulation in H1 MUT versus 
WT mice. Cacna2d2 emerged as an interesting candidate mechanistic target that showed a 
MA-induced decrease in binding of hnRNP H to 3’UTR, a decrease in 3’UTR usage, and 
an increase in overall Cacna2d2 transcript levels in H1 MUT versus WT mice (Figure 34). 
Cacna2d2 is expressed in the cerebellum, striatum, and hippocampus (Dolphin, 2012). It 
codes for a pre-protein that is proteolytically processed into the 2 and 2 subunits of 
presynaptic, voltage-gated calcium channels (VGCCs) (Dolphin and Lee, 2020). These 
22 subunits localize VGCCs to the active zone and promote neurotransmitter release 
(Dolphin, 2013). Overexpression of 22 subunits decreased presynaptic calcium 
elevation in response to an action potential, yet somehow increased vesicular release 




calcium signaling and mitochondrial function (Carboni et al., 2003). Changes in 
intracellular calcium are tightly linked to changes in mitochondrial function as 
mitochondria can serve to buffer intracellular calcium levels (Rizzuto et al., 2012). Our 
proteomic analysis of the striatal synaptosome showed opposite changes in mitochondrial 
protein levels compared  in H1 MUT versus WT mice in response to MA (Ruan et al., 
2020a). A recent study demonstrated in both cell and slice culture that both intracellular 
and extracellular calcium contribute to MA-induced DA release in the ventral striatum 
(Yorgason et al., 2020). Acutely, MA  can inhibit calcium entry into L-type and N-type 
VGCCs, with longer exposure leading to a compensatory upregulation of Cacna1c 
transcript levels in SH-SY5Y cells (Andres et al., 2015), which could potentially mediate 
calcium-mediated neurotoxicity. Repeated treatment with MA increases mRNA and 
protein of 2 subunit in the frontal cortex and limbic forebrain of mice and this 
upregulation is blocked by DA receptor antagonists (Kurokawa et al., 2010). Our 
identification of Cacna2d2 dynamics at multiple levels of analysis following MA 
administration (3’UTR binding, transcriptional, and usage) suggests that regulation of this 
calcium channel subunit and others (Figure 34) could comprise a rapid, adaptive means 
for regulation of calcium entry and consequently, DA release and behavior. As an 
interesting aside, VMAT2 and DAT, the two molecular targets of MA that increase the 
extracellular level of DA at the synapse (Fleckenstein and Hanson, 2003; Siciliano et al., 
2014), were not identified as RNA-binding targets of hnRNP H, which indicates that 




The precise roles of RBPs in drug-induced synaptic plasticity are largely 
unexplored. Revelation of the hnRNP H RNA interactome identified a potential novel role 
for hnRNP H in regulating transport, stability, and/or translation of mRNAs linked to 
excitatory synapse and psychostimulant-induced synaptic plasticity. Dynamic regulation 
of synaptic protein synthesis  following activation of neurotransmitter receptors, plays a 
key role in synaptic plasticity (Bramham and Wells, 2007). FMRP is an example of an RBP 
that localizes to dendrites to regulate mRNA transport and synaptic plasticity (Bassell and 
Warren, 2008).  Loss of FMRP in mice reduced sensitivity to cocaine-induced reward and 
behavioral sensitization (Smith et al., 2014). Stimulation of the metabotropic glutamate 
receptors in primary neuronal culture can rapidly dephosphorylate FMRP, leading to a 
dissociation FMRP from miR-125a and translational activation of PSD-95 mRNA 
(Muddashetty et al., 2011). DA receptor D1 activation in prefrontal cortical neurons leads 
to phosphorylation of FMRP and synthesis of synaptic proteins needed for glutamate 
receptor trafficking (Wang et al., 2008, 2010). Thus, the phosphorylation status of an RBP 
can affect translational regulation in response to receptor activation. We  previously 
reported  that treatment with a D1 DA receptor agonist (but not a D2 agonist) in cultured 
rat primary cortical neurons induced a D1 antagonist-reversible increase in nuclear 
immunocytochemical staining of hnRNP H without altering nuclear protein levels (Ruan 
et al., 2018), suggesting  a potential post-translational modification of hnRNP H and/or its 
protein/RNA complexes. In addition, similar to our findings for hnRNP H RNA-binding 
targets, the FMRP interactome also revealed target mRNAs encoding proteins linked to 




neurotransmission, including voltage-gated potassium channels (Gross et al., 2011; Lee et 
al., 2011), sodium-activated potassium channels (Brown et al., 2010), calcium-activated 
potassium channels (Deng et al., 2013), and N-type VGCCs (Ferron et al., 2014). The 
potential transport and localization of Cacna2d2 (and other VGCC transcripts; Table A8) 
by hnRNP H in response to MA and how this potentially regulates MA-induced DA release 
warrants further investigation.  
To summarize, we provide the first MA-induced RNA interactome study of an RBP 
in the striatum.  Analysis of drug-induced RBP interactomes, especially for drugs of abuse 
is an understudied approach for understanding rapid, synaptic gene regulation as it relates 
to cell biological adaptations in neuronal excitability, neurotransmitter release, synaptic 
plasticity, and behavior. We focused on hnRNP H, given the evidence for its role in MA-
induced DA release and behavior (Yazdani et al., 2015; Bryant and Yazdani, 2016; Ruan 
et al., 2020a, 2020b). We established hnRNP H as a novel gene regulatory link among 
several target mRNAs coding for proteins that are well-established to mediate 
psychostimulant-induced neurotransmission and plasticity. Our study design represents a 
powerful approach for integrating complementary gene sets from different “omic” methods 
(interactome, transcriptome, and spliceome) that can be broadly applied to the study of 
drug-induced RBP-RNA dynamics and discovery of functionally relevant RNA-binding 
targets underlying cell biological responses, adaptations, and organismal phenotypes such 





MATERIALS AND METHODS 
Mice 
H1 MUT were generated via TALENs-mediated induction of a small, 16 bp deletion in the 
first coding exon as described (Yazdani et al., 2015) and have been deposited to The 
Jackson Laboratory repository (#033968). A two-fold increase in hnRNP H protein 
expression was detected in the striatal synaptosome of H1 MUT compared to WT with no 
change in total tissue level (Ruan et al., 2020a). Mice were generated by mating 
heterozygous H1 MUT males with C57BL/6J females purchased from The Jackson 
Laboratory (Bar Harbor, ME USA), yielding offspring that were approximately 50% 
heterozygotes for H1 MUT and 50% WT for Hnrnph1. Both female and male offspring 
(ranging from 50 – 100 days old at the start of the experiment) from this breeding scheme 
were used in the study and were genotyped as described (Yazdani et al., 2015). Mice were 
housed in same-sex groups of 2-5 in standard mouse cages in ventilated racks under 
standard housing conditions on a 12 h:12 h light:dark schedule with food and water 
supplied as libidium. All protocols involving mice were in accordance with the Guideline 
for the Care and Use of Laboratory Animals and were approved by Boston University’s 
IACUC committee.  
MA-induced locomotor activity followed by whole striatum harvesting 
As described (Yazdani et al., 2015), on Days 1 and 2, all mice received a saline injection 
(10 ml/kg, i.p.) and were recorded for locomotor activity in Plexiglas chambers (40 cm 




or MA (2 mg/kg, i.p.; Sigma Aldrich) and were recorded for locomotor activity for 30 min 
and the whole striata (left and right sides) were dissected from each mouse at 30 min post-
injection (Ruan et al., 2020a). Dissected whole striata were stored in RNAlater (Thermo 
Fisher Scientific, Cat# AM7020) following manufacturer’s instructions to stabilize the 
RNA and protein followed by CLI library preparation as described below. 
CLIP 
Striata from four mice were pooled per replicate (3 replicates per Genotype per Treatment). 
Each replicate used for CLIP-seq and RNA-seq was generated by pooling striata from 4 
H1 MUT or WT mice across multiple litters. Each pool consisted of samples from 2 
females and 2 males.  The striatum was chosen because of its involvement in the MA 
locomotor stimulant response, reinforcement and reward (Keleta and Martinez, 2012; 
Lominac et al., 2014). The experimental design and sample size are outlined in Table A4 
and A5, respectively. Tissue was flash frozen in the mortar-filled liquid nitrogen and 
crushed into powder with the pestle and kept on dry ice in a 100 mm Petri dish until use. 
Prior to crosslinking, a portion of the pooled tissue from each replicate was removed and 
stored in -80C for later RNA extraction and bulk RNA-seq library preparation. The tissue 
was kept on dry ice in the dish while crosslinking was performed for three rounds using a 
400 mJ/cm2 dosage of 254 nm ultraviolet radiation. The crosslinked tissue was then 
homogenized in 1 ml of lysis buffer with a mechanical homogenizer followed by addition 
of TURBO DNase (2 l; Thermo Fisher Scientific, Cat# AM2239). The lysate was kept on 




was allowed to incubate in a thermomixer set to 1200 RPM at 37C for 3 min. The lysate 
was then centrifuged at 20,000 x g for 20 mins at 4C and kept on ice until use.  
For RNA-immunoprecipitation, 133.3 l of MyOne Streptavidin T1 beads 
(Invitrogen, Cat# 65602) were incubated with 5.8 l of 1 mg/ml of PierceTM biotinylated 
Protein G (Thermo Fisher Scientific, Cat# 29988) and 20 g of either the hnRNP H 
antibody (Bethyl; Cat #A300-511A) or the rabbit IgG antibody (EMD Millipore, Cat# 12-
370) for 1 h. The antibody-coupled beads were washed five times with 0.5% IgG-free BSA 
(Jackson ImmunoResearch; Cat# 001-000-162) in 1X PBS, followed by three washes in 
lysis buffer. The lysate that was clarified by centrifugation was added to the coated and 
washed beads and incubated with end-to-end rotation at 4C for 2 h followed by 2X wash 
with 500 l of wash buffer (end-over-end rotation at 4C for 5 min each) and another 2X 
wash with 500 l of high salt wash buffer (end-over-end rotation at 4C for 5 min each). 
This was followed by another wash with 500 l each of both wash buffer and high salt 
wash buffer. The final washes were performed 2X with 500 l of wash buffer. The rest of 
the wash buffer was removed and beads resuspended in 20 l of 1X Bolt LDS non-reducing 
sample buffer (ThermoFisher Scientific, Cat# B0007). The beads in sample buffer were 
then heated at 70C for 10 min prior to SDS-PAGE on a 4-12% gradient NuPAGE Bis/Tris 
gels (ThermoFisher Scientific, Cat# NP0322BOX) followed by transfer to nitrocellulose 
membrane (Amersham Protran Premium 0.45 NC; Cat# 10600078) with 10% methanol for 






50 mM Tris-HCl pH7.4 
100 mM NaCl 
1% NP-40 (Igepal CA630) 
0.1% SDS 
0.5% sodium deoxycholate (protect from light) 
Protease and phosphatase inhibitor cocktail (1:100)  
Recombinant RNasin Ribonuclease Inhibitor (1 ul/ml) 
 
Wash buffer  
20 mM Tris-HCl pH7.4 
10 mM MgCl2 
0.2% Tween-20 
Recombinant RNasin Ribonuclease Inhibitor (1 uL/ml) 
 
High salt wash buffer  
50 mM Tris-HCl pH7.4 
1M NaCl 
1 mM EDTA 
1% NP-40 
0.1% SDS 
0.5% sodium deocxycholate 
Recombinant RNasin Ribonuclease Inhibitor (1 uL/ml) 
 
CLIP-seq sequencing library preparation 
Following the completion of membrane transfer, the membrane was cut with a clean razor 
to obtain a vertical membrane slice per lane from 50 kDa (molecular weight of hnRNP H) 
to 75 kDa, which translates to 30 to 70 nucleotide RNA fragments crosslinked to the protein. 
RNA was then extracted from the membrane slices following a previously described 
procedure (Rieger et al., 2018). The same extraction procedure (starting with the addition 
of 7M urea) was used to isolate RNA from samples previously stored for total RNA-seq. 
Following RNA extraction, sample concentration was quantified with Agilent Bioanalyzer 
and approximately 0.2 ng of RNA was used to prepare next-generation sequencing libraries 




RNA adapter on each sample contained a unique barcode, the cDNA libraries generated 
from the sample (12 CLIP-seq and 12 RNA-seq libraries) were multiplexed and pooled for 
increased throughput. A pooled library at a concentration of 10 nM were shipped to 
University of Chicago Sequencing core and subjected to 100 bp paired-end 2 x 100 
sequencing in a single lane on Illumina HiSEQ4000. To increase read coverage for the 
RNA-seq samples, those 12 cDNA libraries were pooled (10 nM concentration) for 
sequencing for a second time in one lane using Illumina HiSEQ4000. The read coverage 
for each sample is shown in Table A12. 
CLIP-seq Analysis of Multi-Mapped Reads 
Reads were trimmed for quality using Trimmomatic (Bolger et al., 2014). Unique 
Molecular Identifier (UMI) sequences were extracted from Read 2 for removal of PCR 
amplification duplicates using the ‘extract’ command in UMI-tools (Smith et al., 2017). 
After the reads were trimmed and UMI extracted, we used STAR (Dobin et al., 2013) to 
map reads to mouse genome, version GRCm38/mm10. Even though the samples had gone 
through the ribosomal RNA (rRNA) depletion prior to library preparation, we used 
BEDTools (Quinlan and Hall, 2010) to intersect the bam files with the RNA annotation 
bed file exported from UCSC Table browser (Karolchik et al., 2004) to remove rRNAs and 
other repetitive RNAs. Using the ‘dedup’ command in UMI_tools (Smith et al., 2017), 
PCR duplicates from the rRNA-depleted bam files were removed based on UMI extracted 
in the previous step. To define the binding sites for hnRNP H for each of the four conditions 
separately, the deduplicated bam files for the three replicates of each condition were used 




Multi-Mapped reads. The BAM file for the CLIP sample and the BAM file for input 
(corresponding RNA-seq sample) were used as input along with a gene annotation file in 
Gene Transfer Format downloaded from GENCODE. Following the steps described in 
CLAM (Zhang and Xing, 2017), in order to allow for peak calling of multi-mapped reads, 
BAM files were preprocessed first to separate multi-mapped reads and unique mapped 
reads followed by realigning and then peak calling and peak annotation.  
Deduplicated BAM files were merged across all 12 CLIP samples and deduplicated 
BAM files were merged across all 12 input (bulk RNA-seq) samples to generate two 
merged BAM files as the input for peak calling in CLAM as described above. The called 
peaks were then annotated. The file containing all the peaks was formatted into a file in 
GTF format to be used for strand-specific feature counting in individual BAM files using 
Subread FeatureCounts (Liao et al., 2014). FeatureCount (Liao et al., 2014) in Subread was 
used to sum reads under each peak for each of the four conditions. To examine the effect 
of Genotype, Treatment, and the interactive effects on hnRNP H binding, differential 
binding sites and peak analysis were performed using limma (Ritchie et al., 2015) and 
edgeR (Robinson et al., 2009) based on summed counts for each peak derived from 
Subread FeatureCount. The interaction of Genotype and Treatment is expressed as: I = 
(MUT_MA – MUT_SAL) – (WT_MA – WT_SAL).  
Homer de novo Motif Discovery 
To identify the top over-represented motif in the peaks (those peaks with CLIP peak 
intensity > 1.5) identified in CLAM, the Homer software (Heinz et al., 2010) was used for 




comprised a list of hnRNP H associated peaks containing the genomic coordinates. The 
“annotatePeak.pl” function was then used to identify motif locations to find genes 
containing a particular motif.  
Differential Gene Expression and Exon and Intron Usage 
To triangulate the CLIP-seq and RNA-seq data and associate the downstream effect of 
hnRNP H binding with changes in gene expression and alternative splicing, we used ASpli 
(Mancini et al., 2020) to analyze differential gene expression as well as differential exon 
and intron usage. To test that hypothesis that some genes interact with Genotype in their 
binding or expression response to Treatment, the interaction was expressed as:  
I = (MUT_MA – MUT_SAL) – (WT_MA – WT_SAL).  
Pathway and Gene Ontology Enrichment Analysis 
To examine the biological function of the hnRNP H targets (peak signal value defined by 
a CLAM value greater than 1.5 for each target), we performed pathway and gene ontology 
(GO) enrichment analysis of those targets in g:Profiler (Raudvere et al., 2019) against the 
following data sources: Reactome, WikiPathways, GO molecular function, GO cellular 
component, and GO biological process. The top 10 pathways and GO terms from each 
these 5 databases (a list of 50 gene sets) were used for network analysis in Cytoscape using 
the EnrichmentMap module (Merico et al., 2010). Highly redundant gene sets were 
grouped together as clusters for clear visualization and easy interpretation. The same 
pathway and GO enrichment analyses were performed in g:Profiler for the hnRNP H 




et al., 2019). To determine enrichment of the hnRNP H targets for each gene subregion 
separately, we performed KEGG (Kanehisa et al., 2019) pathway enrichment analysis in 
WebGestalt (Liao et al., 2019) to examine the biological relevance across each set of targets. 
Data and Code Availability 
Raw and processed sequencing data from CLIP-seq and RNA-seq can be accessed through 



















CHAPTER V: Summary & Future Directions 
OVERVIEW 
The genetic factors underlying risk for psychostimulant addiction remain largely unknown. 
Our lab mapped and validated Hnrnph1 as a QTG for reduced MA stimulant sensitivity. 
Mice with heterozygous deletion of a small region in the first coding exon of Hnrnph1 also 
showed reduced MA-induced reward and reinforcement, as well as a decrease in MA-
induced extracellular DA in the NAc. The combined results indicate reduced addiction 
liability in H1 MUT mice.  hnRNP H1 is an RNA binding protein that regulates every 
aspect of RNA metabolism (from the cradle to the grave, as they say). The objective of my 
dissertation research is to understand the mechanism of hnRNP H1 dysfunction in MA-
induced DA release and behavior through multi-omics data integration including proteome, 
transcriptome, and hnRNP H1 RNA-interactome. The findings from these studies are 
discussed in detail in Chapters II to IV. 
 
SUMMARY 
Chapter II: 5’UTR variants in the quantitative trait gene Hnrnph1 support reduced 
5’UTR usage and hnRNP H protein as a molecular mechanism underlying reduced 
methamphetamine sensitivity 
Our lab previously used positioning cloning to identify a 204 kb region containing 
polymorphisms in two genes, Hnrnph1 and Rufy1, that was necessary for reduced 
sensitivity to the locomotor stimulant effect of MA. We subsequently showed that congenic 




deletion in Hnrnph1 also showed reduced MA-induced locomotor activity. These findings 
supported Hnrnph1 as the QTG, however, causal variants within or near Hnrnph1 are not 
known. Following the discovery of decreased usage of the 5’UTR in Hnrnph1 in 114 kb 
congenic mice using exon-level transcriptomic analysis, we validated this decreased 
5’UTR usage using qPCR, that in turn, was associated with a two-fold decrease in hnRNP 
H protein. To determine which of the 4 polymorphic variants within the 5’UTR contribute 
to the decrease in translation, we cloned the 5’UTR of Hnrnph1 containing either the 
individual variants or the combined set of all four variants for fusion to a luciferase reporter 
for expression analysis in HEK293T and N2A cells.  The reporter assay showed that all 
four variants (but none individually) decreased protein expression.  We identified a set of 
5’UTR functional variants in Hnrnph1 that likely comprise the quantitative trait variants 
underlying decreased hnRNP H protein and likely and decreased MA sensitivity.  
 
Chapter III: A Mutation in Hnrnph1 That Decreases Methamphetamine-Induced 
Reinforcement, Reward, and Dopamine Release and Increases Synaptosomal hnRNP H 
and Mitochondrial Proteins 
We previously discovered Hnnrph1 as a QTG for reduced sensitivity to the locomotor 
stimulant response to MA (Yazdani et al., 2015).  We subsequently validated that this 
reduced MA sensitivity in the H1 MUT mice extends to other addictive properties of MA.  
H1 MUT showed reduced MA reinforcement and intake and a dose-dependent change in 
MA reward. In addition, H1 MUT mice showed a decrease in MA-induced extracellular 




WT in baseline extracellular DA, whole tissue striatal DA, DAT, DA uptake, MA striatal 
metabolite levels, or TH-positive DA neurons.  Importantly, a two-fold increase in hnRNP 
H protein was detected in the striatal synaptosome of H1 MUT mice with no change in 
whole tissue level, indicating a role of hnRNP H in mRNA localization and/or protein 
translation at the synapse. Synaptosomal proteomic analysis identified an increased 
baseline abundance of several mitochondrial complex I and V proteins that rapidly 
decreased at 30 min after MA administration in H1 MUT mice. In contrast, the much lower 
level of basal synaptosomal mitochondrial proteins in WT mice showed a rapid 
increase. Thus, we identified a potential role for hnRNP H in basal and MA-induced 
changes in mitochondrial function that informs the basal and MA-induced cellular 
adaptations that could underlie reduced addiction liability in H1 MUT mice. 
 
Chapter IV: The dynamic, methamphetamine-induced hnRNP H interactome reveals 
synaptic RNA-binding targets associated with reduced dopamine release and behavior 
hnRNP H binds to mRNA transcripts and is involved in every aspect of post-translational 
gene regulation. To understand the mechanism of hnRNP H dysfunction in MA-induced 
DA release and behavior, we surveyed target RNAs of hnRNP H using CLIP-seq in striatal 
tissue at baseline and at 30 min post-MA (2 mg/kg, i.p.). To integrate identification of 
hnRNP H targets with the impact of Hnrnph1 mutation and MA treatment on downstream 
gene expression and splicing, we analyzed the transcriptome of the same samples used in 
CLIP-seq. Analysis of read distribution across transcript subregions revealed enriched 




confirming its role in splicing. De novo motif discovery of significant hnRNP H-associated 
binding sites using the Homer database detected the top over-represented motif to be G-
rich. Genome-wide identification of hnRNP H targets using CLIP-seq in the mouse 
striatum of C57BL/6J revealed targets important for synaptic function. MA treatment 
induced opposite changes in binding of hnRNP H to mRNAs between H1 MUT versus WT 
mice. More specifically, in response to MA, an RNA target that is more likely to show 
increased binding to hnRNP H in the H1 MUT is more likely to show decreased binding 
in WT, demonstrating a negative correlation in hnRNP H binding dynamics between H1 
MUT versus WT in response to acute MA. This dominant negative relationship in hnRNP 
H binding to RNA target was most robust in 3’UTR of the mRNA transcripts encoding for 
synaptic proteins involved in DA release and psychostimulant-induced excitatory synaptic 
plasticity. From the transcriptome analysis of parallel samples, a total of 19 genes showed 
a Genotype x Treatment interaction in differential gene expression, with 6 of these 19 genes 
(including Cacna2d2) overlapping with hnRNP H targets that were identified in CLIP-seq. 
Two of these six genes were the long non-coding RNA Malat1 and microRNA Mir124a, 
both of which are involved in regulation of genes important for synapse formation and 
synaptic transmission. RNA-binding, transcriptome and spliceome analysis triangulated on 
a potentially critical mechanistic target for MA-induced DA release and behavior, 
Cacna2d2. Specifically, we observed increased hnRNP H binding to 3’UTR of Cacna2d2, 
an upregulation of Cacna2d2 transcript, and decreased 3’UTR usage in response to MA in 
H1 MUT mice. Cacna2d2 codes for a presynaptic, voltage-gated calcium channel subunit 




overlapping hnRNP H interactome and transcriptome showing the Genotype x Treatment 
interaction identified Unc13c and Camta1, both of which are calcium-responsive genes. 
Thus, multiple lines of evidence point to the modulation of calcium as likely potential 




Understand the 16-bp deletion in Hnnrph1 in the H1 MUT 
The heterozygous 16-bp deletion within the first coding exon (exon 4, UCSC Genome 
Browser) mediated by transcription activator-like effector molecule in the H1 MUT mice 
should have theoretically led to a premature stop codon and transcription of a truncated 
mRNA transcript that should have been degraded. However, with the caveat that there is 
no specific antibody, we have not detected any decrease in the total level of hnRNP H 
protein that would indicate protein knockdown. Interestingly, H1 MUT mice showed an 
increased level of hnRNP H in the striatal synaptosome relative to the WT but no change 
in total hnRNP H level (Chapter III). This finding prompted us to investigate the 
synaptosomal proteome and hnRNP H RNA interactome in H1 MUT versus WT mice to 
further investigate the effect of this mutation on Hnrnph1 function (Chapters II and III). 
Both the synaptosome proteome and RNA interactome data detected a genotypic difference 
in mitochondrial protein level and hnRNP H interaction with mRNAs coding for synaptic 
proteins involved in psychostimulant-induced synaptic plasticity. Compared to the WT, a 
higher level of mitochondrial protein is detected with the H1 MUT (Chapter III). CLIP-seq 




compared WT (Chapter IV). Acute treatment MA reversed this genotypic difference in 
mitochondrial proteins and hnRNP H binding. These findings suggest the heterozygous 16-
bp deletion might exert a dominant negative effect on Hnrnph1 function at baseline steady 
state. However, in response to MA, there is a reversed effect on Hnrnph1 function.  
This 16-bp deletion is located within the first RRM of Hnrnph1 that might modify 
its interaction with mRNA transcripts. It is worth pointing out that there is an alternative 
start codon downstream of exon 4 where the 16-bp deletion is located. One possibility is 
that the ribosome skips over the premature stop codon and initiates translation from this 
other start codon.  Both the proteome and CLIP-seq data raise the possibility that H1 MUT 
mice harbors truncated hnRNP H1 protein that dominates over the function of the WT 
hnRNP H1 protein. To answer this question, we performed quantitative analysis of protein 
peptides from hnRNP H co-immunoprecipitation followed by mass spectrometry (Chapter 
III). Indeed, we detected a decrease in the level of a peptide containing the amino acid 
residues encoded by the 16-bp deleted region in exon 4 of Hnrnph1. However, this decrease 
did not reach statistical significance. To follow up on this finding, one approach is to clone 
Hnrnph1 and use site-directed mutagenesis to delete the same 16 nucleotides. For detection 
of hnRNP H1 protein, a GFP tag can be added to either the N- or C-term of Hnrnph1. In 
this way, we can determine whether this 16-bp deletion in Hnrnph1 yields a functional 
protein or not. The piece of data can help us with better interpretation of future data 
generated using the H1 MUT mouse model and inform the design of future experiments to 





Subcellular and Cell-Type Specific hnRNP H1 CLIP-seq 
In Chapter IV, we focused on whole tissue analysis of hnRNP H-RNA interaction in the 
striatum. It is clear from the data that the presynaptic, post-synaptic, cytoplasmic, and 
nuclear RNA binding events mediated by hnRNP H are not directly identifiable in our 
whole tissue CLIP.  RBPs contribute to stress-induced regulation of RNA fate and function 
in a nuclear- versus cytoplasmic- specific manner (Backlund et al., 2020). The formation 
of stress granules is one particular stress response mechanism that requires RBPs to 
sequester mRNAs from being translated in the cytoplasm (Ivanov et al., 2020). 
Interestingly, cellular stress induces the accumulation of hnRNP H in the cytoplasm and 
localization to stress granules (Wall et al., 2020). These findings implicate the ability for 
hnRNP H to shuttle between the nucleus and cytoplasm to regulate RNA fate and function 
at the level of splicing (intronic binding or nuclear events) and mRNA stability, 
localization, and translation (3’UTR binding or cytoplasmic events). In our CLIP-seq 
analysis, we also identified binding of hnRNP H to the 3’UTR regions of transcripts.  
To explore the relationship between nuclear and cytoplasmic functions of hnRNP 
H, it will be necessary to define hnRNP H-RNA interactions in the nucleus and cytoplasm 
separately using CLIP-seq. This procedure would be similar to what was done in Chapter 
IV. After crosslinking the mouse striatum to freeze the RNA-protein complex, the extra 
step is to sub-fractionate the tissue into nuclear and cytoplasmic fraction prior to the IP and 
library preparation step. This sub-compartmentalization of hnRNP H-regulated transcripts 




One area worth investigating is the function of hnRNP H at the synapse. While 
most of the binding regions associated with hnRNP H in our CLIP-seq analyses are 
intronic, we also identified binding of hnRNP H to 3’UTR of mRNA transcripts found in 
presynaptic terminal and postsynaptic compartment, such as voltage gated calcium 
channels, phosphatases, calcium signaling and kinases, transporters, synaptic vesicles, 
glutamate receptors (Chapter IV). The interactions of hnRNP H at the 3’UTR implicate a 
role of hnRNP H in mRNA transport and translation at the synapse for new protein 
synthesis in neurons to respond to cellular stimuli (Holt et al., 2019). Since there is 
normally a low level of hnRNP H at the synapse, the use of super high-resolution imaging 
is necessary to define the localization of hnRNP H outside of the nucleus, whether it is 
predominantly found in the vesicle release site of the presynaptic site or at the postsynaptic 
density scaffold. Once the synaptic localization of hnRNP H is confirmed, the use of CLIP-
seq and RNA-seq on sub-fractionated synaptosomes (pre- versus postsynaptic fraction) 
will better define the hnRNP H-RNA interactome and hnRNP H-dependent post-
transcriptional regulation on these synaptic mRNAs. The differentiation of hnRNP H pre- 
versus post-synaptic RNA targets would help us determine whether a pre- and/or post-
synaptic mechanism links Hnrnph1 to MA-induced behavior. 
Even though Hnrnph1 is expressed ubiquitously in the brain, our lab has previously 
established exclusion of Hnrnph1expression in glia (Ruan et al., 2020), implicating a cell 
type-specific function of Hnrnph1 in regulating RNA expression and processing. 
Identifying hnRNP H-RNA interactions at cell type resolution (both at steady state and 




H function in response to acute MA response and the cellular adaptations from repeated 
MA exposure. The use of cTag-CLIP (Ule et al., 2018) will  permit induction of GFP-
tagged hnRNP H1 expression in dopaminergic neurons (by crossing to either a DAT-Cre 
or TH-cre driver mouse line) for cell type specific profiling of hnRNP H 1 targets. This 
method does not require specific hnRNP H1 antibody but rather a high-affinity GFP 
antibody to pull down the tagged hnRNP H1. There is also no need for fluorescence-
activated cell sorting to isolate DA neurons because the Cre driver line will drive GFP-
tagged hnRNP H1 expression in DA neurons which can be readily and specifically isolated 
using a GFP antibody. The floxed-Hnnrph1 mouse (which we currently have) crossed to 
the same Cre driver will serve as a true negative control to narrow down on the high 
confidence RNA-binding targets. Cell type-specific GFP-tagging of hnRNP H1 is versatile 
not just for CLIP.  This approach can be extended for co-immunoprecipitation to identify 
functional cooperative and/or competitive interaction between hnRNP H1 with other RBPs 
in a cell type specific manner in response to MA. 
 
Analysis of hnRNP H regulation of the Cacna2d2 3’UTR Region in a Luciferase Reporter 
System 
As demonstrated in Chapter II, the luciferase reporter assay is highly versatile in the study 
of noncoding regulatory elements in the untranslated region controlling regulation of gene 
expression. This assay is adaptable to probe post-transcriptional function of RBPs through 
their interactions with the UTRs (Sternburg and Karginov, 2020).  Our CLIP-seq and RNA-




and induces alternative splicing of the 3’UTR region (Chapter IV). We hypothesize that 
the interaction of hnRNP H with the 3’UTR of Cacna2d2 controls polyadenylation 
selection to generate 3’UTR of varying lengths, which confer differences in mRNA 
stability and translation efficiency, perhaps in a cell type-specific manner. The luciferase 
report assay can be applied to test this hypothesis to determine whether hnRNP H exerts a 
repressive or stabilizing role on Cacna2d2 expression. This procedure will involve cloning 
the full length 3’UTR region of Cacna2d2 into the 3’UTR of a luciferase reporter gene in 
combination with hnRNP H1 protein level manipulation (knockdown and/or 
overexpression). There are two output results we can quantify: 1) length of the 3’UTR 
through qPCR; 2) protein expression through luciferase signal quantification. Besides 
manipulating expression of hnRNP H1, we can also mutate the hnRNP H1 binding sites 
found in the 3’UTR of Cacan2d2 to examine disruption of hnRNP H1 binding and changes 
in 3’UTR length and protein expression. Through this reporter system, manipulation of 
Malat1 and miR124a expression can be performed to test for co-regulation of hnRNP H1 
with these two noncoding RNAs, which are hnRNP H target RNAs that also show MA-
induced and genotypic difference in gene expression in our analyses. 
 
Profiling of mRNAs under Active Translation in the Synaptosome 
A genome-wide approach for analyzing the functional consequence of 3’UTR binding by 
hnRNP H can involve  the use of TRAP-seq (Heiman et al., 2008) or RiboTag (Sanz et al., 
2009), both of which are common methods for mapping actively translated mRNAs. The 




x Treatment interaction are also being actively, but differentially translated in response to 
MA as a function of Hnrnph1 Genotype. To determine whether hnRNP H plays a role in 
localized protein synthesis to drive synaptic plasticity in response to MA, TRAP-seq or 
RiboTag can even be modified to extract ribosome-bound mRNAs from the dendrites. To 
complement this approach, change in protein synthesis in response to MA in the Hnrnph1 
mutant and WT mice in a temporal manner can be measured using SunSET (Schmidt et al., 































Figure A1. Ponceau S staining for total protein normalization used in immunoblot 
quantification.  
Total protein stains via ponceau S instead of a housekeeping gene were used as loading controls. 
The densitometry value for the total protein stains in each lane is indicated below each immunoblot. 
These are the values that were used for normalization. (A-C): Ponceau S total protein staining for 





Figure A2. DNA sequence of the cloned Hnrnph1 promoter.  
The promoter contains the DNA sequence 2956 bp upstream of transcription start site which 
corresponds to chromosome 11 nucleotide position 50,375,375 to 50,378,330 (mm10). The 
nucleotides indicated in different colors represent the positions of the SNPs, and the nucleotides 
indicated in blue represent the positions of the indels. The exons are highlighted in green. This 





Figure A3. Hnrnph1:luc2 reporter assay in HEK293T cells.  
(A): Schematic representation of the procedure for cloning the Hnrnph1 promoter into 
pGL4.17[luc2/Neo]. The promoter region of Hnrnph1 was PCR-amplified followed by restriction 
enzyme digest by XhoI and HindIII for insertion into pGL4.17[luc2/Neo]. The Hnrnph1 promoter 
was defined as 2956 bp upstream of the transcriptional start site of Hnrnph1 and was fused to the 
firefly luciferase (luc2) to make the Hnrnph1:luc2 reporter. (B): Different numbers of HEK293T 
cells were seeded to determine whether the cloned Hnrnph1 promoter could drive expression of 
firefly luciferase, luc2. Firefly luminescence increased as the cell number increased [two-way 
ANOVA: F(3,16) = 64.19, p = 3.86E-09; Bonferroni’s multiple comparison test: t(16)10,000 = 1.15, 
p > 1; t(16)20,000 = 2.94, *p = 0.005; t(16)30,000 = 8.35, *p = 1.25e-6; t(16)50,000 = 19.36, *p = 6.30e-








Table A1. Primers used for site directed mutagenesis.  
This table supports Figures 12 and 13 and Table 7. 
Mutation 
Position 
Mutagenesis primer Sequences 
SNP/Indel 
T7288C 
50,377,288 Forward: 5'-tgaaagacaccacgaggaaaaggaagccatgccc-3' 
rs29411274 Reverse: 5'-gggcatggcttccttttcctcgtggtgtctttca-3' 
GA7546G 





50,377,795 Forward: 5'-cacctccacacaaagcctcggcgtggctga-3' 
rs29475617 Reverse: 5'-tcagccacgccgaggctttgtgtggaggtg-3' 
G7937C 
50,377,937 Forward: 5'-cggcgagacagtcgcggctccca-3' 


















Table A2. RT-qPCR primers for exon usage. 




Hnrnph1 3-4 Forward: 5’-CGCCCGCTTATCATTTCTCC-3’ 
Reverse: 5’-CTTCACCACGAAGCCCTCT-3’ 
Hnrnph1 6-7 Forward: 5’-ACGGCTTAGAGGACTCCCTTT-3’ 
Reverse: 5’-CGTACTCCTCCCCTGGAAGT-3’ 
Hnrnph1 7-8 Forward: 5’-CAGGAAATAGCTGAAAAGGCTCTA-3’ 
Reverse: 5’-GCCATAAGTTTTCGTGGTGG-3’ 
Hnrnph1 3 Forward: 5’-AGCTTGCTGGAAGGGCTT-3’ 
Reverse: 5’-ACCTCCACAAAAAGCCTCG-3’ 
Hnrnph1 4 Forward: 5’-GACCACCGAAGGGACGAT-3’ 
Reverse: 5’-AAAAAGCGCTGCACTTCATC-3’ 






Table A3. Predicted RNA binding proteins (RBPs) associated with the 5’UTR of Hnrnph1.  
The 5’UTR Hnrnph1 sequence was loaded into RBPDB (Cook et al., 2011) where the sequence 
was scanned for putative sites for binding of RBPs. A list of RBPs that are predicted to bind to 
Hnrnph1 and the binding sites on Hnrnph1 associated with the RBP are shown. The start and end 
positions refer to the nucleotide position for the sequence in Figure A2. This table supports Figure 
13. 
RBP Start End Matching sequence 
ZFP36 328 338 AAUAAGGAAAG 
ZFP36 344 354 AAUAAGGAAAG 
KHSRP 1252 1259 CCCCCCCC 
A2BP1 268 273 UGCAUG 
A2BP1 2769 2774 UGCAUG 
ZRANB2 1772 1777 AGGUAA 
HNRNPA1 1422 1427 UAGGGU 
ybx2-a 443 448 AACAUC 
ybx2-a 443 448 AACAUC 
EIF4B 2807 2813 GCGGGAC 
NONO 2950 2954 AGGGA 
NONO 65 69 AGGGA 
NONO 474 478 AGGGA 
sap-49 742 747 GUGUGA 
sap-49 2619 2624 GUGUGA 
sap-49 621 626 GUGUGA 
PABPC1 605 609 AAAAA 
PABPC1 2151 2155 AAAAA 
PABPC1 2180 2184 AAAAA 
PABPC1 2173 2177 AAAAA 
PABPC1 2179 2183 AAAAA 
PABPC1 2190 2194 AAAAA 
PABPC1 2178 2182 AAAAA 
PABPC1 588 592 AAAAA 
PABPC1 587 591 AAAAA 
PABPC1 2175 2179 AAAAA 
PABPC1 2177 2181 AAAAA 
PABPC1 2174 2178 AAAAA 
PABPC1 1264 1268 AAAAA 
PABPC1 606 610 AAAAA 
PABPC1 2176 2180 AAAAA 
PABPC1 1265 1269 AAAAA 
PABPC1 404 408 AAAAA 
RBMY1A1 546 550 CUCAA 
RBMY1A1 2671 2675 CUCAA 
RBMY1A1 320 324 CUCAA 
RBMY1A1 656 660 CUCAA 
RBMY1A1 1297 1301 CUCAA 




a2bp1 2816 2820 GCAUG 
a2bp1 2770 2774 GCAUG 
a2bp1 2232 2236 GCAUG 
a2bp1 269 273 GCAUG 
a2bp1 2097 2101 GCAUG 
a2bp1 2283 2287 GCAUG 
a2bp1 1898 1902 GCAUG 
RBMY1A1 546 550 CUCAA 
RBMY1A1 2671 2675 CUCAA 
RBMY1A1 320 324 CUCAA 
RBMY1A1 656 660 CUCAA 
RBMY1A1 1297 1301 CUCAA 
RBMY1A1 734 738 CUCAA 
EIF4B 449 455 GUAGGAA 
PABPC1 150 156 ACAAAUA 
RBMY1A1 341 345 CACAA 
RBMY1A1 1855 1859 CACAA 
RBMY1A1 110 114 CACAA 
RBMY1A1 149 153 CACAA 
sap-49 1165 1170 UUGUGA 
sap-49 1343 1348 UUGUGA 
FUS 208 211 GGUG 
FUS 2484 2487 GGUG 
FUS 2332 2335 GGUG 
FUS 2428 2431 GGUG 
FUS 1066 1069 GGUG 
FUS 497 500 GGUG 
FUS 2830 2833 GGUG 
FUS 612 615 GGUG 
FUS 741 744 GGUG 
FUS 1919 1922 GGUG 
Pum2 106 109 UGUA 
Pum2 77 80 UGUA 
Pum2 1334 1337 UGUA 
Pum2 806 809 UGUA 
Pum2 2239 2242 UGUA 
Pum2 1514 1517 UGUA 
SNRPA 1303 1309 GUUGCAC 
SFRS9 316 320 AGGAC 
SFRS9 337 341 AGGAC 
SFRS9 1714 1718 AGGAC 
SFRS9 2248 2252 AGGAC 
SFRS9 2939 2943 AGGAC 
SFRS9 644 648 AGGAC 
ACO1 523 528 CAGUGA 




SFRS9 1844 1848 AGGAG 
SFRS9 2633 2637 AGGAG 
SFRS9 1938 1942 AGGAG 
MBNL1 513 516 UGCU 
MBNL1 918 921 UGCU 
MBNL1 2351 2354 UGCU 
MBNL1 679 682 UGCU 
MBNL1 654 657 UGCU 
MBNL1 1471 1474 UGCU 
MBNL1 2493 2496 UGCU 
MBNL1 2452 2455 UGCU 
MBNL1 1150 1153 UGCU 
MBNL1 2773 2776 UGCU 
EIF4B 2355 2358 GGAA 
EIF4B 1483 1486 GGAA 
EIF4B 452 455 GGAA 
EIF4B 476 479 GGAA 
EIF4B 2645 2648 GGAA 
EIF4B 402 405 GGAA 
EIF4B 67 70 GGAA 
EIF4B 349 352 GGAA 
EIF4B 333 336 GGAA 
EIF4B 813 816 GGAA 
KHSRP 1786 1789 GUCC 
KHSRP 1598 1601 GUCC 
KHSRP 181 184 GUCC 
KHSRP 32 35 GUCC 
KHSRP 2289 2292 GUCC 
KHSRP 2018 2021 GUCC 
KHSRP 794 797 GUCC 
KHSRP 1691 1694 GUCC 
YBX1 2021 2026 CCUGCG 
YBX1 2372 2377 CCUGCG 
MBNL1 2751 2754 CGCU 
MBNL1 2608 2611 CGCU 
MBNL1 2500 2503 CGCU 
MBNL1 1584 1587 CGCU 
MBNL1 2386 2389 CGCU 
MBNL1 2836 2839 CGCU 
MBNL1 2124 2127 CGCU 
Vts1 2597 2603 GCAGGCC 
YTHDC1 2277 2282 UAAUAC 
YTHDC1 2770 2775 GCAUGC 
YTHDC1 2232 2237 GCAUGC 
YTHDC1 2097 2102 GCAUGC 




Vts1 2377 2383 GCAGGCG 
Vts1 2159 2165 GCAGGCG 
Vts1 2533 2539 GCAGGCG 
Vts1 1766 1772 GCGGGCA 
YBX1 1593 1598 GCUGCG 
YBX1 1955 1960 GCUGCG 
YTHDC1 1683 1688 GAGUGC 
Vts1 2539 2545 GCAGGCU 
Vts1 2807 2813 GCGGGAC 
Vts1 1828 1834 GCGGGGC 
Vts1 2316 2322 GCGGGGC 
QKI 2513 2522 UUCUAACCUG 
YTHDC1 2337 2342 GCGUGC 
RBMX 2937 2940 CCAG 
RBMX 893 896 CCAG 
RBMX 2015 2018 CCAG 
RBMX 1789 1792 CCAG 
RBMX 1840 1843 CCAG 
RBMX 2689 2692 CCAG 
RBMX 1091 1094 CCAG 
RBMX 1869 1872 CCAG 
RBMX 35 38 CCAG 
RBMX 2791 2794 CCAG 
RBMX 186 189 CCAG 
SFRS13A 335 341 AAAGGAC 
























Figure A4. Schematics showing Bregma positions of the brain regions in IHC studies and 
Western blots.  
(A): VTA and SNc of midbrain. Left: schematic showing the ventral midbrain region dissected for 
Western blot analysis. Right: coronal brain diagrams showing highlighted VTA (yellow) and SNc 
(teal) for IHC. (B): Coronal brain diagrams showing highlighted dorsal striatum (green) and NAc 








Figure A5. Schematics and puncta count of TH IHC staining in H1 MUT mice.  
(A): A 225,000 x 225,000 µm grid was overlaid onto the images in Image J, and every third field 
(indicated by the black dots) was graded for total number of puncta. Regions of interest were graded 
by subtracting the background, setting a threshold, creating a binary image, and conducting particle 
analysis to count total puncta number based on roundness and total size (as indicated by threshold 
black/white image on bottom right). (B): Stereological analysis of the number of TH-positive 
puncta revealed no genotypic difference on the number of dopaminergic terminals in the dorsal and 
ventral striatum of H1 MUT versus WT mice (dorsal: t(14) = 0.55, p = 0.588; ventral: t(14) = -1.49, 






Figure A6.  Network and pathway analysis of synaptosomal proteome of H1 MUT versus 
WT mice treated with MA or SAL [(H1 MUTMA – H1 MUTSAL) – (WTMA – WTSAL)].  
Enrichment results for the comparisons were visualized using Cytoscape and EnrichmentMap. 
Pathways were clustered and annotated with themes using AutoAnnotate. Nodes (grey circle) 
represent the pathways and the size of each node represents the number of proteins. Each circle 
within each node represents the individual protein (red is up and blue is down relative to WT). An 
enrichment for metabolic processes was detected in the H1 MUT mice and WT in response to MA 
in which MA decreased the expression of proteins involved in metabolic processes in the H1 MUT 
mice. The cut-off for the differential analysis is set to absolute log2FC = 0.2 and p < 0.05. This 



















Table A4. Experimental design. 
Drug 
Treatment 
Genotype IP # of Animals 
per replicate 
# of replicate(s) # of 
animals 
SAL WT IgG 4 1 4 
MA WT IgG 4 1 4 
SAL MUT IgG 4 1 4 
MA MUT IgG 4 1 4 
SAL WT Anti-hnRNP H 4 3 12 
MA WT Anti-hnRNP H 4 3 12 
SAL MUT Anti-hnRNP H 4 3 12 
MA MUT Anti-hnRNP H 4 3 12 
     64 
This table supports Figure 29. 
 
Table A5. Sample size. 
Type of Experiment Conditions 
CLIP-seq WT_SAL (IgG): n = 1 
WT_MA (IgG): n = 1 
MUT_SAL (IgG): n = 1 
MUT_MA (IgG): n = 1 
WT_SAL (anti-hnRNP H IP): n = 3 
WT_MA (anti-hnRNP H IP): n = 3 
MUT_SAL (anti-hnRNP H IP): n = 3 
MUT_MA (anti-hnRNP H IP): n = 3 
RNA-seq WT_SAL: n = 1+ 3 
WT_MA: n = 1 + 3 
MUT_SAL: n = 1 + 3 
MUT_MA: n = 1 + 3 












Figure A7. Optimization of the CLIP conditions for hnRNP H.  
(A): Immunoblot shows the IP condition using the anti-hnRNP H antibody. No nonspecific bands 
were detected in the rabbit IgG pulldown. In the hnRNP H IP, a band of 50 kDa corresponding to 
the size of hnRNP H was detected. (B): Immunoblot showing IP condition using different 
concentrations of hnRNP H antibody. A total of 20 ug of antibody was chosen for the IP. (C): CLIP 
and 32P labeling of bound RNA under different duration of RNase If digestion. Three min was 









Figure A8. cDNA libraries generation followed by visualization with DNA gel electrophoresis.  
(A): No cDNA library was generated from IgG mock IP. Even after 28 cycles, no cDNA library 
(which should be > 200 bp) was detected. For this reason, these four samples were not subjected to 
RNA-seq. (B): In contrast with CLIP cDNA libraries, DNA bands > 200 bp were detected after 20 













Figure A9. Visualization of read density by Integrative Genomics Viewer (Thorvaldsdóttir et 
al., 2013) on top hnRNP H associated target, Oprm1.  
Scale of track height in CPM is the same for both tracks. Top track represents reads from CLIP-


























Table A6.  hnRNP H motif by genomic region in untreated saline WT mice. 
The top 3 Homer de novo motif results are shown for each genomic region type (5’UTR, CDS, 
intron and 3’UTR). The motif discovery was performed in Homer (Heinz et al., 2010). This table 
supports Figure 30C. 




 1e-16 23.49% 
 1e-14 10.87% 
CDS 
 1e-122 18.76% 
 1e-75 15.00% 
 1e-70 18.36% 
Intron 
 1e-47 12.19% 
 1e-34 9.88% 
 1e-34 7.75% 
3’UTR 
 1e-54 15.74% 
 1e-47 9.85% 





Table A7. Top 10 pathways enriched in hnRNP H-associated targets with G-rich motif in 
WT_SAL. 
Pathway Database Adjusted p RNA targets 
Presynaptic 
depolarization and 
calcium channel opening 
pathway_Reactome 9.52E-05 
Cacna1a, Cacnb4, Cacna1e, 
Cacng4, Cacna1b, Cacng2, 
Cacnb2 
Phase 1 - inactivation of 
fast Na+ channels 
pathway_Reactome 0.0225 Kcnd3, Kcnip3, Kcnip2, Kcnd2 
LGI-ADAM interactions pathway_Reactome 6.95E-04 
Dlg4, Adam23, Stx1b, Lgi4, 
Cacng4, Cacng2, Adam22 
Unblocking of NMDA 
receptors, glutamate 
binding and activation 
pathway_Reactome 1.85E-04 
Gria1, Dlg4, Dlg2, Grin2a, 
Gria3, Camk2d, Grin2b, Actn2, 
Camk2a 
Interaction between L1 
and Ankyrins 
pathway_Reactome 0.0186 Sptbn4, Ank3, Ank2, Ank1, Sptb 
CREB phosphorylation 
through the activation of 
CaMKII 
pathway_Reactome 2.86E-04 
Dlg4, Creb1, Dlg2, Grin2a, 
Calm1, Camk2d, Grin2b, Actn2, 
Camk2a 
Ras activation upon 
Ca2+ influx through 
NMDA receptor 
pathway_Reactome 4.41E-04 
Rasgrf1, Dlg4, Dlg2, Grin2a, 
Calm1, Camk2d, Grin2b, Actn2, 
Camk2a 
Reduction of cytosolic 
Ca++ levels 
pathway_Reactome 0.0096 
Atp2a2, Atp2b2, Slc8a2, Atp2b1, 
Calm1, Slc8a1 
Rap1 signaling pathway_Reactome 0.0096 
Rap1gap, Ywhaz, Prkg1, 
Rasgrp2, Rap1gap2, Rasgrp1 
Hypothetical Network 
for Drug Addiction 
pathway_Wikipathway 1.76E-05 
Cacna1a, Cacnb4, Cacna1e, 
Cacng4, Cacna1b, Cacng2, 
Cacnb2 

















Table A8. hnRNP H binding sites on the 7 targets enriched for “presynaptic depolarization 
and calcium channel opening.” 
RNA-binding Target Peak Position(s) Genomic Region Type 
Cacna1a chr8: 84611302-84611402 Intron 
Cacnb4 
chr8: 52629320- 52629420 
chr8: 52560620- 52560720 




Cacna1e chr1:154446931- 154447031 Intron 
Cacng4 chr11:107794366- 107794466 
5’UTR or CDS depending on the 
mRNA isoform 
Cacna1b 
chr2: 24608087- 24608187 
chr2: 24606587-24606687 




chr15: 78045548 - 78045548 





Chr2: 14762588- 14762688 
Chr2:14685188- 14685288 




*only 3 out of 9 peaks lists 























Table A9. Chi-square tests comparing difference in proportion of hnRNP H associated 
binding regions.  
Given the binding events associated with hnRNP H detected in WT_SAL, the proportions of 3’UTR 
and intron targets in the other three conditions are significantly differently as depicted by the p 
values calculated in chi square test. This table supports Figure 32A. 
Subregion 







3'UTR 0.0008 (***) 
< 0.0001 
(****) 
< 0.0001 (****) 
distal intron < 0.0001 (****) 
< 0.0001 
(****) 
< 0.0001 (****) 
proximalx500_intron < 0.0001 (****) 
< 0.0001 
(****) 
< 0.0001 (****) 
proximax200_intron < 0.0001 (****) 0.453 < 0.0001 (****) 
other_exon 0.42 0.864 0.226 
CDS 0.208 0.714 < 0.0001 (****) 























Figure A10.  hnRNP H RNA-binding targets showing Genotype x Treatment interactions are 
enriched in pathways and gene ontology involved in drug-induced synaptic plasticity.  
(A): Venn diagram shows distinct and overlapping hnRNP H targets identified in each of the four 
conditions. (B): Venn diagram shows distinct and overlapping hnRNP H targets as a function of 
Genotype, Treatment, or Genotype x Treatment interaction. Peak calling was performed using 
CLAM to identify peaks based on merged bam files across all conditions. Individual bam files were 
then used to count reads against the identified peaks. Differential peak analysis for Genotype x 
Treatment interaction was performed using limma/edgeR. The Genotype x Treatment interaction 
is expressed as (MUTMA – MUTSAL) – (WTMA – WTSAL). (C): Pathway analysis of the hnRNP H 
targets that showed a Genotype x Treatment interaction. The EnrichmentMap Cytoscape App 
(Merico et al., 2010) was used to build a network of the top 10 gene ontology and pathways 
enrichment results. Each square (or node) represents a gene set and edge represents mutual overlaps. 






Table A10. KEGG pathways and GO cellular components enriched for hnRNP H-associated 
RNA targets with Genotype x Treatment interaction.  
Only those pathways or cellular components that are significantly enriched are shown. This table 
supports Figure 32C. 
(A): KEGG Pathway 
Gene Set RNA targets 
Amphetamine addiction 
Adcy5, Arc, Cacna1c, Calm2, Camk2a, Camk2b, Camk4, Creb3, 
Gnas, Gria1, Gria2, Grin2b, Ppp1cc, Ppp1ccb, Ppp1r1b, Ppp3ca, 
Ppp3r1 
Long-term potentiation 
Adcy1, Braf, Cacna1c, Calm2, Camk2a, Camk2b, Camk4, Ep300, 
Gnaq, Gria1, Gria2, Grin1, Grin2b, Grin2c, Grm1, Grm5, Hras, 
Map2k2, Ppp1cc, Ppp1ccb, Ppp3ca, Ppp3r1, Prkacb, Raf1, Rap1a 
Alcoholism 
Adcy5, Braf, Calm2, Camk4, Creb3, Gnas, Gnb1, Gng7, Grin2b, 
H3f3b, Hdac11, Hdac5, Hras, Ntrk2, Pkia, Ppp1cc, Ppp1ccb, 
Ppp1r1b 
Dopaminergic synapse 
Adcy5, Akt3, Cacna1a, Cacna1c, Calm2, Camk2a, Camk2b, Creb3, 
Gnaq, Gnas, Gnb1, Gng7, Gria1, Gria2, Grin2b, Gsk3b, Ppp1cc, 
Ppp1ccb, Ppp1r1b, Ppp2r1b, Ppp2r2a, Ppp2r5b, Ppp3ca 
(B): GO: Cellular Component 
Gene Set RNA targets 
ATPase complex 
Actl6b, Anp32e, Appl1, Arid1a, Arid1b, Atp1a3, Atp1b1, Atp1b2, 
Atp2a2, Bicra, Bicral, Brd8, Chd4, Chd5, Dpf1, Ep400, Gatad2b, 
Kat5, Mta1, Rbbp7, Ruvbl2, Smarca4, Smarcc2, Smarcd1, Srcap 
neuron spine 
Anks1b, Arc, Arhgap32, Arhgap33, Arrb1, Asic2, Atp2b1, Baiap2, 
Camk2a, Cdk5r1, Dgki, Dlg4, Dlgap3, Dnm1, Fus, Gria1, Grin2b, 
Grm5, Gsk3b, Hspa8, Itpka, Kcna4, Map1b, Myh10, Nrgn, Ntrk2, 
Pde4b, Ppp1cc, Ppp1r1b, Ppp1r9b, Ppp3ca, Pten, Rgs7bp, Sez6, 
Shisa7, Shisa9, Sipa1l1, Strn4, Syne1 
myelin sheath 
Aco2, Actg1, Aldoa, Atp1a3, Atp1b1, Atp5b, Atp5c1, Atp6v1a, 
Atp6v1b2, Car2, Cltc, Dlat, Dnm1, Eef1a1, Eef1a2, Eno1, Gjc2, Gjc3, 
Glul, Gnb1, Gsn, Gstm1, Hrh3, Hspa8, Hspa9, Mbp, Mog, Napb, 
Ncam1, Ndrg1, Nefm, Pdcd6ip, Pdia3, Pebp1, Pkm, Plp1, Pten, 
Rap1a, Slc25a3, Stxbp1, Syn2, Tppp, Tspan2, Vdac1, Ywhag 
nuclear chromatin 
Actl6b, Aldoa, Anp32e, Appl1, Arid1a, Arid1b, Bicra, Bicral, Brd4, 
Brd8, Cenpb, Chd4, Chd5, Clock, Cpsf6, Dpf1, Enc1, Ep400, 
Gatad2b, H1f0, H2afy, Jun, Kat2a, Kat5, Mef2d, Mta1, Nsmf, Polr2a, 
Ppp1r10, Rbbp7, Rcc1, Ruvbl2, Sfr1, Sin3b, Smad4, Smarca4, 












Figure A11. A strong negative correlation is detected between hnRNP H RNA-binding 
dynamic in the WT and MUT in response MA in the 3’UTR (A), introns (B), CDS (C), and 
5’UTR (D).  
The data points highlighted in magenta are those that show significant Genotype x Treatment 






















Figure A12. 3’UTR targets show significant enrichment for both pre- and post-synaptic 
function.  
Interaction plots for 3’UTR targets with significant Genotype by Treatment interaction that are 
enriched for (A) synaptic vesicle cycle and (B) dopaminergic synapse.The interaction plots are 
generated from CLIP-seq data showing average values with standard deviation of the means, with 
n = 3 per condition. This figure supports Table 10. 
 
 
Table A11.  Differential expressed genes overlapping with hnRNP H targets with Genotype 
by Treatment interaction. 
Gene Expression Peak Intensity Peak Location 
 logFC p value logFC p value Coordinate Type 





Mir124a-1hg -0.672 0.021 
-4.020 0.004 chr14:64592731-64592831 Other exon 
-3.306 0.019 chr14:64592631-64592731 Other exon 
-3.062 0.030 chr14:64593631-64593731 Other exon 
Gtf2e2 2.627 0.024 
3.737 0.008 chr8:33774733-33774833 Intron 
3.102 0.035 chr8:33759333-33759433 Intron 





















Unc13c -0.705 0.027 
3.343 0.018 chr9:73765622-73765722 Intron 
2.858 0.037 chr9:73509222-73509322 Intron 
Malat1* -1.029 0.040 
-2.381 2.155E-04 ch19:5801590-5801690 Intron 
-2.296 2.603E-04 chr19:5798090-5798190 Other exon 
-1.872 7.208E-04 chr19:5797290-5797390 
Intron or 
other exon 
-1.774 8.040E-04 chr19:5797390-5797490 
Intron or 
other exon 
-2.093 0.001 chr19:5797990-5798090 Other exon 
*5 out of 48 peaks shown 







Figure A13. The main effect of Genotype is more significant than the main effect of 
Treatment. 
Differential gene expression for interaction of Genotype (MUT – WT) or Treatment (MA – SAL) 
was performed using limma (Ritchie et al., 2015) and edgeR (Robinson et al., 2009). (A): Volcano 
plot showing genes that are differentially expressed between H1 MUT and WT. (B): Volcano plot 




























Figure A14. Putative model for Mir124a- and Malat1-mediated transcriptional regulation 
that could underlie blunted MA-induced DA release observed in H1 MUT mice.  
CLIP-seq and transcriptome analysis indicated that hnRNP H showed decreased binding of hnRNP 
H to Mir124a and Malat1 which we propose leads to a subsequent downregulation of both Mir124a 
and Malat1 at the gene level after acute MA exposure in the H1 MUT relative to WT control. The 
suppression in Mir124a and Malat1 levels that is induced by MA in the H1 MUT leads to an 




target gene), and Getf2e2, and other genes, and a decrease in expression of Unc13c and other genes. 
Out of the 19 significant differentially expressed genes showing a Genotype x Treatment interaction, 
16 genes showed an increase in expression after MA treatment in H1 MUT versus WT mice, 
implicating that a reduction in expression of the two noncoding RNAs, Mir124a and Malat1 leads 
to an increase in expression of genes that are involved in calcium-regulated DA release induced by 
MA (e.g., Cacna2d2 and Camta1). The underlined genes are RNA-binding targets of hnRNP H. 
H1 MUT mice show markedly blunted MA-induced DA release (Ruan et al., 2020a). Interestingly, 
the overlapping hnRNP H interactome and transcriptome that represents the Genotype x Treatment 
interaction revealed Unc13c (Figure 34A-B) as a differential, MA-induced hnRNP H binding 
target in H1 MUT (decrease) versus WT mice (increase) (Figure 34B). Unc13 or Munc-13 couples 
calcium entry through VGCC and synaptic vesicle fusion to plasma membrane, triggered by 
calcium binding to sensor proteins (Eggermann et al., 2012; Dittman and Ryan, 2019). Unc13 
activates the SNARE complex and docks synaptic vesicles close to VGCCs and recruits/positions 
VGCCs to the active zone to couple calcium influx  with neurotransmitter release (Südhof, 2013; 
Böhme et al., 2018; Kusch et al., 2018; Dittman, 2019). Unc13 activity at the active zone is tightly 
associated with synaptic vesicle release dynamics. In turn, calcium and calmodulin binding 
modulates the activity of Unc13 (Lipstein et al., 2012). The calmodulin-binding transcription factor, 
Camta1, was also identified as a differential expressed gene that showed a MA-induced increase in 
expression in H1 MUT relative to WT mice (Figure 34A-B).  Our previous transcriptome analysis 
in drug-naïve mice indicated differential splicing of Ppp3ca in the H1 MUT compared to WT (Ruan 
et al., 2020b). Ppp3ca codes for the  catalytic subunit of calcineurin, which is a 
calcium/calmodulin-response protein phosphatase involved in dopamine receptor signaling and 
behavioral responses to psychostimulants (Oliver and Shenolikar, 1998). Thus, multiple lines of 
evidence point to perturbations in calcium signaling as likely potential mechanism linking blunted 
MA-induced dopamine release observed in the H1 MUT mice. Convergent analysis of the hnRNP 
H interactome and transcriptome also identified non-coding RNAs, miR-124a and Malat1 as 
showing differential binding to hnRNP H between H1 MUT and WT in response to MA (Figure 
34A-B). Both non-coding RNAs showed a MA-induced decrease in expression in H1 MUT versus 
WT (Table A11). Drug-induced synaptic plasticity requires changes in gene expression and post-
transcriptional regulation (McClung and Nestler, 2008; Nestler, 2008), which can be  orchestrated 
by microRNAs (miRs) and long noncoding RNAs (lncRNAs). miRs like miR-124a that suppress 
mRNA  translation by targeting the 3’UTR (Lipovich et al., 2012). lncRNAs like Malat1 serve as 
precursors to small RNAs and regulate RNA processing, transcriptional and post-transcriptional 
modulation of gene expression(Mercer et al., 2009; Xie et al., 2014). Malat1  can promote neuronal 
cell apoptosis by sequestering miR-124a in  models of Parkinson’s Disease (Liu et al., 2017). 
Changes in ventral striatal gene expression after repeated MA exposure depend on miRNAs and 
lncRNAs (Zhu et al., 2016). Multiple studies show evidence for a downregulation of miR-124 in 
response to psychostimulants and concomitant upregulation of genes involved in drug-induced 
plasticity (Guo et al., 2016; Cabana-Domínguez et al., 2018; Liu et al., 2019). For example, MA 
treatment in  cultured astrocytes decreased MIR-124 expression and SIGMAR1  by alleviating 
translational repression of MIR-124  at the 3’UTR (Huang et al., 2017). Also, striatal 
overexpression of miR-124 overexpression inhibited cocaine-mediated locomotor hyperactivity 
(Periyasamy et al., 2018). Binding of hnRNP H to both miR-124 and Malat1 and the subsequent 
genotype-interactive effect on MA-induced gene expression could impact transcriptional and 
posttranscriptional regulation of their downstream targets. Accordingly, the miRNA-target 
(TargetScan, 134) and lncRNA-target (LncRRIsearch, 135) algorithms predicted Camta1 as 
putative target of miR-124 and Cacna2d2 as putative target of Malat1, respectively. This figure 




Table A12.  Read Coverage in CLIP-seq and input RNA-seq samples. 




CLIP_WT_SAL_1 CLIP-seq WT SAL 1 ACAGTG 16,446,905 
CLIP_WT_SAL_2 CLIP-seq WT SAL 2 GATCAG 12,440,933 
CLIP_WT_SAL_3 CLIP-seq WT SAL 3 AGTCAA 22,826,085 
CLIP_WT_MA_1 CLIP-seq WT MA 1 GCCAAT 24,419,809 
CLIP_WT_MA_2 CLIP-seq WT MA 2 TAGCTT 16,402,702 
CLIP_WT_MA_3 CLIP-seq WT MA 3 AGTTCC 13,376,067 
CLIP_MUT_SAL_1 CLIP-seq MUT SAL 1 CAGATC 25,759,157 
CLIP_MUT_SAL_2 CLIP-seq MUT SAL 2 GGCTAC 27,432,645 
CLIP_MUT_SAL_3 CLIP-seq MUT SAL 3 ATGTCA 25,812,360 
CLIP_MUT_MA_1 CLIP-seq MUT MA 1 ACTTGA 17,903,276 
CLIP_MUT_MA_2 CLIP-seq MUT MA 2 CTTGTA 16,116,861 
CLIP_MUT_MA_3 CLIP-seq MUT MA 3 CCGTCC 12,899,100 
INPUT_WT_SAL_1 RNA-seq WT SAL 1 GTTTCG 44,421,956 
INPUT_WT_SAL_2 RNA-seq WT SAL 2 ACTGAT 48,930,085 
INPUT_WT_SAL_3 RNA-seq WT SAL 3 CAACTA 53,470,359 
INPUT_WT_MA_1 RNA-seq WT MA 1 CGTACG 53,843,037 
INPUT_WT_MA_2 RNA-seq WT MA 2 ATGAGC 55,822,205 
INPUT_WT_MA_3 RNA-seq WT MA 3 CACGAT 44,088,258 
INPUT_MUT_SAL_1 RNA-seq MUT SAL 1 GAGTGG 43,697,136 
INPUT_MUT_SAL_2 RNA-seq MUT SAL 2 ATTCCT 45,817,909 
INPUT_MUT_SAL_3 RNA-seq MUT SAL 3 CACTCA 42,147,542 
INPUT_MUT_MA_1 RNA-seq MUT MA 1 GGTAGC 37,184,152 
INPUT_MUT_MA_2 RNA-seq MUT MA 2 CAAAAG 39,745,547 
INPUT_MUT_MA_3 RNA-seq MUT MA 3 CAGGCG 33,706,973 
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